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Exercising muscle needs a constant supply of oxygen for the aerobic metabolism of 
carbohydrate and fat, and regulation of the blood supply to muscle during exercise is 
therefore critical.  Heart rate, stroke volume and minute ventilation all increase during 
exercise, and sympathetic vasoconstriction diverts blood to exercising muscle.  It is well 
recognised that receptors in skeletal muscle play a vital role in the regulation of blood 
flow, including receptors sensitive to products of anaerobic metabolism such as lactate and 
hydrogen ions: metaboreceptors.  Activation  of the muscle metaboreflex signals the need 
for an increase in blood flow, and leads to an increase in cardiac output, ventilation and 
sympathetic vasoconstriction to non-essential organs.
Exercise intolerance is one of the most disabling symptoms in patients with a range of 
cardiorespiratory   diseases.     Abnormalities   of   skeletal   muscle   favouring   anaerobic 
metabolism have been documented in both chronic heart failure and chronic obstructive 
pulmonary disease (COPD), and this is thought to be relevant to exercise limitation in 
these diseases.  Studies looking at patients with chronic heart failure have demonstrated an 
increase in muscle metaboreflex activity.   It is thought that abnormal skeletal muscle 
generates greater quantities of anaerobic metabolites, leading to increased metaboreceptor 
activation.  This in turn causes an increased sympathetic nervous system and ventilatory 
response to exercise.  Patients with COPD have been shown to demonstrate similar skeletal 
muscle abnormalities, so we hypothesised that we would also find an increase in muscle 
metaboreflex activity in this group.
iiIt is possible to quantify muscle metaboreflex activity by exercising a small muscle group 
to fatigue then isolating it from the rest of the circulation with a sphygmomanometer cuff. 
This traps the metabolic products of exercise in the muscle and leads to prolonged 
stimulation of metaboreceptors.  This can be measured as a sustained increase in blood 
pressure and ventilation when compared with control recovery without cuff inflation.
The aims of this thesis were as follows: (i) to assess if it is possible to quantify the muscle 
metaboreflex in a group of patients with COPD and to determine whether muscle 
metaboreflex activity is increased in patients with more severe disease, (ii) to determine 
whether supplementation with oral creatine monohydrate alters muscle metaboreflex 
activity, upper limb strength or endurance and respiratory muscle strength in patients with 
COPD, (iii) to assess the effects of diabetic autonomic neuropathy on muscle metaboreflex 
function, and (iv) to evaluate whether pulse transit time is of use in the measurement of 
muscle metaboreflex activity.
In our first study, we looked at a group of patients with stable COPD and found that 
rhythmic forearm exercise followed by post-exercise forearm ischaemia led to a sustained 
increase in blood pressure and minute ventilation when compared with control recovery. 
These findings are in keeping with previously published observations in normal subjects 
and in patients with chronic heart failure.  We found that there was no difference in muscle 
metaboreflex activity between the groups of patients with moderate or severe disease.
We then performed a randomised, double-blind, placebo-controlled, crossover trial looking 
at the effects of loading a group of patients with stable COPD with creatine monohydrate. 
We demonstrated a small increase in body weight and an increase in peak inspiratory and 
iiiexpiratory mouth pressures, but there were no effects on muscle metaboreflex activity or 
forearm muscle strength, endurance or recovery.
A group of patients with type I diabetes mellitus was then used to study the effects of 
autonomic neuropathy on muscle metaboreflex function.  We found that there was no 
difference in metaboreflex activity between subjects with diabetic autonomic neuropathy 
and subjects with diabetes but no evidence of autonomic neuropathy, suggesting that the 
afferent and efferent limbs of the muscle metaboreflex were intact.
Our final study evaluated whether pulse transit time could be used to assess muscle 
metaboreflex activity.  Pulse transit time is defined as the time taken for a pulse wave to 
travel between two arterial sites, and can be easily and non-invasively measured.  It is 
thought to reflect blood pressure and arterial tone.  In a group of healthy subjects, we found 
that pulse transit time fell with rhythmic handgrip exercise, and post-exercise muscle 
ischaemia led to a sustained fall in pulse transit time when compared with control recovery. 
Pulse transit time therefore shows promise in the measurement of muscle metaboreflex 
activity, but further studies are required.  Studies comparing pulse transit time with more 
invasive measurements such as muscle sympathetic nerve activity would be of particular 
interest.
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xxviChapter 1
Introduction and Literature Review1.1 Regulation of oxygen delivery to exercising muscle
1.1.1 General principles
The human body has a remarkable ability to adapt to the demands placed upon it during 
exercise.   Exercising skeletal muscle requires a constant source of energy, and the 
ability to increase energy supply immediately  is essential.    The conversion of 
phosphocreatine to creatine through the creatine kinase reaction provides an immediate 
source of adenosine triphosphate (ATP), although stores are limited and this is only the 
major source of energy during the first few seconds of intense exercise .  The anaerobic 
metabolism of muscle glycogen then becomes important, although this is inefficient 
with the production of only 3 mmol of ATP per mmol of glycogen .   Oxidative 
metabolism of carbohydrate and free fatty acids is a much more efficient form of 
energy production, with 1mmol of glycogen providing 36mmol of ATP, and 1mmol of 
lipid (eg palmitate) providing 130 mmol of ATP .  As exercise progresses, skeletal 
muscle therefore relies on the oxidative metabolism of carbohydrates and free fatty 
acids, and this necessitates a vast increase in oxygen delivery.  This is achieved through 
the following mechanisms:
· Cardiac output increases up to 6-fold through an increase in heart rate and 
stroke volume, increasing pulmonary blood flow and blood flow to exercising 
muscle .
· An increase in sympathetic nervous system activity causes vasoconstriction of 
the vascular bed of non-essential organs (eg intestine) and non-exercising 
muscle .· Minute ventilation increases up to 30-fold through an increase in respiratory rate 
and tidal volume, thus increasing the delivery of oxygen to the pulmonary 
capillaries .
· Local factors play a role, with the increase in temperature and reduction in pH 
associated   with   exercising   muscle   assisting   oxygen   unloading   from 
haemoglobin through a rightward shift in the oxygen-haemoglobin dissociation 
curve .
A feedback mechanism must exist to match oxygen availability to the demand of the 
exercising muscle.  If demand for oxygen exceeds availability, either through a high 
intensity of exercise or impairment of blood flow or oxygenation (as may happen in 
certain disease states), anaerobic metabolism of glycogen leads to the production of 
lactate and the onset of intramuscular acidosis with the creation of an oxygen debt . 
Accumulation of lactate and acidosis are associated with the onset of muscular fatigue .
1.1.2 Central command
The   exact   mechanisms   behind   this   feedback   mechanism   are   controversial,   and 
mechanisms driving ventilation and cardiovascular responses during exercise differ. 
“Central command” is important during the initial stages of exercise in humans . 
Anticipation of exercise leads to a withdrawal of resting parasympathetic tone and a 
resultant increase in heart rate and cardiac output .  The idea of central command was 
first suggested by Krogh and Lindhard in 1913 , who talked about the “irradiation” of 
the command to exercise from the cerebral cortex to the cardiovascular and respiratory centres.   This idea is supported by experiments looking at partial neuromuscular 
blockade both in man and in animal models, where the increased central command to 
generate equivalent work causes an increased blood pressure and heart rate response to 
exercise .  Further insight into the importance of central command has been gained from 
experiments on a series of patients with Brown-Séquard syndrome, where hemisection 
of the spinal cord leads to sensory loss on one side of the body and paralysis on the 
other side .  Attempts to contract the leg with a motor deficit led to the highest ratings 
of perceived exertion and the greatest elevations in blood pressure and heart rate, 
despite generation of the lowest force.  Central command does not, however, appear to 
play an important part in the increase in sympathetic nerve activity with exercise.  It has 
been observed that during forearm exercise, muscle sympathetic nerve activity (MSNA) 
does not start to increase until about 2 minutes of exercise has been completed, well 
after the initial heart rate and blood pressure response usually attributed to central 
command .  Studies using partial neuromuscular blockade to increase central command 
suggest that near maximal levels of central command are necessary to evoke an increase 
in muscle sympathetic nerve activity .   Other factors are therefore involved in the 
generation of an increase in MSNA with exercise, with central command merely 
initiating the efferent activity to the heart and blood vessels in parallel with recruitment 
of motor units to perform work.1.1.3 Afferents arising from exercising muscle
With the progression of exercise, cardiovascular responses are modulated by a feedback 
mechanism arising from working muscle.   Mechanoreceptors probably contribute to 
circulatory regulation at the start of exercise, and are sensitive to pressure and tension 
stimuli.   Dejours in 1964   postulated that a reflex from moving limbs, probably 
originating in the muscle spindle, could be responsible for the fast adaptation of the 
cardiorespiratory system to exercise.  Mechanoreflex activation would appear to have 
rapid effects on the cardiovascular system, with static contraction of triceps surae 
increasing renal sympathetic nerve activity after a delay of only 1 second .  Passive 
stretch of triceps surae has been shown to lead to rapid increases in heart rate and blood 
pressure in animals: the immediate onset and rapid recovery of group III afferent nerve 
activity is consistent with mechanoreceptor activation .  It has, however, been shown 
that muscle spindles and Golgi tendon organs, the afferent fibres of which are large 
group I and II afferents, do not elicit cardiovascular reflexes , and blockade of group I 
and II afferents does not affect cardiovascular responses to muscle contraction . 
Evidence suggests  that mechanoreceptors  are  particularly   important  during mild 
handgrip exercise .
Metaboreceptors are the other main form of receptor within skeletal muscle involved in 
cardiorespiratory responses to exercise.   These sense metabolic changes within the 
working muscle.
This thesis will concentrate on the role of the muscle metaboreflex.1.2 A review of the muscle metaboreflex
1.2.1 The history of the muscle metaboreflex
The first mention of the possibility of the existence of muscle metaboreceptors was by 
Zuntz and Geppart in 1886 .  They postulated that any mismatch between muscle blood 
flow and metabolism would change the concentration of metabolites within the muscle, 
which would be detected by chemosensitive afferent fibres in the muscle.  The efferent 
arm of the reflex, the sympathetic nervous system, would increase blood pressure, 
increasing blood flow to muscle, which would reduce the concentration of accumulated 
metabolites.  This theory, however, was not tested until 1937, when Alam and Smirk 
performed their classic experiments looking at the arrest of blood flow following 
localised exercise of a small group muscles.  They inflated a sphygmomanometer cuff 
round one upper arm and then asked the subject to perform repetitive exercise of the 
forearm muscles.  Blood pressure increased with exercise, and fell rapidly to resting 
levels on cessation of exercise.   If the cuff remained inflated beyond cessation of 
exercise, they discovered that blood pressure remained at peak exercise levels until the 
cuff was deflated.   This experiment produced similar results when repeated on the 
lower limb, and when circulatory arrest was achieved by exercising the forearm in a 
bath of mercury.  They also observed that the rise in blood pressure during exercise 
with circulatory occlusion depended on the total work done, and that the maintained 
elevation in blood pressure with circulatory occlusion post-exercise occurred in the 
absence of pain, and was independent of the degree of pain.  The conclusion drawn was 
that the arrest of the circulation on cessation of exercise led to the accumulation of metabolic products of exercising muscle and the stimulation of afferent nerves, causing 
a sustained increase in blood pressure.
The physiological responses to the arrest of blood flow following exercise were 
revisited by Asmussen and Nielsen in 1963 .  They asked healthy volunteers to exercise 
on a cycle ergometer until steady state was reached, then inflated sphygmomanometer 
cuffs round both thighs to 300mmHg.  Subjects were asked to continue exercising for 5 
minutes with the cuffs inflated.   During this period, pACO2  was kept constant by 
addition of CO2 to inspired air.  VO2 fell by 50% due to the isolation of exercising 
muscle from the circulation: the muscle was therefore reliant on anaerobic metabolism 
to provide energy.  Ventilation steadily increased throughout this period, as did blood 
pressure and peripheral resistance.  The conclusions drawn were that either anaerobic 
metabolism led to stimulation of intramuscular chemoreceptors, or that a reduction in 
tension and shortening in each muscle fibre led to an increase in recruitment of muscle 
fibres.  The possibility of muscle chemoreceptor activation stimulating the respiratory 
control centres was raised.  It was noted that pain was not experienced during the 
experiments, thus discounting the possibility of pain during cuff inflation stimulating 
ventilation and the pressor response.1.2.2 Neural mechanisms of the muscle metaboreflex
Much of our insight into the mechanisms of the muscle metaboreflex has been gained 
from experiments on anaesthetised animals, allowing us to separate responses to 
exercise from other factors such as voluntary control and responses to pain or 
discomfort.  McCloskey and Mitchell established beyond any doubt the existence of a 
neural signal arising from exercising muscle in 1972 using anaesthetised cats . 
Isometric exercise of the hindlimb muscles was elicited by stimulating ventral spinal 
roots L7-S1, which led to a rise in blood pressure, ventilation and heart rate.  Blood 
pressure and ventilatory responses were abolished by severing the dorsal (sensory) 
roots, which demonstrated the importance of afferent signals from muscle, but did not 
confirm the nature of the receptors.  The investigators then exercised the triceps surae 
muscle by ventral root stimulation with the femoral blood vessels occluded during and 
after exercise.  Blood pressure remained elevated after cessation of exercise until the 
occlusion was removed, though heart rate and ventilation were not affected.  This led to 
the conclusion that a local metabolite of exercise was eliciting these responses. 
Injection of an irritant in the form of either 5% sodium chloride or isotonic potassium 
chloride into the muscle led to similar cardiovascular and ventilatory responses as 
isometric exercise, though this was not seen with isotonic sodium chloride: again these 
responses   were   abolished   by   severing  the  dorsal  roots.     The  final  experiment 
demonstrated that preferential blockade of unmyelinated and small myelinated nerve 
fibres abolished cardiovascular and respiratory responses, but blockade of large nerve 
fibres did not.  The conclusion drawn was that the metaboreceptor response to exercise 
is mediated by group III and IV (small myelinated and unmyelinated) nerve fibres. 
Experiments by Tibes  on anaesthetised dogs support these conclusions, as does work by Kaufman et al , who demonstrated that ischaemic contraction of cat hindlimb muscle 
leads to an increased discharge of group IV afferents compared with non-ischaemic 
contraction despite the same amount of work being performed.  Ischaemic contraction 
was presumed to have led to an increased production of metabolites of anaerobic 
metabolism with a resultant increase in metaboreflex activation.  Although it is clear 
that muscle ischaemia during exercise potentiates the metaboreflex, a work stimulus is 
required, with muscle ischaemia alone insufficient to generate a pressor response . 
Many of the animal experiments looking at the metaboreflex have used electrical 
stimulation of ventral roots or peripheral nerves.  Adreani et al noted that this leads to 
recruitment of α-motoneurones with the fastest conduction velocities first, the opposite 
of what is seen during dynamic exercise .  They addressed this issue by looking at 
electrical stimulation of the mesencephalic locomotor region in the midbrain to simulate 
dynamic exercise in cats.  It was found that group III afferents discharged in synchrony 
with muscle contraction, consistent with mechanoreflex activation, unlike group IV 
afferents, which probably responded to a metabolic stimulus.  1.2.3 The muscle metaboreflex: mechanisms of activation
As the metaboreflex has evolved to sense the need to increase oxygen delivery to 
skeletal muscle, it follows that it must be a product of muscle metabolism that 
stimulates the metaboreceptors.  What that metabolic stimulus is has been a source of 
much debate.  Rotto & Kaufman  attempted to address this question in a cat model 
through the intra-arterial injection of exogenous substances believed to be the metabolic 
products of muscular contraction.  Substances used were chosen on the basis of studies 
looking at contraction of skeletal muscle and which metabolites are elevated in the 
venous outflow of working muscle.   Only lactic acid and arachidonic acid had 
excitatory actions on the discharge of group III and IV afferents innervating the triceps 
surae muscle.  Lithium, sodium lactate and adenosine did not have a substantial effect. 
Further work by the same group   suggested that arachidonic acid potentiates the 
responses of group III muscle afferents to static contractions, probably through 
increased sensitivity of the mechanoreflex.  Indomethacin and aspirin, both inhibitors of 
cyclo-oxygenase, appear to attenuate the response of group IV afferents to static 
contraction , and the prostaglandins PGE2 and PGF1α in effluent blood from exercised 
muscle haven been shown to correlate with metaboreflex activity in patients with heart 
failure . Adenosine has also been implicated in the generation of the metaboreflex in 
patients with heart failure: caffeine, an adenosine receptor antagonist, attenuates the rise 
in muscle sympathetic nerve activity (MSNA) with isometric handgrip exercise .  The 
role of interstitial potassium, as suggested by Wildenthal et al   and Rybicki et al  has 
been called into question following experiments on humans documenting the lack of 
correlation   between  venous  potassium  from  the  exercising  forearm  and  MSNA response during static and dynamic handgrip exercise .  A recent review promoted the 
idea that ATP could be important in evoking the metaboreflex .
Hydrogen ion and the development of acidosis within skeletal muscle are thought to 
stimulate the metaboreflex.   Hydrochloric acid injected into the arterial supply of 
triceps surae of the cat increases heart rate, blood pressure and ventilation .  Equimolar 
lactic acid had an even more potent effect on cardiorespiratory reflexes, though 
injection of sodium lactate at neutral pH did not have any effect.  Lactic acid is a 
metabolite of anaerobic glycolysis, so it would make sense that it has a part to play in 
the generation of a signal that more oxygen is required.  With the advent of 
31P Nuclear 
Magnetic Resonance Spectroscopy (
31P NMR), it has become possible to test this 
hypothesis on humans.  Victor et al  asked 11 healthy human volunteers to perform 
static and rhythmic handgrip exercise whilst recordings of 
31P NMR spectra and MSNA 
were made.  During the first 2 minutes of exercise, ADP increased and PCr/Pi (ratio of 
phosphocreatine to inorganic phosphate) declined with no change in pH or MSNA. 
During the 3
rd and 4
th minutes of exercise, there was little further change in PCr/Pi, but 
pH decreased.  MSNA increased progressively as pH decreased, suggesting that the 
development of acidosis is a potent stimulant of MSNA.  Prolonged bouts of rhythmic 
handgrip exercise at a low workload, however, can lead to a progressive rise in MSNA 
without   the   development   of   significant   muscle   acidosis   ,   suggesting   that   the 
mechanoreflex is perhaps more important in this setting.
Interesting insight into the role of lactic acid and acidosis has been gained from a group 
of patients with McArdle’s disease, who do not produce lactic acid due to a hereditary 
deficiency of myophosphorylase.  Even this has proven to be controversial.  Pryor et al found that there was an abnormal MSNA response to static handgrip exercise in 
patients with McArdle’s disease, and Fadel  et al    produced similar results, whilst 
demonstrating that the MSNA response to other reflex stimuli (for example the cold 
pressor test) is intact.   These data suggest that the glycogenolytic pathways are 
necessary for metaboreflex-mediated sympathoexcitation to occur during static exercise 
in humans.  This is contradicted by the work of Vissing et al , who found that patients 
with McArdle’s disease had a normal MSNA response to static handgrip exercise to 
fatigue, despite muscle pH not falling with exercise as happened in the healthy control 
subjects. They also studied one patient with mitochondrial myopathy, who developed a 
profound muscle acidosis with exercise, but did not have an enhanced MSNA response 
to exercise.   It could be argued that MSNA in patients with McArdle’s disease is 
stimulated by an increase in central command or mechanoreflex activation, though if 
this were the case, an immediate increase in MSNA would be expected: the time course 
of the MSNA response to exercise more closely resembles that of a metaboreflex 
mediated increase in MSNA.  Further work by the same group looking at post-exercise 
muscle ischaemia, which causes prolonged metaboreceptor activation, found that 
metaboreflex activity was normal in this group despite a failure to produce lactate . 
Finally, it was noted in one study on healthy human volunteers that muscle pH 
continued to fall after cessation of exercise, whereas MSNA, heart rate and blood 
pressure all rapidly returned to baseline : this was taken as evidence that intramuscular 
acidosis is not the sole factor driving cardiovascular responses to exercise.1.2.4 The function of the muscle metaboreflex: whole body versus small muscle 
group exercise
Although it is clear that combined mechanoreflex and metaboreflex activation during 
systemic exercise serves to divert blood flow away from non-essential organs such as 
kidney and gut, it is more controversial whether an increase in MSNA causes 
vasoconstriction which may actually limit blood flow to exercising skeletal muscle. 
This probably depends on the type of exercise that is being performed.  It is recognised 
that maximal vasodilatation of the vascular bed of all skeletal muscle can theoretically 
lead to a muscle blood flow that would exceed maximal cardiac output .  Given that 
blood pressure does not fall with exercise, is can be assumed that muscle blood flow is 
therefore regulated by tonic vasoconstriction during exercise which is driven by 
metaboreceptors, as hypothesised by Rowell .
The situation is different in the case of exercise of a small muscle group.  Maximal 
exercise, and therefore maximal blood flow to that muscle group, will obviously not 
exceed the ability of the heart to increase cardiac output.  It could therefore be argued 
that the metaboreflex limits exercise performance in this setting by limiting muscle 
blood flow unnecessarily, as it has been documented that exhausting handgrip exercise 
reduces blood flow to the exercising calf muscle , and that activation of the muscle 
metaboreflex in the forearm using ischaemic handgrip leads to an increase in vascular 
resistance in the exercising calf .  Kardos et al  attempted to address this question by 
looking at a group of patients before and after thoracoscopic sympathetic trunkotomy 
for idiopathic hyperhidrosis.   It was found that there was an increase in forearm 
exercise capacity, a decrease in muscle acidification and phosphocreatine depletion at matched workloads and a decreased pressor response to exercise following thoracic 
sympathetic trunkotomy.   This suggests that it is possible to improve exercise 
performance of a small muscle group by attenuating the sympathetic nervous system 
response to exercise.  It is also possible to augment blood flow to exercising skeletal 
muscle by blocking sympathetic afferents .  Metaboreflex downregulation may play a 
part in responses to training of a small muscle group.   It is known that exercise 
conditioning increases skeletal muscle vasodilator capacity  and reduces sympathetic 
vasoconstrictor responses .  It is not unreasonable to suggest that improved muscle 
bioenergetics with training leads to a reduction in metaboreflex activity, a reduction in 
reflex MSNA and an increase in forearm blood flow.  This in turn may further improve 
muscle oxygenation during exercise.  Mostoufi-Moab et al , however, were unable to 
show an improvement in deep venous oxygen saturation with exercise training despite 
an attenuation of the metaboreflex.
1.2.5 Functional sympatholysis
As discussed above, it is possible that vasoconstriction during exercise due to 
metaboreflex activation and an increase in sympathetic activity compromises blood 
flow to exercising muscle.  It is clear, however, that local vasodilator effects offset the 
metaboreflex-mediated vasoconstriction to some extent.  In the 1960’s, Remensnyder et 
al coined the term “functional sympatholysis” to describe the relative insensitivity of 
the exercising muscle vascular bed to sympathetic activation .  They applied negative 
pressure to the carotid sinus to simulate systemic hypotension, which led to an increase 
in sympathetic nervous system activity.   It was found that despite an increase in systemic   blood   pressure,   blood   flow   to   the  resting   limb   was   reduced   due   to 
sympathetically mediated vasoconstriction.  Conversely, blood flow to the exercising 
limb increased in proportion to the increase in systemic blood pressure.   This was 
thought to be due to the local release of substances that impair noradrenaline release or 
α-receptor responsiveness such as adenosine  and nitric oxide  when skeletal muscle 
contracts.  In a more recent study by Tschakovsky et al , tyramine was injected into the 
brachial artery to stimulate endogenous release of noradrenaline.  It was found that 
tyramine infusion evoked a vasoconstrictor response that was blunted by forearm 
exercise   in   an   exercise   intensity-dependant   manner.     Sodium   nitroprusside 
administration further attenuated the vasoconstrictor response to tyramine, suggesting 
that nitric oxide is an important mediator of functional sympatholysis in humans. 
Given that type II (fast twitch) skeletal muscle fibres fatigue more rapidly than type I 
(slow twitch) fibres, it is not a surprise that functional sympatholysis is more important 
in fast twitch muscle in rats , and that neuronal nitric oxide synthetase (nNOS) is 
preferentially located in type II fibres . 
The concept of functional sympatholysis has been called into question by Shoemaker et 
al  , who performed experiments on humans looking at rhythmic handgrip exercise 
during lower body negative pressure.  Lower body negative pressure causes pooling of 
blood in the lower limbs and a consequent reduction in venous return: this leads to an 
increase in sympathetic nervous system output to counteract this.  It was found that 
during forearm exercise and recovery following the application of lower body negative 
pressure, forearm blood flow velocity, venous oxygen saturation and pH were lower 
and lactate was higher than with control forearm exercise without lower body negative 
pressure.  They drew the conclusion that the vasodilatatory effects of local metabolites produced   during   forearm   exercise   were   unable   to   counteract   the   sympathetic 
vasoconstriction that was a result of the lower body negative pressure.  The conclusion 
drawn was that functional sympatholysis during exercise of a small muscle group is not 
important in humans.
1.2.6 Baroreflex modulation of the muscle metaboreflex
Post-exercise muscle ischaemia, as first studied by Alam and Smirk , can be used to 
evaluate   the   contribution   of   the   metaboreflex   to   the   effects   of   exercise   on 
cardiovascular regulation.  By exercising a small muscle group and then isolating it 
from the rest of the circulation during recovery, metabolites produced during exercise 
are trapped within the muscle, and cause prolonged metaboreflex activation.  As the 
subject is now at rest, the effects of the mechanoreflex and central command are no 
longer important, and any differences in heart rate or blood pressure relative to recovery 
without muscle ischaemia are due to metaboreflex activation.  This technique has been 
used widely to assess metaboreflex activity .Figure   1.1  Schematic   diagram   of   the   measurement   of   the   ergoreflex   (muscle 
metaboreflex) in humans: this could also apply to blood pressure, heart rate and muscle 
sympathetic nerve activity (MSNA).  PH-RCO= Post-Handgrip Regional Circulatory 
Occlusion.  Diagram reproduced from Scott et al . 
A striking finding of most studies looking at post-exercise muscle ischaemia is that 
although blood pressure remains elevated as a result of continued metaboreflex 
activation, heart rate very rapidly recovers to resting levels .  This could be considered 
surprising, given that metaboreflex activation causes an increase in sympathetic 
activity, and this in turn should cause a sustained increase in heart rate.   This 
observation can be explained by the effect that the metaboreflex-mediated rise in blood 
pressure has on the arterial baroreflex.Arterial baroreceptors are located in the carotid sinus and aortic arch, and they alter 
both cardiac function and vasomotion in response to acute changes in arterial blood 
pressure .  Arterial baroreflex unloading causes a reflex tachycardia and peripheral 
vasoconstriction to restore blood pressure to the “set point”: loading of the baroreflex 
has the opposite effects.  During exercise, the baroreflex is probably reset to a new set 
point to allow a rise in blood pressure .  Dogs lacking an arterial baroreflex (following 
sinoaortic denervation) do not exhibit an immediate rise in blood pressure at the onset 
of exercise .  As it is central command that initiates the initial rise in blood pressure, 
this suggests that resetting of the baroreflex at the start of exercise is also modulated by 
central command.   The baroreceptors then perceive resting blood pressure to be 
“hypotensive” relative to its new operating point with heart rate and systemic vascular 
resistance increasing as a consequence . 
The immediate increase in heart rate that is seen at the onset of exercise is not thought 
to be metaboreflex mediated .  As discussed before, central command causes the initial 
rise in heart rate through withdrawal of resting parasympathetic tone, with metaboreflex 
activation and an increase in sympathetic nerve activity only becoming important as 
exercise progresses .  Work looking at sustained passive stretch of triceps surae in 
humans  suggests that small fibre muscle mechanoreceptors also inhibit cardiac vagal 
activity and therefore increase heart rate . 
During post-exercise muscle ischaemia, central command has been withdrawn, and 
parasympathetic tone therefore returns to resting levels.  This has an inhibitory effect on 
heart   rate   and   therefore   partially   offsets   the   positively   chronotropic   effects   of 
metaboreflex activation on heart rate.  The withdrawal of central command probably also means that the baroreflex “set point” returns to resting levels, and the metaboreflex 
mediated elevation in blood pressure is perceived as abnormal, leading to a further 
increase in parasympathetic activity and a negatively chronotropic effect .  It is the 
combination of these two mechanisms that leads to the rapid fall in heart rate during 
post-exercise   muscle   ischaemia.     The   sustained   elevation   in   blood   pressure   is 
maintained   by   increased   sympathetic   nervous   system   activity   from   continued 
metaboreflex   activation.     In   support   of   this   idea,   it   has   been   observed   that 
administration of atropine during metaboreflex activation in dogs causes a reflex 
tachycardia, with the inhibition of the return of resting parasympathetic tone leading to 
unopposed sympathetic activity .  It has also been observed that there is an increase in 
heart rate variability in humans during post-exercise muscle ischaemia, reflecting an 
increase in parasympathetic nervous system activity during activation of the muscle 
metaboreflex .
Baroreceptor activation also appears to alter the metaboreflex-driven changes in blood 
pressure and MSNA that are seen during exercise.  Work by Cui et al suggests that 
during metaboreceptor activation, the sensitivity of baroreflex control of MSNA in 
humans is elevated and the baroreflex curve is reset, and drew the conclusion that this 
allows “finer tuning” of blood pressure control during exercise .  Attempting to alter 
pharmacologically the rise in blood pressure seen with handgrip exercise also appears 
to have an effect on the baroreflex, with suppression of the blood pressure response 
with nitroprusside augmenting the rise in heart rate and MSNA by 300% and 
administration of phenylephrine to accentuate the increase in blood pressure having the 
opposite effect .   The inhibitory effects of baroreceptor activation on MSNA are 
underlined by the observation that baroreceptor denervation in dogs causes a greater pressor response to exercise following graded reductions in hindlimb perfusion.  The 
mechanism of the blood pressure increase with metaboreceptor activation also appears 
to change with baroreflex denervation, with the increase in blood pressure mediated 
through peripheral vasoconstriction rather than increased cardiac output .
1.2.7 Metaboreflex control of ventilation: a source of controversy.
Although there is clear evidence that the metaboreflex is intimately involved with the 
regulation of blood supply to muscle during exercise in humans, the mechanism of the 
control of ventilation is less clear.
In healthy human subjects at sea level, ventilation at rest is controlled very tightly by 
paCO2.  A small rise in paCO2 leads to diffusion of carbon dioxide across the blood brain 
barrier into the cerebrospinal fluid, creating an acidosis, which is a potent stimulus of 
central chemoreceptors near the ventral surface of the medulla .  Even during exercise, 
when VCO2 may increase 15-fold, there is an almost perfect straight-line relationship 
between ventilation and VCO2 .  It is therefore frequently assumed that a rise VCO2 is 
the main stimulus to increase ventilation at the start of exercise.  This would, however, 
require a rise in paCO2 to initiate the feedback loop, which does not happen : in healthy 
subjects, paCO2 remains steady during exercise and decreases when exercising beyond 
the lactate threshold to correct the resultant metabolic acidosis .  It has also been stated 
that the control of ventilation during heavy exercise cannot be explained fully by lactic 
acid stimulation of arterial chemoreceptors .  Central command  and mechanoreceptors 
may play a role in the sudden increase in ventilation at the start of exercise, and it has been suggested that the increase in pulmonary blood flow caused by an increase in 
cardiac output at the start of exercise is sensed by receptors in the lungs , though a study 
by Grucza  et al  calls this idea into question, by showing no relationship between 
cardiac output and ventilation in the early phase of dynamic exercise and rhythmic-
static exercise .  
Metaboreflex control of ventilation has been studied extensively in animal models, and 
the general consensus is that the metaboreceptor activation does cause a reflex increase 
in ventilation .  It is not possible to conduct such detailed studies on humans, and 
research has therefore focussed on the effects of post-exercise muscle ischaemia on 
ventilation.     Clark  et  al  asked   healthy   volunteers  to   run  on   a  treadmill   with 
sphygmomanometer cuffs inflated round the thighs to arrest blood flow .   It was 
observed that the slope relating ventilation and VCO2 (the ventilatory equivalent) was 
steeper than during control exercise (without thigh cuffs), and this result was taken as 
evidence of a metabolic stimulus arising from working skeletal muscle.  The same 
group also demonstrated that post-exercise muscle ischaemia in healthy subjects leads 
to an increase in ventilation compared with control recovery , and it has been shown 
that restriction of blood flow to exercising muscle using lower body positive pressure 
causes an increased ventilatory response to exercise, even before the production of 
substantial quantities of lactate .  Oelberg et al again addressed this issue using lower 
body negative pressure during leg exercise , and found that this increased ventilatory 
response to exercise correlated strongly with quadriceps pH, with the conclusion that 
metaboreflex-induced hyperventilation is stimulated by muscle acidosis.   It is also 
interesting to note that the small increase in systemic arterial lactate seen with this form 
of exercise was not nearly enough to account for the large increase in ventilation when compared with previously published data.   Electromyographic (EMG) studies in 
humans have shown that the increase in ventilation seen with ischaemic forearm 
exercise is concomitant with the EMG signs of neuromuscular fatigue in the absence of 
the release of metabolites into the systemic circulation, suggesting that neural pathways 
arising from the fatigued muscle cause the ventilatory response . 
Many of the studies that cast doubt on the role that the muscle metaboreflex plays in the 
control of ventilation during exercise involve either differential anaesthetic blockade  or 
patients with a sensory neuropathy .  With anaesthetic blockade, it is difficult to effect a 
complete sensory loss whilst leaving all motor fibres intact, and this raises the question 
of whether subjects exhibit increased levels of central command to compensate, leading 
to an increased ventilatory response.   Strange  et al  exercised a group of patients 
following epidural anaesthesia using electrical stimulation of leg muscle .   The 
ventilatory response to electrical stimulation remained intact even though blood 
pressure responses were abolished.   This could be construed as evidence against a 
ventilatory   metaboreflex,   although   is   raises   the   possibility   of   the   ventilatory 
metaboreflex being a redundant control mechanism that is only important in humans 
under certain circumstances .  It should also be noted that electrical stimulation of 
skeletal muscle leads to a different recruitment order of nerve fibres to voluntary 
exercise, calling into question the validity of experiments using electrical nerve 
stimulation .1.2.8 Post-exercise muscle ischaemia: potential confounding factors
It is important to deal with the subject of muscle discomfort during post-exercise 
muscle ischaemia, as one of the criticisms of the metaboreflex theory of ventilatory 
control during exercise is that occluding the blood supply to a working muscle can be 
uncomfortable and may therefore cause a reflex increase in MSNA and ventilation . 
The numerous experiments on anaesthetised animals go some way to addressing this 
issue, but these data can not necessarily be directly applied to human subjects.  This 
question was dealt with as early as 1938 by Alam and Smirk , who noted that 
discomfort was not necessary to elicit a pressor response to post-exercise muscle 
ischaemia.     Experiments   looking   at   graded   muscle   ischaemia   in   humans   also 
demonstrated a pressor response to post-exercise muscle ischaemia in the absence of 
pain .  The effects of pain on MSNA have not been extensively studied , although it has 
been documented that painful electrical skin stimulation does not have an effect on 
MSNA .  Studies on patients with McArdle’s syndrome also address this question with 
MSNA falling rapidly to resting levels despite the sensation of intense muscle pain 
continuing post-exercise .  It is still possible that muscle discomfort could have an 
effect on ventilation during post-exercise muscle ischaemia, as ventilation is under 
voluntary control to a greater extent than either MSNA or blood pressure.1.3 The muscle metaboreflex in the context of chronic disease
1.3.1 Introduction
The possibility that abnormal metaboreflex function could contribute to exercise 
limitation in chronic disease has been attracting attention.  The first study looking at the 
metaboreflex in disease was probably conducted by Lorentsen in 1972 .  Patients with 
unilateral intermittent claudication were asked to perform leg exercise, and it was found 
that the blood pressure response to exercise was greatly enhanced in the diseased limb 
compared with the normal side.  In contrast, the exercise-induced increases in heart rate 
were similar between the two legs.   This is consistent with flow limitation during 
exercise leading to anaerobic metabolism of glycogen, the development of a muscular 
acidosis and metaboreflex overactivation.   All of the recent studies looking at the 
metaboreflex in disease have, however, concentrated on patients with chronic heart 
failure.
1.3.2 Exercise limitation in heart failure: peripheral factors
Chronic heart failure is a syndrome in which cardiac output is unable to match the 
metabolic demands of the body due to pump failure.  Exercise limitation is a hallmark 
of   chronic   heart   failure,   and   the   cause   of   exercise   limitation   would   appear 
straightforward with a reduction in cardiac output causing inadequate blood flow and 
oxygen delivery to exercising muscle.  There is, however, a lack of correlation between exercise capacity and traditional indices of cardiac function such as cardiac output , 
suggesting that this is not the whole story.  In addition, pharmacological interventions 
aimed at acutely improving cardiac output and femoral artery blood flow do not 
immediately improve leg exercise capacity , and cardiac transplant does not improve 
exercise tolerance immediately .  This raises the possibility that it is not cardiac output 
that limits exercise tolerance in heart failure, but it is a failure of skeletal muscle to take 
up oxygen . 
Numerous studies have documented skeletal muscle abnormalities in patients with 
chronic heart failure.  There is a reduction in muscle bulk and strength  and a shift in 
fibre type towards type 2 (fast twitch glycolytic) .  There are also alterations in muscle 
biochemistry with a reduction in enzymes required for oxidative metabolism of 
glycogen .   This leads to increased reliance on anaerobic metabolism, with earlier 
production of lactate and premature muscle fatigue .  In addition, interventions aimed at 
conditioning the skeletal muscle such as cardiac rehabilitation programmes have been 
shown to improve quality of life and exercise capacity by improving peripheral muscle 
function rather than indices of cardiac function . 1.3.3 The “muscle hypothesis” in chronic heart failure
It has been observed that patients with chronic heart failure demonstrate an exaggerated 
sympathetic nervous system and ventilatory response to exercise .  This has led some 
authors to speculate that anaerobic metabolism in skeletal muscle during exercise 
causes early build-up of metabolites such as lactate and hydrogen ion, which stimulates 
muscle metaboreceptors and leads to an increase in MSNA and ventilation .   The 
increase in sympathetic nervous system activity increases afterload on the already 
failing heart, which has further deleterious effects.  This vicious cycle has been termed 
the “muscle hypothesis” of exercise limitation in heart failure (see fig. 1.2) .Figure 1.2 The “muscle hypothesis” of chronic heart failure.  Reproduced from Piepoli 
et al .  This is an attempt to link the muscle metaboreflex to the pathophysiology of the 
development of skeletal muscle dysfunction and exercise intolerance in chronic heart 
failure.  LV = Left Ventricular, TNF = Tumour Necrosis Factor.1.3.4 The muscle metaboreflex in chronic heart failure
Piepoli  et al  studied the metaboreflex in patients with chronic heart failure using 
rhythmic handgrip exercise to fatigue followed by post-exercise circulatory occlusion 
with a sphygmomanometer cuff .  It was found that the subjects with chronic heart 
failure demonstrated an increased metaboreflex contribution to ventilation and blood 
pressure during post-exercise muscle ischaemia compared with healthy control subjects. 
Leg vascular resistance was assessed using strain-gauge plethysmography, and this was 
also found to be increased during forearm post-exercise muscle ischaemia, suggesting 
an increase in sympathetic nervous system activity.  All subjects were then asked to 
train the forearm muscles for 6 weeks using a “gripper” device, and it was found that 
training led to a reduction in muscle metaboreflex activity in both groups, and this was 
more marked in the group with chronic heart failure.  The conclusion drawn was that 
increased anaerobic metabolism led to an increase in metaboreceptor stimulation, and 
that this could be partially reversed by training the muscle.  More recent studies have 
demonstrated an increase in metaboreflex activity in the lower limb muscles of patients 
with chronic heart failure , that there is a correlation between upper and lower limb 
metaboreceptor activity in heart failure , and that the technique of post-exercise muscle 
ischaemia to assess the metaboreflex in heart failure is reproducible on a different day . 
Other work by the same group looks at metaboreflex activity in relation to symptoms as 
defined by New York Heart Association (NYHA) class of heart failure .  It was found 
that metaboreflex activity correlated with severity of symptoms and VO2 max: there 
was only a very weak correlation between left ventricular ejection fraction and VO2 
max.  The observation that increased metaboreceptor sensitivity is a strong predictor of 
baroreflex impairment and sympathetic nervous system activation  would appear to suggest that a blunted baroreceptor response in chronic heart failure may result in a 
reduction of baroreceptor-mediated inhibition of the metaboreflex, leading to further 
increases in sympathetic activity.  The authors suggest that metaboreflex overactivation 
may initially be a beneficial compensatory mechanism that assists in the physiological 
response to exercise, but in the chronic disease state, excessive stimulation of the 
metaboreflex leads to sympathetic activation and blunted baroreflex control, which may 
be deleterious in the long term with increased cardiac afterload and fluid retention.
Other centres have come to contrasting conclusions regarding the muscle metaboreflex 
in chronic heart failure.   Sterns  et al   studied MNSA responses to static handgrip 
exercise and post-handgrip circulatory arrest in subjects with heart failure and healthy 
controls.  They found a marked attenuation in MSNA response to post-exercise muscle 
ischaemia in subjects with heart failure despite 
31P NMR confirming a similar degree of 
muscle acidosis.  It was concluded that heart failure leads to the attenuation of the 
muscle metaboreflex, perhaps causing a less efficient use of cardiac output during 
exercise.  Shoemaker et al assessed the metaboreflex by asking patients to perform 
rhythmic handgrip exercise whilst the whole exercising forearm was subjected to 
50mmHg of positive pressure .  It was found that metaboreflex contribution to the rise 
in blood pressure was normal in heart failure, despite increased production of lactate 
and hydrogen ions, and the authors speculated that chronic metaboreflex activation 
leads to desensitisation of the nerve fibres, which is offset by the increased production 
of lactate.  Interestingly, it was also found that the augmented blood pressure brought 
about by activation of the metaboreflex did not lead to an improvement in venous 
oxygen saturation or venous metabolite concentrations, again suggesting that this might 
be a redundant control mechanism.Silber et al re-visited the observation that the MSNA rise during non-fatiguing rhythmic 
handgrip exercise is not metaboreflex mediated .  They studied a group of patients with 
heart failure and asked them to perform rhythmic handgrip exercise at 25% of 
maximum voluntary contraction (MVC) .  It was found that this exercise protocol did 
lead to the development of a muscular acidosis in the heart failure patients, but not in 
the control subjects, and it was therefore not surprising that post-handgrip muscle 
ischaemia led to an increased MSNA in this group.  Notarius et al also came to the 
conclusion that metaboreflex activity is increased in heart failure and that this may 
further impair exercise performance and accelerate disease progression . 
In summary, muscle metaboreflex activity is increased in patients with chronic heart 
failure and may contribute to the pathophysiology of exercise limitation and disease 
progression.  Whether chronic over-stimulation of the metaboreflex by the metabolites 
of anaerobic exercise leads to desensitisation of the metaboreflex is a matter that has 
been disputed.  Sinoway and Li, in a recent review article, summarise the issues nicely 
by stating that “whether the muscle metaboreflex is attenuated or accentuated may 
depend on the relative degree of muscle metabolic abnormalities, the degree of 
metaboreceptor desensitisation, and the mode of exercise being performed (rhythmic 
vs. static)” .  The last point is important given the important physiological differences 
between rhythmic and static exercise, and between exercise of a small muscle group 
and whole body exercise.  Experiments on dogs using graded reduction of terminal 
aortic blood flow to stimulate the metaboreflex reveal that heart failure causes a change 
in the mechanism of metaboreflex-mediated increases in blood pressure .  Healthy dogs 
increased blood pressure through an increase in cardiac output, whereas dogs with heart failure, unable to increase cardiac output, responded through an increase in peripheral 
vasoconstriction, presumably through stimulation of the arterial baroreflex.   It can, 
however, be assumed that metaboreflex mechanisms will be different in the context of 
small muscle group exercise in heart failure, when cardiac output will not limit the 
ability to maintain blood pressure.
1.4 Exercise limitation in chronic obstructive pulmonary disease
1.4.1 Pathophysiology of chronic obstructive pulmonary disease (COPD)
Chronic Obstructive Pulmonary Disease (COPD) is one of the major causes of death 
and disability in Scotland, and it is predicted to become the 3
rd most important cause of 
death globally by 2020 .  It is caused by an inflammatory response to inhaled irritants, 
particularly cigarette smoke.  Neutrophilic infiltration and cytokine production lead to 
the development of airway inflammation, and inhaled free radicals cause a disturbance 
of the protease/ anti-protease balance and the development of emphysema .   The 
physiological consequences are progressive airflow limitation and lung hyperinflation, 
the hallmarks of the disease.  It is disappointing that there are no pharmacological 
interventions that influence disease progression.  Inhaled bronchodilators only provide 
symptomatic relief , although there is some debate over whether inhaled corticosteroid 
may slow the decline in FEV1 in severe disease .1.4.2 Exercise limitation in COPD: the role of peripheral skeletal muscle
Exercise limitation is probably the most distressing symptom of COPD, and as lung 
damage is often severe by the time dyspnoea is an important feature, current treatments 
could be considered palliative.  It is often assumed that exercise limitation is caused by 
dyspnoea, with airflow limitation and air trapping causing increased work of breathing 
and dynamic hyperinflation , but it is noteworthy that a significant proportion of 
patients with COPD are limited by peripheral factors such as muscle fatigue .  This 
raises the question of whether exercise is limited by abnormalities in the peripheral 
skeletal muscle .  Similar to the story in chronic heart failure, where exercise capacity 
correlates poorly with indices of haemodynamic function, exercise tolerance in COPD 
is poorly correlated with FEV1.  A much stronger correlation exists between exercise 
capacity and leg muscle mass , and muscle strength is also a good predictor of exercise 
tolerance .  A recent study by Saey et al found that half of their group of patients with 
COPD developed contractile fatigue following a constant work-rate cycle ergometer 
test to exhaustion, and those who developed contractile fatigue did not improve their 
exercise   performance   following   bronchodilator   administration   despite   a   15% 
improvement in FEV1 .  The conclusion drawn was that a significant number of patients 
with COPD are limited by peripheral factors and not ventilatory constraints.  Lactate 
production   by   exercising   muscle   is   also   of   importance.     Patients   with   COPD 
demonstrate a reduced anaerobic threshold, beyond which lactate enters the systemic 
circulation .  The resultant acidosis is a potent stimulus to ventilation, further increasing 
the load on the respiratory system.  Casaburi et al demonstrated that an exercise training programme leads to a lower ventilatory requirement at a given level of work, and this is 
in proportion to the reduction in lactic acidosis .
Although there is no doubt as to the existence of skeletal muscle abnormalities in 
COPD, it should be noted that there is considerable debate as to whether this is simply 
due to deconditioning and whether skeletal muscle dysfunction truly limits exercise 
tolerance . 
1.4.3 Skeletal muscle abnormalities in COPD
Functional, histological and metabolic abnormalities of skeletal muscle have all been 
described in patients with COPD.  Fat free mass may be reduced with preservation of 
body weight , and a reduction in quadriceps muscle cross sectional area has been 
reported .   Numerous studies document a reduction in skeletal muscle strength , 
endurance   and fatigability   compared with control subjects.   Upper limb muscles 
appear to be better preserved than lower limb muscles , possibly due to a greater 
reduction in activity of the lower limbs.   Reduction in strength appears to be 
proportional to the degree of muscle atrophy .   Structural abnormalities include a 
reduction in the proportion of type I (oxidative) fibres, an increase in the proportion of 
type II (glycolytic) fibres and a reduction in muscle capillarity compared with control 
subjects .  Changes in muscle metabolism all favour anaerobic glycolysis: quadriceps 
muscle biopsies have demonstrated reductions in oxidative enzyme capacity in COPD 
patients , and 
31P NMR studies suggest early depletion  and prolonged recovery  of 
phosphocreatine in the quadriceps muscle following exercise.  Oxygen kinetics are slow in COPD , and lactic acidosis is seen earlier in exercise in patients with COPD , placing 
a further load on the respiratory system . 
The various causes of skeletal muscle dysfunction in COPD are a source of much 
discussion.  The abnormalities of muscle function and metabolism are similar to those 
seen in healthy subjects following acute deconditioning .  This has led some observers 
to speculate that skeletal muscle dysfunction in COPD is simply a “side effect” of a 
reduction   in   activity   forced   upon   patients   by   ventilatory   constraints.     Acute 
exacerbations of COPD are known to cause a reduction in skeletal muscle strength , and 
corticosteroid therapy may cause a myopathy .  Other possible contributors include the 
effects of hypoxia and hypercapnia, malnutrition and oxidative stress.  Couillard et al 
demonstrated that exhaustive quadriceps exercise induces local oxidative stress in 
patients with COPD by obtaining muscle biopsies before and 48 hours after quadriceps 
exercise.  They also found a reduction in post-exercise antioxidant activity (as measured 
by glutathione peroxidase activity) in patients with COPD compared with healthy 
control subjects .  Muscle oxidative stress in the patients with COPD in this study was 
associated with reduced quadriceps endurance.1.4.4 Exercise training in COPD
The benefits of exercise training in COPD further underline the importance of 
peripheral skeletal muscle in the development of exercise intolerance.  In the past, it has 
been believed that the benefits of exercise training in COPD are simply psychological, 
as ventilatory constraints would surely prevent the attainment of the critical training 
intensity required to train skeletal muscle .   It is now clear that exercise-based 
pulmonary rehabilitation programmes lead to an improvement in exercise capacity and 
quality of life  and prescription of such programmes is now part of routine care in 
patients with COPD .  Exercise training programmes reduce lactate production at a 
given workload and may therefore also reduce the “burden” on the ventilatory system. 
Benefits have been seen with both strength and endurance training , and high intensity 
endurance training has been shown to provide greater benefit than low intensity training 
.   Troosters  et al  studied a method of distinguishing patients who will respond to 
exercise training from those who will not .  It was found that ventilatory reserve and 
peripheral muscle strength are predictors of the training response, perhaps suggesting 
that patients with no ventilatory reserve do not achieve a muscle training effect and may 
therefore not benefit from pulmonary rehabilitation.  Studies using inspiratory  and 
bilevel  pressure support suggest that such interventions may “offload” the respiratory 
muscles to allow an increase in training intensity, with patients subsequently deriving a 
greater training benefit, but further studies are required.  Heliox, a mixture of helium 
and oxygen which is lower density than room air, does not appear to enable patients to 
increase training intensity .1.4.5 Cachexia in COPD
The development of cachexia in COPD is an important and ominous sign.  Schols et al 
looked retrospectively at body mass index (BMI) and survival in COPD and found that 
low BMI is an independent predictor of mortality .  Body composition also appears to 
correlate with exercise performance, with fat free mass more important than total body 
weight .   BMI may in fact be a misleading measurement, as it fails to distinguish 
between body fat and lean mass.  Subjects with a normal BMI may have a significantly 
reduced fat free mass , and muscle mass appears to be a better predictor of outcome in 
COPD than body weight .  The potential causes of weight loss in COPD are somewhat 
diverse, and include reduced calorie intake, increased energy expenditure due to 
increased oxygen cost of breathing and mechanical inefficiency of skeletal muscle , 
acute exacerbations of COPD  and systemic inflammation.  Reduced skeletal muscle 
mass as determined by creatine-height index has been associated with increased 
circulating levels of IL-6 and TNF-α  and increased levels of acute phase proteins have 
been found in the serum of patients with COPD and a raised resting energy expenditure 
with reduced fat free mass .   Systemic inflammation may also contribute to the 
increased cardiovascular mortality seen in patients with COPD . 
If cachexia and muscle dysfunction in COPD are such strong predictors of mortality, do 
interventions aimed at increasing body mass index lead to an improvement in outcome? 
Studies have looked at both dietary and pharmacological intervention.  The effects of 
dietary intervention have been disappointing, with a number of studies reporting 
negative  results.     A  meta-analysis   by  Ferreira  et  al  concluded  that   nutritional 
supplementation is probably not of benefit in patients with COPD in terms of anthropometric measures or functional exercise capacity .  A more recent study by 
Steiner et al  looked specifically at nutritional supplementation during an exercise-
based pulmonary rehabilitation programme, when a negative calorie balance is likely. 
It was found that the supplemented group gained weight, but only the well nourished 
patients (body mass index > 19kg/m
2) demonstrated a benefit in terms of exercise 
performance.  It is possible that the malnourished patients did not respond because of 
the systemic inflammatory response: Creutzberg et al, in a study looking at nutritional 
supplementation in 24 patients with COPD and fat free mass depletion, discovered that 
an elevated systemic inflammatory response was associated with failure to gain weight . 
Post-hoc analysis of an earlier study by Schols et al  looking at the effects of nutritional 
supplementation on patients with COPD suggested that those who did manage to put on 
weight over the course of the study had a reduced mortality . 
Attempts at pharmacological intervention have also been disappointing.  Burdet et al 
studied the effects of growth hormone in a placebo-controlled study, and found that 
IGF-1 levels increased, but there were no benefits in terms of functional parameters, 
even though lean body mass increased to a greater extent in the treated group compared 
with the placebo group .  Schols et al investigated the effects of the anabolic steroid 
nandrolone in combination with nutritional supplementation in a placebo-controlled 
trial on 217 patients with COPD: there was a greater increase in fat-free mass in the 
nandrolone-treated group, but no effects on functional status .  Other studies looking at 
stanozolol  and oxandrolone  have demonstrated similar results, with increases in lean 
body mass with no improvement in functional status.A recent placebo controlled trial in our department looked at the effects of creatine 
monohydrate supplementation, administered in conjunction with an exercise based 
pulmonary rehabilitation programme.  It was found that creatine supplementation led to 
significant improvements in fat free mass and peripheral skeletal muscle strength and 
endurance  compared  with   placebo  .    More  importantly,   a  clinically   significant 
improvement in quality of life was seen, as assessed by the St George’s Respiratory 
Questionnaire.1.5 Creatine supplementation: a therapeutic intervention?
1.5.1 Creatine metabolism
Creatine is a naturally occurring amino acid found in abundance in skeletal muscle, 
mainly in the form of phosphocreatine .   In healthy adults, the liver and kidneys 
synthesise 1-2 grams per day, supplemented by 1-2 grams daily as part of the normal 
diet : meat and fish have a particularly high content .  The body excretes about 1-2 
grams per day in the form of creatinine, which is cleared by the kidneys.  There is 
evidence that creatine supplementation suppresses endogenous creatine production , 
and excess ingested creatine is simply excreted.  Creatine plays an integral role in 
skeletal muscle energy metabolism, with phosphocreatine acting as a high energy 
buffer: the creatine kinase reaction converts phosphocreatine to creatine, donating a 
phosphate molecule to ADP to create ATP .  It is therefore of particular importance 
during high intensity exercise.  
1.5.2 Creatine supplementation in healthy subjects
Creatine has become one of the most widely used nutritional supplements amongst 
athletes, based on the results of numerous trials in the 1990’s suggesting benefit.  It was 
initially shown in 1993 that short-term creatine supplementation increases the muscle 
creatine pool and improves ability to perform rapid intermittent muscle contractions . 
Numerous trials since then have suggested improvements in athletic performance in sprint events , and it is therefore commonly used as an ergogenic aid in many sports.  It 
is not currently on the International Olympic Committee (IOC) list  of banned 
substances.  There are, however, many negative trials which counter those suggesting 
benefit.  In particular, creatine supplementation does not appear to have an effect on 
endurance exercise.  Ingestion of 20g of creatine daily for 5 days has been shown to 
increase muscle creatine concentration by 20% in healthy subjects, although there is 
significant inter-subject variability in muscle uptake.  Addition of carbohydrate solution 
to creatine supplements increases uptake by skeletal muscle through the effects of 
increased insulin secretion on creatine transport . 
1.5.3 Creatine supplementation in disease
It has also been demonstrated that creatine supplementation may benefit patients with 
chronic   diseases   affecting   the   skeletal   muscles.     Several   months   of   creatine 
supplementation attenuated loss of dominant hand muscle strength and increased fat 
free mass in patients with Duchenne muscular dystrophy ,
 though this was not seen in a 
group of patients with type I myotonic dystrophy   or Huntingdon’s disease .  The 
specific effects of creatine supplementation on respiratory muscles were evaluated in 
patients with amyotrophic lateral sclerosis.  There were no differences in functional 
score, forced vital capacity or maximum voluntary ventilation between creatine and 
placebo .  Short term creatine supplementation in a group of 81 patients with a variety 
of neuromuscular diseases led to an increase in body weight and handgrip strength, 
though this study was not placebo- controlled for the first part, and only single-blinded 
for the second part .  Creatine supplementation has been evaluated in patients with congestive cardiac failure, with significant increases in skeletal muscle total creatine 
and lower limb muscle function following 10 days of supplementation in the absence of 
an exercise training programme .   Creatine has also been shown to attenuate the 
abnormal skeletal muscle response to exercise seen in chronic heart failure, with a 
reduction in lactate at a given work rate . 
1.6 Could the muscle metaboreflex be relevant in COPD?
1.6.1 Chronic heart failure and COPD: a similar story
The  above  literature  review   highlights   some  of   the  striking   similarities   in   the 
pathogenesis of exercise intolerance between chronic heart failure and COPD .  Both 
diseases are now recognised to cause more than simple single-organ failure leading to 
exercise dysfunction, with traditional markers of disease severity (ejection fraction and 
FEV1) shown to be poor predictors of exercise capacity.   Similar skeletal muscle 
functional and metabolic abnormalities have been described with similar improvements 
in   quality   of   life   and   exercise   performance   with   exercise-based   rehabilitation 
programmes.  The development of cachexia conferring a poor prognosis and the role of 
systemic inflammation has been recognised in both diseases.   Even the “dyspnoea 
spiral” proposed by Préfaut et al , reproduced in  figure 1.3, bears similarities to the 
“muscle hypothesis” proposed in cardiac failure by Piepoli et al , with a cyclical model 
of exercise intolerance due to dyspnoea and early muscle fatigue with subsequent 
avoidance   of   physical   activity   and   deconditioning   leading   to   further   exercise 
intolerance.Figure 1.3  The dyspnoea spiral of COPD.  Reproduced from Serres et al .  1.6.2 Autonomic nervous system function in COPD
Another important area in which there are similarities between chronic heart failure and 
COPD concerns the development of abnormalities of the autonomic nervous system. 
Several studies have documented reduced heart rate variability in patients with COPD, 
suggesting a loss of resting parasympathetic tone .  Heindl et al studied 11 patients with 
chronic respiratory failure and noted an increase in heart rate and MSNA at rest 
compared to control subjects .  It was found that oxygen inhalation decreased MSNA, 
which is consistent with the observation that acute hypoxaemia is known to increase 
muscle sympathetic nerve activity (MSNA) in healthy humans through stimulation of 
arterial chemoreceptors .   This would appear to suggest that increased sympathetic 
nervous system activity is due to chronic hypoxaemia, but it has also been speculated 
that increased work of breathing in COPD leads to stimulation of the muscle 
metaboreflex.  A study by St Croix et al looked at the effects of fatiguing inspiratory 
muscle work in healthy humans demonstrated an increase in MSNA in the leg as 
fatigue approached .  The same group then demonstrated that similar exercise causes an 
increase in leg vascular resistance .  It was noted in the discussion that the diaphragm is 
richly innervated by group III and IV afferent nerve fibres, which led to the conclusion 
that this increase in MSNA was due to activation of the metaboreflex in the diaphragm 
muscle.  It is interesting to note that metaboreflex activation may also have effects on 
the respiratory system, with one study showing that metaboreflex activation leads to a 
reduction in airway resistance following methacholine-induced bronchospasm in a 
group of asthmatic patients, presumably also mediated by the sympathetic nervous 
system .  Excessive   sympathetic   nervous   system   activation   in   COPD,   together   with   the 
observation that there are similar skeletal muscle abnormalities as are seen in chronic 
heart failure, leads to the intriguing possibility that there is up-regulation of muscle 
metaboreflex activity in COPD.  Creatine supplementation improves skeletal muscle 
function in COPD, which raises the question of whether it also leads to a reduction in 
metaboreflex activity.
1.7 The Aims of this thesis.
The muscle metaboreflex has been shown to be of importance in the regulation of 
oxygen delivery to exercising skeletal muscle through its effects on ventilation, blood 
pressure and systemic vascular resistance.  Studies on metaboreflex activity in chronic 
heart failure, a disease characterised by alterations in muscle structure and metabolism, 
have suggested that metaboreflex over-activity may contribute to the pathophysiology 
of exercise limitation.  As patients with chronic obstructive pulmonary disease (COPD) 
suffer from similar abnormalities of skeletal muscle, this thesis aims to evaluate further 
the metaboreflex in COPD and to determine whether it is possible to alter metaboreflex 
activity in COPD by supplementation with creatine monohydrate.A review of the literature has identified the following research questions:
1. Is it possible to measure the muscle metaboreflex in patients with COPD using 
post-exercise forearm muscle ischaemia, and is the muscle metaboreflex up-
regulated in patients with more severe COPD?
2.  Can pulse transit time be used to measure muscle metaboreflex activity during 
post-exercise muscle ischaemia?
3. Is the muscle metaboreflex attenuated in patients with autonomic nervous 
system dysfunction secondary to diabetes mellitus?
4. Does creatine loading have any effects on forearm strength or endurance, 
respiratory muscle strength or body weight in patients with COPD?
5. Does creatine loading have any effects on forearm muscle metaboreflex activity 
in patients with COPD?Chapter 2
Materials and MethodsMaterials and Methods
2.1  The muscle metaboreflex in patients with stable COPD
The aim of the initial study was to measure the muscle metaboreflex in a group of 
subjects with COPD and to determine whether markers of disease severity correlate 
with ergoreflex activity.  The protocol described is adapted from that of Piepoli et al .
2.1.1 Ethical considerations
Ethical approval for this study was obtained from the Glasgow Royal Infirmary Local 
Research Ethics Committee before this study commenced.   All patients provided 
written informed consent prior to participation in the study.
2.1.2 Patient recruitment
Sixteen subjects were recruited from the outpatient clinics of the Department of 
Respiratory Medicine at Glasgow Royal Infirmary.  Adverts were placed in the clinics 
to alert medical staff of the study, and permission was sought from patients to contact 
them by telephone at a later date.  Patients with stable Chronic Obstructive Pulmonary 
Disease (COPD) were invited to participate in the study, which involved two visits to 
the Pulmonary Function Testing laboratory- one for a standard set of pulmonary function tests (as part of routine care) and one for muscle metaboreflex measurement. 
We defined “stable” COPD as the absence of hospitalisation, oral corticosteroid or 
antibiotic use or exacerbation in the preceding 6 weeks.  COPD was defined according 
to  the  criteria  of  the  Global  Initiative  for  Obstructive  Lung  Disease  (GOLD): 
FEV1/FVC ratio <70% with less than 15% bronchodilator reversibility .  All patients 
had a smoking history of at least 20 pack years.  A clinical history was taken and 
hospital casenotes were reviewed to exclude patients with unstable cardiac disease or 
cardiac failure, significant neurological or locomotor disease, active malignancy or 
advanced renal or hepatic disease.
2.1.3 Pulmonary function testing
Pulmonary Function Testing was performed as part of routine care, and organised from 
the   outpatient   clinic.     All   equipment   was   calibrated   in   accordance   with   the 
manufacturers’ instructions on the morning of the visit.  Patients were asked to refrain 
from taking inhaled or nebulised therapy on the morning of the visit, and spirometry 
was performed according to standard procedures (V6200 Autobox, SensorMedics Corp, 
Anaheim, USA).  The best of three efforts was taken for FEV1 and FVC, ensuring that 
there was less than 10% variability between the three tests.  Reversibility testing was 
then performed using 5mg of nebulised salbutamol.  Spirometry was repeated after 15 
minutes.   Standard protocols were used to measure lung volumes by body box 
plethysmography (V6200 Autobox, SensorMedics Corp, Anaheim, USA) and single 
breath transfer factor for carbon monoxide (Transflow system, Model 540, Morgan 
Medical, Kent, UK).2.1.4 Patient information
A full medical history was taken from all patients, including past medical history, 
recent  use  of  corticosteroids,   smoking  history,   medication  history  and  Baseline 
Dyspnoea Index .  A brief physical examination was also conducted, and height and 
weight were measured with shoes removed.
2.1.5. Muscle metaboreflex assessment
The activity of the muscle metaboreflex was assessed using the method of forearm 
exercise followed by post-exercise muscle ischaemia.  Forearm exercise to fatigue leads 
to the production of metabolites such as lactate, hydrogen ion, prostaglandins and 
adenosine, which have been shown to stimulate the muscle metaboreflex.  Occlusion of 
the circulation to and from the exercised muscle on cessation of exercise traps such 
metabolites in the muscle, leading to sustained metaboreflex activation for as long as 
the occlusion is maintained.  This manifests itself as a sustained rise in blood pressure 
and ventilation, which can be measured non-invasively.  A direct comparison can then 
be made with “control” recovery (exercise followed by recovery without circulatory 
occlusion), to allow estimation of metaboreflex activity.  We also assessed the effects of 
circulatory occlusion at rest to exclude the possibility that this was having an effect on 
measured variables.Subject preparation
Subjects were asked to refrain from drinking caffeine or smoking in the 4 hours 
preceding the visit.  Where possible, subjects were also asked to refrain from taking 
inhaled beta agonists during this period.  The protocol was explained in detail to the 
patient, following which there was an opportunity for familiarisation with the exercise 
and monitoring equipment.
Exercise
The forearm muscles of the dominant arm were exercised using a hand strengthener 
device designed to train the muscles of rock climbers (Gripmaster Hand Strengthener, 
DMM Products, Pawcatuck, CT, USA).  Subjects were asked to squeeze the device to 
the beat of a metronome set at 40 beats per minute.  Encouragement was given to 
squeeze the device as hard as possible, and the forearm was supported on the arm of a 
chair to avoid the use of other muscles.  Subjects were asked to exercise to fatigue, and 
verbal encouragement was given to this effect throughout the exercise run.   On 
cessation of exercise, instructions were given to relax completely, and the handgrip 
device was taken away.  The time exercised was noted, and subjects were asked to 
exercise for the same time during the second exercise run.Measurements made
Throughout all parts of the protocol, blood pressure and heart rate were measured every 
30 seconds using an automated sphygmomanometer with the cuff on the non-dominant 
arm.   Results were documented by hand.   A metabolic cart (Medical Graphics 
Corporation, St Paul, Minnesota) was used to measure minute ventilation, respiratory 
rate, VCO2, and VO2 continuously.  The nose was sealed with a clip, and an analyser 
sampled expiratory gas continuously from the mouthpiece.   Results were displayed 
online on a computer screen, and downloaded to an Excel spreadsheet at the end of the 
test.     Familiarisation   with   the  rubber   mouthpiece   took   place   before   the  study 
commenced, and it was ensured that all variables were stable for at least 2 minutes 
before the start of exercise.
Protocol
There were 3 parts to the protocol:
1. Cuff inflation at rest.      
This always took place at the start of the study to allow familiarisation with the 
equipment.  Once all variables to be measured had been stable for 2 minutes, 
the sphygmomanometer cuff was inflated to 200mmHg (or 20mmHg above 
systolic blood pressure, whichever was greater) for 3 minutes, using a hand 
pump.  The mercury column of a manual sphygmomanometer was connected 
to the cuff with oxygen tubing, and this was used to ensure that the pressure 
was maintained.  The pressure was topped up if necessary using the hand pump.  The cuff was then deflated, and measurements continued for a further 3 
minutes.  The subject was encouraged to relax at all times, and it was recorded 
at the end whether there had been any pain or discomfort.
2. Control exercise.      
Once all measured variables had been stable for 2 minutes, the subject was 
given the handgrip device and asked to start exercising as described above. 
Encouragement was given to exercise for as long as possible and not to move 
any part of the body except the exercising muscle.  When the patient gave a 
pre-arranged hand signal suggesting an inability to continue, the handgrip 
device was taken away and measurements continued for a further 6 minutes.
3. Exercise followed by cuff occlusion.      
Once all measured variables had been stable for 2 minutes, the same exercise 
protocol   as   described   above   was   followed.     At   peak   exercise,   the 
sphygmomanometer cuff was inflated round the upper part of the exercising 
arm using a hand pump, and the subject was asked to relax completely.  The 
pressure in the sphygmomanometer cuff was monitored using a mercury 
column, and care was taken to maintain the pressure at 200mmHg or 20mmHg 
above systolic blood pressure, whichever was higher.  The hand pump was 
used to top up the pressure in the sphygmomanometer cuff as necessary.  Cuff 
occlusion was maintained for 3 minutes, at which point the cuff was deflated 
and measurements continued for a further 3 minutes.Cuff inflation at rest took place at the start of the study, and the other 2 parts of the 
protocol followed in random order.  We allowed 30 minutes of rest between the two 
parts of the protocol involving forearm exercise.
2.1.6. Data analysis
Data were tested for normality using a Shapiro-Wilk test.  Results are all given as mean 
± standard error of the mean (SEM).  Resting values were taken as the mean of the 60 
seconds before the start of exercise.  Peak exercise values are the mean of the last 30 
seconds of exercise.  To evaluate the effects of regional circulatory occlusion (RCO) 
(and therefore metaboreflex contribution to measured variables), the area under the 
curve was calculated for the 3 minutes of post-exercise RCO and the equivalent 3 
minute period of control recovery.  Resting values were subtracted, and this figure was 
expressed as a percentage of the difference between resting and peak exercise 
measurements.  The following formula was therefore used:
% Metaboreflex contribution = (Peak exercise value – Resting value) divided by 
(Mean of period of RCO – Resting value) multiplied by 100
To compare the effects of cuff inflation with control recovery, either a paired Student’s 
t-test or a Wilcoxon signed-rank test was used after testing for normality with a 
Shapiro-Wilk test (GB-Stat version 8, Dynamic Microsystems Inc, Silver Spring, MD, USA).  To compare the effects of post-exercise RCO between patient groups, either an 
unpaired Student’s t-test or a Mann-Whitney U test was used, depending on normality. 
Changes in each variable across time were compared using two-way ANOVA followed 
by Newman-Keuls post hoc analysis when significant F-values were obtained.  A p 
value of <0.05 was considered statistically significant.2.2. The Assessment of the muscle metaboreflex using pulse transit time
The aim of this study was to determine whether Pulse Transit Time (PTT) can be used 
to measure muscle metaboreflex activity.
2.2.1 Pulse transit time measurement
Pulse Transit Time is defined as the time taken for a pulse wave to travel between two 
arterial sites.  The physiological basis of pulse transit time is discussed in more detail in 
chapter 4.  It is difficult to measure a pulse wave at two sites, so the “R” wave of the 
ECG tracing can be used as a surrogate for one site, with a pulse oximetry probe on a 
finger or toe detecting the pulse wave at a peripheral site.  Commercial software is 
available to measure the time difference between such signals.  One such device is the 
RM 60, manufactured by DeVilbiss, and this is designed for use in the field of sleep 
medicine (RM60; DeVilBiss, France).  Electrocardiogram leads are attached to stickers 
on both shoulders and the area of the chest overlying the apex beat of the heart, and a 
pulse oximetry probe is placed on a finger or toe.  Both devices are then plugged into a 
battery-operated box and measurements of heart rate, oxygen saturations and PTT are 
made continuously.  The data is then downloaded onto a computer and it is possible to 
access the raw data for further analysis (figure 2.1).Some improvements were made to the equipment used for this experiment.  To achieve 
more rapid sphygmomanometer cuff inflation following exercise, a foot pump was 
connected to the circuit using oxygen tubing.  This enabled inflation of the cuff from 
0mmHg to 200mmHg in about 0.5 seconds, preventing some escape of metabolites 
from the forearm circulation.  
We also used a different method of forearm exercise.  The Medical Physics department 
at the Southern General Hospital, Glasgow made us a handgrip device to our own 
specifications (figure 2.2).
A   commercially   available   spring   loaded   handgrip   device   (Power   Hand   Grip, 
Rehabmart, Winterville, GA, USA) was fitted with a sensor which measured the 
distance between the two arms of the device.  This was connected to an electronic box 
which converted this signal to an LED display of 10 lights, allowing the operator to 
visualise the force generated by squeezing the handgrip device.   To calibrate the 
handgrip device, it was clamped horizontally to a table and weights were suspended 
from the upper arm.  A dial allowed us to calibrate the LED display according to which 
weights were used.  A careful record was kept of how the device was calibrated before 
each patient visit to ensure reproducibility.
The handgrip device was calibrated at the start of each patient visit as follows.  The 
subject was familiarised with the equipment and encouraged to try gripping the device. 
The subject was then asked to grip the device as hard as possible with the dominant 
hand, and at maximum force, the dial on the side of the box was turned until all of the 
LED lights lit up.   On relaxation, all of the LED lights went out.   Subsequent contractions then lit up a number of the lights according to the force generated- it was 
therefore possible to ensure that each contraction represented a fixed percentage of 
maximum voluntary contraction.Figure 2.1 Recording Pulse Transit Time
RM60 Data Recorder
Pulse Oximetry Probe
ECG Pads
Photograph of the DevilBiss RM60 equipment used to measure pulse transit time.  The 
pulse oximetry probe and ECG electrodes both plug in to the data box.  Data can be 
viewed “online” on a laptop computer.Figure 2.2 Handgrip exercise device
LED Display (1-10) Sensor
Arms of handgrip device
Photograph of the forearm exercise equipment, custom-built by the Department of 
Medical Physics at the Southern General Hospital, Glasgow.2.2.2 Ethical considerations
Ethical approval for this study was obtained from the Glasgow Royal Infirmary Local 
Research Ethics Committee before this study commenced.   All patients provided 
written informed consent prior to participation in the study.
2.2.3 Subject recruitment
We recruited eight healthy volunteers for this study, which involved one 2-hour visit to 
our laboratory.  All subjects were members of staff at Glasgow Royal Infirmary.  A 
medical history was taken to exclude subjects with significant cardiac, respiratory, 
neurological, locomotor or neoplastic disease.  Subjects were all non-smokers.
2.2.4 Exercise protocol
Subject preparation
The protocol was thoroughly explained to the subject, and there was an opportunity for 
familiarisation with the exercise equipment.  The handgrip device was then calibrated 
as described above, with the subject performing a maximal voluntary contraction with 
the dominant arm whilst seated: the forearm was supported on the arm of the chair.  The 
RM60 was then set up using a laptop computer: the time on the computer was 
synchronised with a wristwatch, and data recording commenced.   With the subject 
seated upright on a chair, the pulse oximetry probe was placed on the 2
nd toe of the right foot.  A blanket was wrapped round the foot to secure the probe and ensure adequate 
circulation, and it was plugged into the data recorder.  Three ECG electrodes were fixed 
to the chest wall: on the anterior of the right and left shoulders over a bony prominence, 
and over the apex of the heart at the 5
th intercostal space in the mid-clavicular line.  A 
wrist sensor was then placed over the radial artery of the non-dominant arm to measure 
blood pressure.  Blood pressure was measured every 10-15 seconds using the principle 
of arterial tonometry.  The wrist device intermittently applies gentle pressure to the 
radial artery to create a waveform, from which blood pressure is calculated (Vasotrac 
205A; Medwave, St Paul, Minnesota).   This machine has been validated against 
invasive blood pressure monitoring, with excellent correlation .   The machine was 
calibrated each time it was used as per the instructions of the manufacturer.  The subject 
was asked not to move this arm for the entire duration of the experiment.
Exercise
The subject was seated comfortably with the dominant forearm rested horizontally on a 
table.  At the commencement of exercise, the metronome was started at a rate of 45 
beats per minute and the handgrip device was placed in the subject’s dominant hand. 
The subject was asked to squeeze the device intermittently to the beat of the 
metronome, and encouragement was given to achieve “7” on the LED display with each 
contraction.  Exercise was terminated when a pre-arranged signal was given to suggest 
fatigue, or when “7” was not reached on the display on 3 consecutive contractions 
despite verbal encouragement.Protocol
There were 3 parts to the protocol: cuff inflation at rest, control exercise, and exercise 
followed by cuff occlusion.  The protocol was identical to that followed in section 1, 
where it is described in detail.  Cuff inflation at rest took place at the start of the study, 
and the other 2 parts of the protocol followed in random order to allow for any potential 
effects of low frequency muscle fatigue on the second exercise run.  Thirty minutes of 
rest was allowed between the two parts of the protocol involving forearm exercise.
Measurements made
Blood pressure and heart rate were measured every 10-15 seconds with the “Vasotrac”, 
and readings were stored in the memory for later analysis.  Pulse transit time was 
monitored continuously with the RM60.   At the end of each visit, the RM60 was 
connected to a laptop, and the results were downloaded using dedicated software. 
Blood pressure and heart rate readings were entered into an excel spreadsheet direct 
from the “Vasotrac”.
2.2.5 Data analysis
Data from the RM60 was displayed in a dedicated programme as a graph, with time on 
the “x” axis and pulse transit time, heart rate and oxygen saturation on the “y” axis.  A 
readout of the exact pulse transit time at any given time was displayed to the left hand 
side of the graph: moving the cursor along the “x” axis generated a PTT reading every 
second.  It was not possible to download the raw data directly onto a spreadsheet, so the 
data was entered manually.To obtain resting values, readings were averaged over the 60 seconds before the 
commencement of exercise.  Peak exercise values were obtained by averaging readings 
over the last 30 seconds of exercise.  To quantify the effects of regional circulatory 
occlusion (RCO), the area under the curve was taken for each variable for the 3 minutes 
following   peak   exercise   during   cuff   inflation.     This   was   compared   with   the 
corresponding 3 minute period following peak exercise during the protocol without 
RCO.  For the control cuff inflation, resting values were taken as described above and 
compared with the area under the curve for the duration of cuff inflation.
Data were checked for normality using a Shapiro-Wilk test.  Statistical analysis was 
then carried out using a paired Student’s  t-test or repeated-measures analysis of 
variance where appropriate (GB-Stat version 8, Dynamic Microsystems Inc, Silver 
Spring, MD, USA).  Figure 2.3 Sample of Pulse Transit Time Tracing
Sample tracing printed out from the computer screen.  Oxygen saturations, pulse transit 
time and heart rate are displayed along the “y” axis, and time is displayed along the “x” 
axis.  This chart displays PTT so that a fall in PTT leads to movement up the “y” axis.
1.  The effects of handgrip exercise followed by control recovery: there is a gradual fall 
in PTT throughout the duration of exercise, which then returns to baseline during 
recovery.  
2.  The effects of post-exercise cuff inflation: PTT again falls with handgrip exercise, 
and remains below baseline values for the duration of sphygmomanometer cuff 
inflation.  PTT then returns to baseline with cuff deflation.
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tracing2.3 The Muscle Metaboreflex in Patients with Diabetic Autonomic Neuropathy
The aim of this study was to determine whether the muscle metaboreflex is attenuated 
in patients with diabetic autonomic neuropathy.
2.3.1 Ethical considerations
This study was approved by the Glasgow Royal Infirmary Local Research Ethics 
Committee, and all subjects provided written informed consent prior to participation in 
the study.
2.3.2 Subject recruitment
We recruited patients from the outpatient department of the Department of Diabetes and 
Endocrinology at Glasgow Royal Infirmary.  Patients with autonomic neuropathy were 
selected from a database and invited to participate in the study.  A group of patients 
with diabetes and no symptoms of autonomic neuropathy was recruited from the clinic. 
As far as possible the two groups were matched for age and duration of diabetes 
mellitus.
Subjects with a definite diagnosis of Type I diabetes mellitus were included in the 
study.  The nature of this group of patients meant that a significant number had other 
complications of diabetes such as hypertension, diabetic retinopathy and ischaemic heart disease.   We excluded subjects with unstable ischaemic heart disease, atrial 
fibrillation, cardiac failure, respiratory disease, neoplastic disease or locomotor disease 
which precluded exercise testing.  All patients on beta blockers or other rate limiting 
cardiac drugs were excluded.
2.3.3 Baseline data collection
Baseline blood tests were taken as part of routine clinical care.   Casenotes were 
reviewed for recent urea and electrolytes and haemoglobin A1C.  A detailed history was 
taken of duration of diabetes, smoking habits, past medical history and current 
medications.
2.3.4 Protocol
The study consisted of 2 visits.  The first visit lasted an hour and included consent, 
medical   history   and   autonomic   function   testing.     Assessment   of   the   muscle 
metaboreflex took place during the second visit, which lasted about 90 minutes.
Visit 1. Autonomic function testing.
The protocol that we used was that of Ewing and Clarke .  This is a series of 5 tests 
designed to assess the sympathetic and parasympathetic components of the autonomic 
nervous system.  Testing took place in a quiet room, and the subject was asked to lie on the couch and relax for 10 minutes before testing.  There were 5 components to the 
autonomic testing:
· Heart rate variation  during deep breathing.       This depends  on an intact 
parasympathetic nervous system.  With the patient lying supine, 12-lead ECG 
electrodes were fitted in the standard manner.  The ECG recording commenced, 
and the subject was asked to breathe deeply at 6 breaths per minute (5 seconds 
in, 5 seconds out).  Recording continued for 1 minute.  The maximum and 
minimum R-R intervals during each breathing cycle were then measured with a 
ruler and converted to beats per minute: the result was expressed as the mean of 
the difference between maximum and minimum heart rates for the six measured 
cycles.  “Normal” was defined as >14 beats per minute (bpm), “borderline” as 
11-14 bpm and “abnormal” as <11 bpm.
· Heart   rate   response   to   Valsalva   manoeuvre.        This   is   again   a   test   of 
parasympathetic function.  During the strain period of the Valsalva manoeuvre, 
the blood pressure drops and the heart rate rises: after release, the blood 
pressure rises and “overshoots” leading to a fall in heart rate mediated by the 
vagus nerve.  The subject was asked to sit on the couch at 45 degrees and ECG 
recording commenced.  The subject was then given a mouthpiece attached to a 
sphygmomanometer and asked to blow into the mouthpiece, maintaining the 
pressure at 40mmHg for 15 seconds.  This test was performed 3 times with one 
minute of rest in between.  The result was expressed as the Valsalva ratio, the 
ratio of the longest R-R interval after the manoeuvre to the shortest R-R interval during the manoeuvre.  “Normal” was defined as a ratio of >1.20, “borderline” 
as 1.10-1.20 and “abnormal” as <1.10.
· Heart rate response to standing.       On standing, there is an immediate reflex 
tachycardia, which should be followed by a relative overshoot bradycardia 
mediated by the vagus nerve.  The subject was asked to lie supine on the couch 
during continuous ECG monitoring, then stand up unaided: this point was 
marked on the ECG.  The shortest R-R interval at or around the 15
th beat and the 
longest R-R interval at or around the 30
th beat after standing were measured 
with a ruler.  This was expressed as the 30:15 ratio: “normal” was defined as 
>1.04, “borderline” as 1.00-1.04 and “abnormal” as <1.00.
· Blood pressure response to standing.      Pooling of blood in the legs on standing 
causes a drop in blood pressure, which should be rapidly offset by peripheral 
vasoconstriction mediated by the sympathetic nervous system.  Before the heart 
rate response to standing test described above, blood pressure was measured 
using an automated sphygmomanometer.  Blood pressure was then repeated 
after the subject stood up.  A normal result was defined as a fall in systolic 
blood pressure of less than 10mmHg, “borderline” was 10-29mmHg and 
“abnormal” was >29mmHg.
· Blood pressure response to sustained handgrip.      During sustained handgrip there 
should be a rise in blood pressure due to a sympathetically-mediated heart rate-
dependent increase in cardiac output.  Blood pressure was measured 3 times at 
rest.  A handgrip dynamometer was then used to determine maximal voluntary contraction (MVC) of the dominant arm whilst seated.  The subject was then 
asked to maintain handgrip at 30% of MVC for a total of 5 minutes, and blood 
pressure was recorded from the non-dominant arm at 1 minute intervals.  The 
result was expressed as the difference between the highest diastolic blood 
pressure during handgrip exercise and the mean of the three resting readings.  A 
normal result was defined as a rise in diastolic blood pressure of more than 
15mmHg,   “borderline”   was   11-15mmHg   and   “abnormal”   was   less   than 
11mmHg.
There were two doctors present during autonomic function testing: one to operate the 
ECG machine and mark the tracings, and one to instruct the patient.  All tracings were 
analysed at the end of the study so that the doctor performing visit 2 was blinded from 
the results of the autonomic testing.  All ECG tracings were analysed by Dr Babulyeb 
Mukhopadhyay, a Specialist Registrar in Diabetes and Endocrinology at Glasgow 
Royal Infirmary.  Autonomic neuropathy was defined as definite abnormalities in 2 or 
more of the above tests.
Visit 2. Metaboreflex assessment.
Assessment of the metaboreflex followed a similar protocol to that described above. 
Subjects were asked to refrain from smoking or caffeine during the 4 hours prior to the 
visit.   Repetitive forearm exercise to fatigue was carried out at 70% of maximum 
voluntary contraction at a rate of 45 contractions per minute.  Blood pressure and heart 
rate were measured every 10-15 seconds by arterial tonometry (Vasotrac 205A; 
Medwave, St Paul, Minnesota).  Minute ventilation, VO2, VCO2 and respiratory rate were measured continuously from exhaled gas sampled from a rubber mouthpiece by a 
metabolic cart (Medical Graphics Corporation, St Paul, Minnesota).  There were again 
3 parts to the protocol, the order of which was varied randomly: 
· Cuff inflation at rest:     3 minutes of resting measurements, following which a 
sphygmomanometer cuff was rapidly inflated, using a foot pump, to 200mmHg 
(or 20mmHg above systolic blood pressure) for 3 minutes.  Three minutes of 
recovery.
· Forearm exercise followed by control recovery:     3 minutes of rest followed by 
repetitive forearm exercise to fatigue.   This was followed by 6 minutes of 
normal recovery.
· Forearm   exercise   followed   by   cuff   occlusion:      3   minutes   of   resting 
measurements followed by repetitive forearm exercise to fatigue.   At peak 
exercise, a sphygmomanometer cuff was inflated round the upper part of the 
exercising arm to 200mmHg (or 20mmHg above systolic blood pressure) for 3 
minutes and the subject was asked to relax.  Following this, there was a further 
3 minutes of recovery.
The control cuff inflation always took place first, followed by the two parts involving 
exercise in random order.  2.3.5 Data analysis
Results are all given as mean ± standard error of the mean.  Resting values were taken 
as the mean of the 60 seconds before the start of exercise.  Peak exercise values are the 
mean of the last 30 seconds of exercise.  To evaluate the effects of regional circulatory 
occlusion (RCO), a mean was taken of the 3 minutes of post-exercise RCO and 
compared with the equivalent period of control recovery.  As the two exercise runs 
were performed on the same group of patients, a paired Student’s t-test was used after 
testing for normality using a Shapiro-Wilk test.  To compare the effects of post-exercise 
RCO between groups, an unpaired Student’s  t-test was used after checking for 
normality.   Changes in each variable across time were compared using two-way 
ANOVA followed by Newman-Keuls post hoc analysis when significant F-values were 
obtained (GB-Stat version 8, Dynamic Microsystems Inc, Silver Spring, MD, USA).  A 
p value of <0.05 was considered statistically significant.2.4 The effects of creatine supplementation on patients with stable COPD
The purpose of this study was to determine the effects of creatine supplementation on a 
group   of   patients   with   stable   COPD.     Primary   outcome   measure   was   muscle 
metaboreflex activity, and other variables measured included body weight, forearm 
muscle strength, forearm muscle endurance and respiratory muscle strength.
2.4.1 Ethical considerations
This study was approved by the Glasgow Royal Infirmary Local Research Ethics 
Committee, and all subjects provided written informed consent prior to participation in 
the study.
2.4.2 Subject recruitment
Fifteen patients were recruited from the outpatient department of the Department of 
Respiratory Medicine at Glasgow Royal Infirmary.  All patients had a diagnosis of 
COPD as per the guidelines of the Global Initiative for Obstructive Lung Diseases 
(GOLD) .  Patients who had suffered an exacerbation during the previous 6 weeks were 
excluded: we defined an exacerbation as a deterioration in symptoms requiring 
hospitalisation, a visit to primary care or a course of antibiotics or oral corticosteroids. 
Other exclusion criteria were unstable cardiac disease or cardiac failure, significant 
neurological or locomotor disease, active malignancy or advanced renal or hepatic 
disease  as  determined  by  hospital casenote  review,  patient  history  and  clinical examination.  We also excluded patients with diabetes mellitus because of the glucose 
load in the creatine supplements.
2.4.3 Patient screening
Suitable patients were identified at outpatient clinics and followed up through telephone 
contact.  A series of questions was asked to confirm suitability, and pulmonary function 
tests were conducted as part of routine clinical care to confirm the diagnosis of COPD, 
as described above.   At the first visit, a full medical history was taken, including 
smoking   history,   current   and   previous   medications,   exacerbation   history   and 
corticosteroid use.
2.4.4 Study design
This was designed as a randomised, double-blind, placebo-controlled crossover study 
looking at the effects of loading with creatine monohydrate for 10 days compared with 
placebo.  There was at least a 2 week washout period between the 2 arms of the study 
(figure 2.4).2.4.5 Creatine supplementation
A dose of creatine monohydrate was chosen based on previous studies demonstrating 
benefit .  We chose to use 5 grams of creatine monohydrate three times daily for 10 
days.  The addition of glucose to creatine during a period of loading has been shown to 
augment creatine retention by skeletal muscle through the actions of insulin .  We 
therefore elected to mix 30 grams of glucose monohydrate with each dose.  This also 
allowed a placebo to be developed consisting of 30 grams of glucose monohydrate 
alone.
The   creatine   monohydrate   used   in   this   study   was   obtained   from   Flamma 
pharmaceuticals (Flamma, Bergamo, Italy), and a certificate provided by the company 
confirmed its purity.  The creatine was delivered by Arena Pharmaceuticals (Arena 
Pharmaceuticals Ltd, Buckingham, UK) and given to our hospital pharmacy for storage. 
The pharmacy department at the Western Infirmary, Glasgow prepared the creatine 
supplements and the placebo, which were stored until use by the pharmacy at Glasgow 
Royal Infirmary.   Each individual supplement was dispensed in a brown medicine 
bottle, and the bottles holding the creatine supplement and the placebo were identical in 
appearance.  Each patient “pack” therefore consisted of 30 identical bottles, enough for 
10 days of supplementation.  Randomisation was carried out by the pharmacist at the 
Western Infirmary, and the “break codes” were held in a sealed envelope until 
completion of the study.Figure 2.4 Design of the creatine study
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(10 days) (2 weeks) (10 days)
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VISIT 1 VISIT 2 VISIT 3              VISIT 4
This was a randomised, double-blind, Placebo-controlled crossover study with a 2 week 
washout period between the two arms.2.4.6 Study protocol
Each patient visit was identical, and tests were always carried out in the same order.  As 
far as was possible, all patient visits took place at the same time of the day and in the 
same laboratory.  The visit was divided up as follows:
At the start of the visit, questions were asked about recent symptoms, medication use 
and any exacerbations.  At visits 2 and 4, specific questions were asked about side 
effects and compliance.  All bottles were returned and counted to confirm compliance. 
Height and weight were then taken with jacket and shoes off using the equipment in the 
pulmonary function lab, calibrated regularly according to the instructions of the 
manufacturer.
Venesection
The non-dominant arm was used for venesection.  20ml of blood was withdrawn from 
the antecubital fossa using a vacutainer system with a tube containing clot activator. 
The blood was left to stand for 30 minutes, then centrifuged at 3500rpm for 15 minutes. 
The plasma was immediately separated using a pipette and divided into 4 aliquots.  The 
samples were then stored in a -70
oC freezer for future analysis.Forearm muscle function
This part of the protocol was aimed at testing strength, endurance and recovery of the 
muscles of the forearm.  Tests were always performed in the same order.
i) Strength: 
The subject was seated comfortably on a chair and asked to relax.  A handgrip 
dynamometer (Grip-A, Takei Scientific Instruments Co, Tokyo, Japan) was 
placed in the dominant hand and the subject was asked to pull the lever as hard as 
possible with the arm extended towards the floor.  After a short rest, this was 
repeated with the non-dominant hand and the readings were recorded.  This test 
was repeated 5 times with each hand, with time for recovery in between each test. 
The highest recording of the 5 readings was taken as maximum handgrip strength.
ii) Endurance: 
The subject was asked to sit with the dominant forearm resting on a table with the 
palm facing the ceiling.   Detailed instructions were given before the test 
commenced and there was the opportunity to have a “trial run”.  A metronome 
was set to a beat of 40 per minute and instructions were given to pull and release 
the lever of the dynamometer to each beat of the metronome.  Before the start of 
the test, the subject was told what the target was for each pull of the handgrip, 
corresponding to 70% of the maximum handgrip.  Verbal encouragement was 
given during the test to continue for as long as possible and to achieve the target 
strength with each pull of the lever.  The test was discontinued when the subject 
failed to achieve the target with three consecutive pulls of the lever.  The number of repetitions managed was recorded and the test was repeated with the non-
dominant forearm after an adequate period of rest.
iii) Muscle Recovery: 
This test immediately followed the endurance testing.   The subject had been 
informed of the protocol before commencement of the endurance test.  At the end 
of the endurance test, a stopwatch was reset and the clock was started.  The 
subject was asked to perform maximum handgrips at set points over the next 5 
minutes to document muscle recovery.   Time points chosen were as follows 
(reference point being the end of the endurance test): 10 seconds, 20s, 40s, 80s, 
160s, 300s.  This part of the protocol was performed with both the dominant and 
the non-dominant forearms and readings were recorded for later analysis.
Respiratory muscle strength
This was tested using a hand-held mouth pressure meter (Pearson Medical, North 
Yorkshire, UK).  The subject was asked to stand up and the protocol was explained.  A 
disposable mouthpiece was attached to the meter and it was zeroed.  The lips were 
placed round the mouthpiece in maximal inspiration and the subject was asked to blow 
as hard as possible.  This was repeated, with adequate rest in between tests, until there 
were 3 readings with less than 10% variability.  Inspiratory muscle strength was then 
tested by asking the subject to suck through the mouthpiece as hard as possible from 
maximal expiration.  This was also repeated until there were 3 readings with less than 10% variability.   The highest readings were taken as peak inspiratory and peak 
expiratory pressure.
Muscle Metaboreflex Measurement
Assessment of the metaboreflex followed a similar protocol to that described earlier in 
the chapter.  An identical exercise protocol was used, with repetitive forearm exercise 
to fatigue at 70% of maximum voluntary contraction at a rate of 45 contractions per 
minute.  Blood pressure and heart rate were measured every 10-15 seconds by arterial 
tonometry (Vasotrac 205A; Medwave, St Paul, Minnesota).  Minute ventilation, VO2, 
VCO2 and respiratory rate were measured continuously from exhaled gas sampled from 
a rubber mouthpiece by a metabolic cart (Medical Graphics Corporation, St Paul, 
Minnesota).  Pulse Transit Time was measured using the RM60 (DevilBiss, France) as 
described in chapter 2.2.1.  There were again 3 parts to the protocol:
· Cuff inflation at rest:     
3 minutes of resting measurements, following which a sphygmomanometer 
cuff was rapidly inflated (<1 second) to 200mmHg (or 20mmHg above 
systolic blood pressure) using a foot pump for 3 minutes.  Three minutes of 
recovery.
· Forearm exercise with control recovery:     
3 minutes of resting measurements followed by repetitive forearm exercise to 
fatigue.  This was followed by 6 minutes of normal recovery.· Forearm exercise followed by cuff occlusion:     
3 minutes of resting measurements followed by repetitive forearm exercise to 
fatigue.  At peak exercise, a sphygmomanometer cuff was inflated round the 
upper part of the exercising arm to 200mmHg (or 20mmHg above systolic 
blood pressure) for 3 minutes and the subject was asked to relax.  Following 
this, there was a further 3 minutes of recovery.
The control cuff inflation at rest always took place first, followed by the two parts 
involving exercise in random order.  During the first visit, it was noted which order the 
tests were performed in, and this order was repeated at subsequent visits.
It was decided that it was important to ensure that the same total amount of work was 
performed during metaboreflex assessment at each visit.  Time to fatigue was therefore 
recorded and the subject was asked to exercise for the same time at subsequent visits. 
Following the first visit, the settings of the handgrip device used for exercise were 
recorded.  At the start of subsequent visits, the device was calibrated with weights to 
ensure identical settings at each visit.
Creatine Administration
At the end of each visit, a package containing the creatine supplements or placebo was 
collected from pharmacy and given to the patient.  A prescription was filled out for 
each course, and pharmacy issued a package according to patient number and patient 
visit.  Instructions were given to take one dose first thing in the morning, one dose at lunch time and one dose just before bed.  Patients were asked to add the whole pot of 
powder to a cup of lukewarm water, stir well and consume the drink as quickly as 
possible.  If there was still residue left in the cup, it was to be rinsed with a small 
quantity of warm water and the contents consumed.  Visits were planned so that visit 2 
or 4 took place on the day of the final dose of creatine or placebo.
2.4.7   Plasma analysis
Stored plasma was analysed at the end of the study for C-reactive protein (using a 
highly sensitive assay), interleukin-6 and homocysteine.
2.4.8 Data analysis
Normality of distribution of data was assessed using a Shapiro-Wilk test (GB-Stat 
version 8, Dynamic Microsystems Inc, Silver Spring, MD, USA).   All data are 
presented as mean ± standard error of the mean.   Pre- and post-loading data were 
compared using a paired Student’s t-test.  The effects of creatine supplementation were 
compared to the effects of placebo using a paired Student’s t-test.
For assessment of the muscle metaboreflex, resting values are the mean of the 60 
seconds before the start of exercise.  Peak exercise values are the mean of the last 30 
seconds of exercise.  To evaluate the effects of regional circulatory occlusion (RCO), 
the area under the curve was calculated for the 3 minutes of post-exercise RCO and compared to the equivalent period of control recovery using a paired Student’s t-test. 
Changes in any variable across time were assessed using two-way analysis of variance 
(ANOVA) followed by Newman-Keuls  post-hoc  analysis when significant F-values 
were obtained.  A p value of <0.05 was considered statistically significant.Chapter 3
The Muscle Metaboreflex in Patients with Stable Chronic 
Obstructive Pulmonary Disease3.1 Chapter introduction
Chronic Obstructive Pulmonary Disease (COPD) is one of the most common causes of 
death and disability in the Western World .  Inhaled irritants such as cigarette smoke 
lead to chronic inflammation of the airways and the development of progressive airflow 
limitation.  Disturbance of the protease/ anti-protease equilibrium causes destruction of 
the alveolar membrane with a loss of elastic tissue .  The physiological consequences of 
fixed airflow obstruction, increased lung compliance and reduced alveolar membrane 
surface area include flow limitation, impairment of gas exchange and dynamic 
hyperinflation on exercise .  These are all thought to contribute to increased work of 
breathing and exercise intolerance, the most distressing symptom of COPD.  It has, 
however, been noted that a significant proportion of patients with COPD cite muscle 
fatigue as the reason for terminating an incremental exercise test ,  and there has 
therefore been substantial interest in the role of peripheral skeletal muscle dysfunction 
in exercise limitation, with atrophy, a change in fibre type and altered metabolism 
described .
It has been speculated that exercise limitation in COPD and chronic heart failure may 
have similar contributing causes, and there are striking similarities in the changes seen 
in skeletal muscle .  Traditional indices of disease severity (FEV1 and ejection fraction) 
correlate poorly with exercise capacity    and exercise-based rehabilitation classes 
partially reverse muscle abnormalities whilst improving exercise performance and 
quality of life .  Excessive ventilation for a given workload and an increased ventilatory 
equivalent (VE/VCO2) have been noted in both COPD and chronic heart failure, and 
these abnormalities can be partially reversed with exercise training .The muscle metaboreflex has been of particular interest in patients with chronic heart 
failure.   Studies have looked at assessing the muscle metaboreflex using forearm 
exercise followed by post-exercise circulatory occlusion, as previously described in 
chapter 1 of this thesis.   It has been shown that there is an increase in muscle 
metaboreflex activity in patients with chronic heart failure , with activity correlating 
with NYHA symptom classification .    This observation has been attributed to 
abnormalities in muscle metabolism, with an increase in lactate production and 
intramuscular acidosis causing increased metaboreceptor stimulation .   It has been 
speculated that this contributes to the excessive sympathetic nervous system and 
ventilatory response to exercise in chronic heart failure .  It has also proven possible to 
reduce metaboreflex activity in patients with chronic heart failure through training of 
skeletal muscle .   As patients with COPD suffer from similar skeletal muscle 
abnormalities , this chapter set out to investigate whether it is possible to measure the 
muscle metaboreflex in patients with stable COPD, and whether patients with more 
severe disease demonstrate an increase in metaboreflex activation.3.2 Research questions
The aims of this study were to answer the following research questions:
i) Is it possible to measure muscle metaboreflex activity in patients with stable 
COPD?
ii) Is there a difference in muscle metaboreflex activity between patients with 
moderate and severe COPD?
3.3 Patient characteristics and pulmonary function testing
Sixteen patients with stable Chronic Obstructive Pulmonary Disease (COPD) were 
recruited into this study: all met the criteria described in chapter 2.   Metaboreflex 
assessment followed the protocol described in chapter 2.  Two patients were unable to 
complete the protocol: one subject could not tolerate the rubber mouthpiece of the 
metabolic cart, and one subject found the sphygmomanometer cuff too uncomfortable 
to tolerate.  Subject characteristics are described in table 3.1.  This was a group of 
patients with significant airflow limitation, as seen by the mean FEV1 of 46.4 ± 3.7% of 
predicted and the mean FEV1/ FVC ratio of 37.9 ± 3.0%.  There was also evidence of 
hyperinflation at rest and impaired diffusion capacity.   Table 3.2 outlines what 
medications the patients were taking.3.4   The effects of exercise and post-exercise regional circulatory occlusion: 
whole group
3.4.1 The effects of rhythmic handgrip exercise
Rhythmic handgrip exercise led to a significant increase in blood pressure, heart rate, 
ventilation, VCO2 and VO2.  There was no significant difference between resting or 
peak values between the control exercise run and the exercise followed by RCO (table 
3.3, figures 3.1-3.6).
3.4.2 The effects of post-exercise regional circulatory occlusion
Regional circulatory occlusion (RCO) at the end of rhythmic handgrip exercise led to a 
sustained increase in systolic blood pressure (p<0.005), diastolic blood pressure 
(p<0.0001), ventilation (p<0.005), VO2 (p<0.005) and VCO2 (p<0.001) when compared 
with control recovery (table 3.4).  Post-exercise RCO had no effect on heart rate.
3.4.3 The effects of control regional circulatory occlusion at rest
Control regional circulatory occlusion at rest did not affect blood pressure, heart rate or 
ventilation (table 3.5, figures 3.1-3.6).  There was a significant fall in VO2 and VCO2 
during RCO, confirming “isolation” of the forearm muscle from the rest of the 
circulation.Table 3.1 Subject characteristics
Male/ Female (n) 8/ 6 (14)
Age (years) 63.7±3.1
Height (cm) 164 ± 2.6
Weight (kg) 73.3±4.8
Body mass index (kg/m
2) 27.5±1.7
Smoking history (pack years) 57.3±9.1
MRC dyspnoea score 2.9±0.2
FEV1 (litres) 1.18±0.12
FEV1 (% predicted) 46.4±3.7
FEV1/ FVC 37.9±3
Bronchodilator reversibility (%) 7.1±2.7
Bronchodilator reversibility (ml) 67.1±27.2
Corrected TLCO (% predicted) 50.6±5.3
Residual volume (% predicted) 174.7±15.5
Total lung capacity (% predicted) 122.7±6.1
Maximum handgrip (kg) 30.8±2.7
Maximum handgrip (% predicted) 93.4±4.2
Peak inspiratory pressure (cmH2O) 74.9±7.1
Peak inspiratory pressure (% predicted) 107.8±11.6
Peak expiratory pressure (cmH2O) 71.6±4.2
Peak expiratory pressure (% predicted) 69+5.1
Exacerbations in previous year 3.5±1.0
Age, height, weight, sex and lung function of this subject group.  Data are presented as 
mean ± standard error of the mean.   Standard formulae and tables were used to 
calculate predicted mouth pressures and handgrip strength .Table 3.2 Medication history
Medication Total Moderate group Severe group
N 14 7 7
Seretide 8 5 3
Symbicort 1 0 1
Nebulised pulmicort 1 1 0
Salbutamol inhaler 10 4 6
Serevent 4 2 2
Tiotropium 7 4 3
Theophylline 4 2 2
Oral Beta-2 agonist 1 1 0
Carbocysteine 1 0 1
Nebulised salbutamol 8 4 4
Nebulised atrovent 5 2 3
Combivent inhaler 2 2 0
Aspirin 3 1 2
Calcium channel blocker 
(non-rate limiting) 2 1 1
Statin 1 0 1
ACE inhibitor 3 2 1
This table details the inhaled and oral COPD medications that were taken by patients. 
Cardiovascular medications are also listed.Table 3.3 The effects of rhythmic handgrip exercise to fatigue on this group
Control exercise run Exercise followed by RCO
Rest Peak exercise Rest Peak exercise
Systolic BP (mmHg) 128.0±5.0 156.1±5.5* 129.3±4.5 160.5±5.2*
Diastolic BP (mmHg) 77.5±3.7 102.1±5.3* 77.8±2.9 95.7±4.4*
Heart rate (bpm) 80.6±3.5 91.2±3.5* 79.2±3.0 89.2±3.0*
Ventilation (l/min) 10.7±0.4 18.1±0.7* 10.8±0.4 17.6±0.8*
VO2 (ml/min) 187±10 301±18* 188±11 300±19*
VCO2 (ml/min) 183±10 344±22* 182±10 323±22*
All data are presented as mean ± standard error of the mean.  To compare resting and 
peak exercise values, statistical significance was tested using a paired Student’s t-test 
after checking for normality.  *p<0.0001 compared with resting values.
  Table 3.4 The effects of post-exercise regional circulatory occlusion
Post-exercise recovery Post-exercise RCO
Systolic BP (mmHg) 132.5±4.0 153.5±5.7*
Diastolic BP (mmHg) 79.1±3.3 94.6±3.6
††
Heart rate (bpm) 80.9±3.6 81.5±3.5
Ventilation (l/min) 12.4±0.5 14.7±0.8*
VO2 (ml/min) 205±13 231±15**
VCO2 (ml/min) 220±15 261±19
†
Values given represent the “area under the curve” of the 3 minutes following peak 
exercise, either during recovery from exercise without regional circulatory occlusion 
(RCO) or during post-exercise RCO.   Statistical significance was assessed using a 
paired   Student’s  t-test   after   checking   for   normality   using   a  Shapiro-Wilk   test. 
Comparison between control recovery and RCO: *p<0.005, **p<0.0005,  
†p<0.001, 
††p<0.0001.Table 3.5 The effects of regional circulatory occlusion at rest
Control rest period RCO at rest
Systolic BP (mmHg) 130.6±4.2 131.9±4.5
Diastolic BP (mmHg) 78.1±3.2 79.0±3.0
Heart rate (bpm) 79.4±3.3 79.3±3.3
Ventilation (l/min) 11.1±0.5 11.1±0.5
VO2 (ml/min) 193±10 184±10**
VCO2 (ml/min) 193±11 183±11*
Values given represent the “area under the curve” of the 3 minutes of either a control 
period of rest or regional circulatory occlusion (RCO) at rest.  Statistical significance 
was assessed using a paired Student’s t-test after checking for normality using a 
Shapiro-Wilk test.   Comparison between control rest and RCO at rest: *p<0.05, 
**p<0.005.Figure 3.1 The effects of exercise followed by RCO on systolic blood pressure
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Figure 3.2 The effects of exercise followed by RCO on diastolic blood pressure
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
** ** **
** ** **Figure 3.3 The effects of exercise followed by RCO on heart rate
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Figure 3.4 The effects of exercise followed by RCO on ventilation
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
** **
**Figure 3.5 The effects of exercise followed by RCO on oxygen consumption (VO2)
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Figure 3.6 The effects of exercise followed by RCO on carbon dioxide production 
(VCO2)
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
* **
**
**
**
**3.5 Stratification into moderate and severe COPD
Analysis of results was performed following stratification of patients into 2 groups.  It 
should be pointed out that stratification occurred after completion of the study: this is 
therefore a post-hoc analysis.  FEV1 was used to determine severity of COPD.  The 
seven patients with the lowest FEV1 were put in the “severe” group, and the remaining 
patients were put in the “moderate” group.  Characteristics of the 2 groups are shown in 
table 3.6, and a medication list is given in table 3.2.
3.5.1 Anthropometry
There was no significant difference in age or height between the two groups.  The 
“severe” group was significantly lighter than the “moderate” group (62.2±4.1kg vs. 
84.4±6.3kg, p<0.05), with a lower body mass index (22.4±1.4kg/m
2 vs. 32.7±1.4kg/m
2). 
Patients in the “severe” group had a trend towards a heavier smoking history, a greater 
number of exacerbations in the previous year and greater functional impairment as 
measured by the baseline dyspnoea index, although these small differences were not 
statistically significant.
3.5.2 Pulmonary function testing
The “severe” group of patients had a significantly greater degree of airflow limitation 
than the “moderate” group, as seen by the lower FEV1 and FEV1/FVC ratio (p<0.05). 
Diffusion capacity for carbon monoxide was impaired in both groups, more so in the 
“severe” group (60.2±6.2% predicted vs. 41±5.1% predicted, p=0.06).  The “severe” group had a greater degree of air trapping, with a residual volume of 204.1% of 
predicted compared with 140.3% of predicted in the “moderate” group (p<0.05).  There 
was a trend towards greater impairment of respiratory muscle strength in the “severe” 
group, although this did not reach statistical significance.  This cannot be explained by 
a difference in height, as the “severe” group was slightly taller.   There was no 
difference in handgrip strength between the groups.3.6   The effects of exercise and post-exercise regional circulatory occlusion: 
stratified groups
3.6.1 The effects of rhythmic handgrip exercise
There were no significant differences in resting blood pressure, heart rate, ventilation, 
oxygen consumption or carbon dioxide production between the “moderate” and 
“severe” groups (Table 3.7).  Rhythmic handgrip exercise to fatigue led to a significant 
increase in blood pressure, heart rate, ventilation, oxygen consumption and carbon 
dioxide production in both groups (all p<0.005).  Both groups achieved similar peak 
exercise blood pressure and heart rate.  The exercise-induced increase in ventilation, 
oxygen consumption and carbon dioxide production was smaller in the “severe” group, 
although this did not achieve statistical significance.  Resting ventilatory equivalent 
(ventilation (VE) divided by carbon dioxide production (VCO2)) was significantly 
greater in the “severe” group (62.8±3.4 vs. 53.6±3.4, p<0.05), presumably reflecting a 
combination of increased dead space ventilation and reduced muscle bulk.3.6.2 The effects of post-exercise regional circulatory occlusion
Systolic blood pressure, diastolic blood pressure, ventilation, oxygen consumption and 
carbon dioxide production were all significantly greater during post-exercise RCO 
compared with control recovery in both the “moderate” and “severe” groups (tables 3.8 
and 3.9, figures 3.7-3.18).  There was no difference in the magnitude of the effects of 
post-exercise RCO between the groups.  Post-exercise RCO did not significantly affect 
heart rate in either group.
Stratification of the patients with COPD by handgrip strength, MRC dyspnoea score 
and body mass index was carried out.   There was no correlation between muscle 
metaboreflex activity and any of these variables (data not shown).Table 3.6 Subject characteristics
Moderate COPD Severe COPD
N 7 7
Age 66.3±3.4 61.1±5.4
FEV1 (litres) 1.3±0.2 1.0±0.1
FEV1 (% predicted) 56.1±4.9 36.6±1.6*
FEV1/FVC 46.1±2.9 29.7±2.8*
TLCO (corrected, % predicted) 60.2±6.2 41±5.1
Residual volume (% predicted) 140.3±18.9 204.1±11.8*
Total lung capacity (% predicted) 108±5.8 135.3±5.7
Smoking (pack years) 50.8±10.0 62.9±15.4
Baseline dyspnoea index (BDI)  3.0±0.4 3.7±0.8
Exacerbations in previous year 3.4±1.6 3.6±1.5
Height (cm) 160.1±4.2 166.9±2.7
Weight (kg) 84.4±6.3 62.2±4.1*
Body mass index (kg/m
2) 32.7±1.4 22.4±1.4**
Max handgrip (kg) 29.6±4.9 32.1±2.4
Max handgrip (% predicted) 98.8±6.0 87.1±5.5
Peak inspiratory pressure (cmH2O) 85.1±10.6 64.6±8.4
Peak inspiratory pressure (% predicted) 125.4±15.6 90.3±15.3
Peak expiratory pressure (cmH2O) 76.4±4.7 66.7±6.8
Peak expiratory pressure (% predicted) 76.8±4.0 61.2±8.6
Comparison of age, height, weight and lung function between the “moderate” and 
“severe” groups.  Data are presented as mean ± standard error of the mean.  *p<0.05, 
**p<0.005 for between-group comparisons.  Statistical significance was assessed using 
an unpaired Student’s t-test after checking for normality.  Predicted values for mouth 
pressures and handgrip strength were taken from standard formulae and tables .Table 3.7 Comparison of the effects of rhythmic handgrip exercise
Moderate COPD Severe COPD
Rest Peak exercise Rest Peak exercise
Heart rate (bpm) 81.3±5.3 91.3±4.9** 79.9±5.1 91.1±5.4**
Systolic BP (mmHg) 135.3±5.9 158.3±4.2** 120.7±7.5 154±10.5**
Diastolic BP (mmHg) 78±3.3 100.7±5.7** 76.9±7 103.6±9.5**
Ventilation (l/min) 10.2±0.4 18.9±1.1** 11.4±0.6 17.3±0.8**
VO2 (ml/min) 198.1±17.3 331.6±30** 181.7±13 279.6±16**
VCO2 (ml/min) 190.3±16.1 378.4±35.7** 181.4±14 309.3±20.1**
VE/VCO2 53.6±3.4 49.9±4 62.8±3.4† 55.9±1.4
All data are presented as mean ± standard error of the mean.  To compare resting and 
peak exercise values, a paired Student’s t-test was used after checking for normality 
using a Shapiro-Wilk test.  To compare values between groups, an unpaired Student’s t-
test was used after checking for normality.  *p<0.05, **p<0.005, rest vs peak exercise; 
†p<0.05, resting values between groups.Table 3.8 Comparison of the effects of post-exercise RCO between groups: 
absolute values
Moderate COPD Severe COPD
Control RCO Control RCO
Systolic BP (mmHg) 142.9±4.6 156±2.8* 129±6.5 150.8±11.2
Diastolic BP (mmHg) 80.9±3.2 98.6±2.6** 79±6.1 92.4±6.0
Heart rate (bpm) 81.4±5.6 82.3±4.8 80.55.0 80.4±5.0
Ventilation (l/min) 13.1±0.9 15.5±1.2 13.5±0.7 14.3±0.9
VO2 (ml/min) 244.4±23.8 257.1±26.0 208.6±14.2 226.7±14.3
VCO2 (ml/min) 263.7±28.1 291.7±29.9 226.4±16.2 243.4±20.9
Values represent the “area under the curve” of the three minutes of post-exercise RCO 
compared with the equivalent period of control recovery.  All data are presented as 
mean ± standard error of the mean.  To compare control and RCO values, a paired 
Student’s t-test was used after checking for normality using a Shapiro-Wilk test.  To 
compare values between groups, an unpaired Student’s t-test was used after checking 
for normality.  *p<0.05, **p<0.005, rest vs peak exercise.Table 3.9 Comparison of the effects of post-exercise RCO between groups: 
percentage values
Moderate COPD Severe COPD
Control RCO Control RCO
Systolic BP (%) 37.2±16.5 73.8±9.2 27.4±8.5 70.7±13.8*
Diastolic BP (%) -10.4±19.4 122.3±19.2** -6.3±17.6 114.4±23.0**
Heart rate (%) -23.9±21.6 20.6±17.1 11.0±10.9 11.8±30.7
Ventilation (%) 34.7±8.9 69.1±30.8* 34.4±4.2 56.6±7.3*
VO2 (%) 35.6±5.7 52.3±8.8 23.9±6.6 42.5±14.9
VCO2 (%) 42.2±7.4 64.6±10.7 33±5.0 59.3±10.3
This time, values following either three minutes of post-exercise RCO or the equivalent 
period of control recovery are expressed as a percentage of the effects of exercise (see 
text in chapter 2 for further information).  All data are presented as mean ± standard 
error of the mean.  To compare control and RCO values, a paired Student’s t-test was 
used after checking for normality using a Shapiro-Wilk test.   To compare values 
between groups, an unpaired Student’s t-test was used after checking for normality. 
*p<0.05, **p<0.005, rest vs peak exercise.Figure 3.7 The effects of exercise followed by RCO on systolic blood pressure: 
moderate COPD
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Figure 3.8 The effects of exercise followed by RCO on systolic blood pressure: 
severe COPD
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
** ** **
** **
** ** **Figure 3.9 The effects of exercise followed by RCO on diastolic blood pressure: 
moderate COPD
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Figure 3.10 The effects of exercise followed by RCO on diastolic blood pressure: 
severe COPD
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**
**Figure 3.11 The effects of exercise followed by RCO on heart rate: moderate 
COPD
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Figure 3.12 The effects of exercise followed by RCO on heart rate: severe COPD
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.Figure 3.13 The effects of exercise followed by RCO on ventilation: moderate 
COPD
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Figure 3.14 The effects of exercise followed by RCO on ventilation: severe COPD
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
**
*
*
* ** **Figure 3.15 The effects of exercise followed by RCO on oxygen consumption 
(VO2): moderate COPD
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Figure 3.16 The effects of exercise followed by RCO on oxygen consumption 
(VO2): severe COPD
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**Figure 3.17 The effects of exercise followed by RCO on carbon dioxide production 
(VCO2): moderate COPD
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Figure 3.18 The effects of exercise followed by RCO on carbon dioxide production 
(VCO2): severe COPD
100
150
200
250
300
350
400
Rest Peak
exercise
Cuff 1min Cuff 2min Cuff 3min Rest
1min
Rest
2min
V
C
O
2
 
(
m
l
/
m
i
n
)
 
 
.
RCO
Control
Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**3.7 Chapter discussion
The aim of this study was to evaluate the contribution of the muscle metaboreflex to 
ventilatory and pressor responses to forearm exercise in patients with moderate and 
severe COPD.  We have shown that post-exercise regional circulatory occlusion causes 
a sustained increase in ventilation and blood pressure, but not heart rate, when 
compared with control recovery without circulatory occlusion.   This supports our 
hypothesis that the skeletal muscle plays an important role in the control of ventilatory 
and pressor responses to exercise.  When comparisons were made between patients with 
moderate and severe COPD, there was no difference in exercise responses or duration 
of exercise, although patients with severe disease had a non-significantly lower peak 
VO2, presumably reflecting decreased skeletal muscle bulk and impaired aerobic 
capacity.  There was no difference in metaboreflex activity between the 2 groups.  The 
efficacy of regional circulatory occlusion is supported by the fall in resting VO2 seen 
with cuff inflation at rest, reflecting “isolation” of that muscle group from the rest of the 
circulation.
Further stratification of patient groups into categories of body mass index, MRC 
dyspnoea score and handgrip strength did not reveal any relationships between these 
variables and muscle metaboreflex activity.
The presence of a pressor reflex arising from exercising skeletal muscle is not a new 
idea, having first been demonstrated by Alam & Smirk in 1937 .  It was thought that 
metabolites   produced   by   exercising   muscle   were   trapped   by   circulatory   arrest, 
stimulating receptors in the muscle, with the sympathetic nervous system forming the efferent arm of the reflex loop.  The metaboreflex is abolished in anaesthetised animals 
by severing the dorsal nerve root , and it has since been shown that small myelinated 
and unmyelinated group III and IV afferent nerves mediate the reflex .  Metaboreflex 
activity is attenuated in patients with Brown-Séquard syndrome ,  confirming the 
importance of the sensory nervous system.   Hydrogen ion, lactate, potassium and 
prostaglandins,   produced   by   exercising   muscle,   have   all   been   implicated   in 
metaboreflex activation , and intramuscular acidosis (measured using 
31P NMR) appears 
to correlate with metaboreflex activity in normal subjects .
The role of the muscle metaboreflex in the control of ventilation during exercise has 
been more controversial, although animal studies suggest that it is of importance . 
Human studies have also shown that the ventilatory response to dynamic handgrip 
exercise persists during post-exercise regional circulatory occlusion .  The contribution 
of muscle fatigue (as determined by EMG) to metaboreflex activation and consequent 
hyperventilation has been documented in normal humans, with measurement of venous 
lactate and potassium during circulatory occlusion demonstrating the efficacy of 
isolating the exercised muscle from the rest of the circulation .
Our observation that post-exercise circulatory occlusion has no effect on heart rate has 
previously been noted in normal subjects.  The increase in heart rate at the start of 
exercise is predominantly due to central command (or “anticipation” of exercise), 
mediated through withdrawal of resting vagal tone .  It is the increase in sympathetic 
activation that is thought to be metaboreflex driven.  With post-exercise circulatory 
occlusion, metaboreceptor stimulation by trapped metabolites causes a sustained 
increase in sympathetic activity, and consequently an increase in peripheral vascular resistance and therefore blood pressure.   However, the chronotropic effects of the 
sympathetic nervous system are offset by the activation of the baroreflex and the 
withdrawal of central command, leading to an increase in vagal tone.  This hypothesis 
is supported by the observations that R-R variation increases during post-exercise RCO 
and   administration   of   atropine     during   post-exercise   RCO   causes   a   persistent 
tachycardia .
All previous work looking at the potential clinical importance of the metaboreflex has 
been carried out in patients with chronic heart failure, who are known to demonstrate an 
exaggerated   ventilatory   and   sympathetic   nervous   system   response   to   exercise. 
Metaboreflex overactivity in chronic heart failure appears to correlate with disease 
severity when assessed symptomatically with the New York Heart Association criteria . 
A six week forearm exercise training programme attenuates the abnormal metaboreflex 
response in heart failure, confirming that this is a reversible phenomenon .  In view of 
the similarities in muscle metabolic abnormalities between advanced COPD and heart 
failure, we hypothesised that we would also see an increase in metaboreflex activity in 
patients with severe COPD.
Our failure to detect a difference in muscle metaboreflex activity between patients with 
moderate and severe COPD could be for several reasons.  We chose FEV1 to define 
patients with severe disease, and it is known that FEV1 correlates poorly with exercise 
capacity .  This parallels the picture seen in cardiac failure with left ventricular ejection 
fraction showing a poor correlation with exercise capacity .  Severity of symptoms 
appears to be more important, with NYHA class correlating with metaboreflex activity , 
so further work should perhaps look at MRC dyspnoea score as a marker of symptom severity.  This study was not large enough to allow us to stratify according to MRC 
dyspnoea score.  Another possibility is that we studied the wrong muscle group.  It is 
well documented that the upper limb muscles in patients with COPD are relatively 
preserved compared to the leg muscles , presumably reflecting relatively greater disuse 
of the locomotor muscles of the lower limbs.   It is therefore possible that the 
metaboreflex would be more active in the lower limbs: the metaboreflex has already 
been shown to be upregulated in the legs of patients with chronic heart failure .  It is 
also possible that the difference in nutrition between the groups is important, with the 
muscle metaboreflex having been shown to be attenuated in obese subjects .  One final 
confounding factor could be the presence of abnormalities of the autonomic nervous 
system.  Patients with COPD are known to develop an autonomic neuropathy , perhaps 
contributing to the increase in resting heart rate and muscle sympathetic nervous 
activity seen at rest.  Presence of a neuropathy could potentially attenuate an augmented 
metaboreflex, negating any difference between moderate and severe groups.
One potential source of criticism of this chapter is the lack of a “normal” control group 
for comparison.  We had initial difficulty recruiting activity-matched control subjects, 
so decided instead to compare patients with moderate and severe COPD.  It could be 
argued that many of the changes seen in skeletal muscle with advanced COPD are due 
to “detraining”, with a lack of physical activity leading to muscle deconditioning.  It has 
been shown that training a muscle group attenuates the metaboreflex response, so it 
could be argued that it is not valid to include a group of control subjects unless they are 
age and activity matched.3.8  Chapter conclusions
In conclusion, the muscle metaboreflex appears to contribute to blood pressure and 
ventilatory responses to rhythmic handgrip exercise in COPD, although we have not 
been able to show a difference in metaboreflex activity between moderate and severe 
disease when stratified by FEV1.  Larger studies are needed to determine whether the 
metaboreflex is as relevant to symptom generation and exercise limitation in COPD as 
it appears to be in chronic heart failure.  The following additional research questions are 
raised:
1. Do indices of functional disability such as MRC dyspnoea score correlate with 
muscle metaboreflex activity (as is the case with chronic heart failure and 
NYHA class)?
2. Is autonomic nervous system dysfunction important in the measurement of the 
muscle metaboreflex in patients with COPD?
3. Do patients who are not “ventilatory limited” on maximal exercise testing 
exhibit exaggerated muscle metaboreflex activity?
4. Does muscle fibre type and oxidative capacity determine muscle metaboreflex 
activity?Chapter 4
The Assessment of the Muscle Metaboreflex using
Pulse Transit Time4.1 Chapter introduction
Measurement of blood pressure during exercise can be achieved through use of a 
traditional mercury sphygmomanometer, although this method is cumbersome and 
unable to provide continuous readings.   Other methods, such as arterial tonometry 
(used in this study) and finger blood-volume clamping (eg the Finapres) can provide 
more continuous readings, although the equipment is expensive and susceptible to 
movement artefact.   The “gold standard” for continuous blood pressure monitoring 
involves arterial cannulation, which is uncomfortable and potentially risky.   An 
alternative is measurement of the transit time of the pulse pressure wave as it moves 
through the arterial tree, termed the “pulse transit time”.  Pulse transit time (PTT) has 
been shown to correlate inversely with blood pressure .  It can be measured by timing 
the pressure wave at two different sites (e.g. the finger and the toe) using infrared 
photoplethysmography.     Alternatively,   the   electrocardiograph   “R”   wave,   which 
correlates with ventricular depolarisation, can be used as a proximal starting point: PTT 
measured using this technique is known as the rPTT .  It should be noted, however, that 
the rPTT also includes the pre-ejection period (the PEP), the time between ventricular 
depolarisation and the onset of ventricular contraction , thus introducing another 
potential source of error.
The ability of pulse transit time to detect sudden changes in blood pressure has led to its 
use in the field of sleep medicine.  Patients with obstructive sleep apnoea suffer from 
“microarousals” following apnoeic episodes, which lead to a burst of sympathetic 
nervous system activity and a rise in blood pressure.  The ability of pulse transit time to 
detect such microarousals   has led to the development of commercially available portable equipment designed to be worn overnight by a patient.  A pulse oximetry probe 
is worn on the finger and three ECG electrodes are attached to the chest.  These are fed 
into a battery operated unit which records PTT, heart rate and oxygen saturations.  The 
data can then be downloaded onto a laptop computer as either a continuous tracing or 
raw data.   Pulse transit time is dependent on vascular tone, so an increase in 
sympathetic output causes arterial wall stiffening and a decrease in pulse transit time . 
Other areas of research in PTT have included its use as a measure of sympathetic 
nervous system activity in panic disorder .   Sympathetic blockade with epidural 
bupivocaine has been shown to increase pulse transit time through a decrease in arterial 
wall tone, with the change in pulse transit time detecting sympathetic blockade with a 
higher reliability than the routine methods of skin temperature and arterial blood 
pressure .
The effects of exercise on pulse transit time have not previously been documented, 
neither have the effects of muscle metaboreflex activation.  We hypothesised that pulse 
transit time would fall with rhythmic handgrip exercise,  and that post-exercise 
circulatory occlusion, in causing sustained activation of the muscle metaboreflex, 
would also affect PTT.  The potential value of this finding would be that PTT could be 
used as a method of evaluating the muscle metaboreflex continuously and non-
invasively without the need for expensive and cumbersome blood pressure monitoring 
equipment.  We also set out to investigate the relationship between rPTT and blood 
pressure during rhythmic handgrip exercise and post-exercise RCO.4.2  Research questions
The aims of this study were to answer the following research questions:
i) What are the effects of rhythmic handgrip exercise and muscle metaboreflex 
activation on pulse transit time?
ii) Is there a relationship between pulse transit time and blood pressure during 
rhythmic handgrip exercise and muscle metaboreflex activation?
4.3  Subject characteristics
We recruited 7 healthy male volunteers from the staff of Glasgow Royal Infirmary 
(height 179.6 ± 2.7cm, weight 82.6 ± 2.8kg, age 32.3 ± 2.2 years, all values mean ± 
standard error of the mean (SEM).  None had significant cardiovascular, neurological, 
respiratory or metabolic diseases, and none were taking any medication.4.4  The effects of exercise and post-exercise regional circulatory occlusion
All subjects completed the three parts of the test.  There was no difference in exercise 
duration between the 2 bouts of handgrip exercise:  132.4 ± 13.8 seconds during the 
control run and 132.7 ± 13.7 seconds during the run followed by post-exercise regional 
circulatory   occlusion   (RCO).     Four   subjects   described   post-exercise   RCO   as 
uncomfortable, and one subject described light-headedness after the cuff was released.
4.4.1 The effects of post-exercise regional circulatory occlusion at rest
There were no significant changes from resting levels in blood pressure, heart rate or 
pulse transit time when the cuff was inflated round the upper arm for 3 minutes at rest 
(see table 4.2, figures 4.1-4.4).
4.4.2 The effects of rhythmic handgrip exercise
Handgrip exercise caused an increase in systolic blood pressure, diastolic blood 
pressure and heart rate.  Pulse transit time fell from 312.2 ± 17.8 milliseconds (ms) to 
287.2 ± 17.4 ms with handgrip exercise.  There was no significant difference in any 
measured variables between peak exercise during the control run and peak exercise 
during the run followed by RCO (table 4.3, figures 4.1-4.4).4.4.3 The effects of post-exercise regional circulatory occlusion
Following control exercise, blood pressure, heart rate and pulse transit time all fell 
rapidly towards baseline.  We calculated the area under the curve for all variables for 
the 3 minutes of post-exercise RCO and compared it with the area under the curve for 
the  corresponding  3  minutes  during  the  control  exercise  run.    RCO  caused  a 
significantly increased systolic and diastolic blood pressure compared with normal 
recovery, as previously reported, but did not affect recovery of heart rate towards 
resting levels.   Pulse transit time remained near peak exercise levels until the 
circulatory occlusion was released, and this was statistically significant compared with 
control recovery from exercise (table 4.4, figures 4.1-4.4).Table 4.1 Subject characteristics
Male/ Female (n) 7/0
Age (years) 32.3±2.2
Height (cm) 179.6±2.7
Weight (kg) 82.6±2.8
Age, sex, height and weight for the subject group.  Data presented as mean ± standard 
error of the mean.
Table 4.2 The effects of post-exercise regional circulatory occlusion at rest
Rest RCO Rest
Systolic BP (mmHg) 124.9 ± 7.3 126.8 ± 7.3 125.2 ± 7.9
Diastolic BP (mmHg) 67.4 ± 2.2 69.3 ± 2.4 67.3 ± 3.0
Heart Rate (mmHg) 70.2 ± 4.6 69.4 ± 4.1 70.4 ± 3.6
Pulse Transit Time (ms) 310.1 ± 18.3 310.1 ± 16.9 310.9 ± 16.7
Data presented as mean ± standard error of the mean.  For comparison of rest and 
control regional circulatory occlusion (RCO), a paired Student’s t-test was used after 
checking for normality using a Shapiro-Wilk test.Table 4.3 The effects of handgrip exercise to fatigue on this group
Rest Peak exercise 3 min normal 
recovery
Systolic BP (mmHg) 127.1 ± 6.1 158.9 ± 5.5* 130.2 ± 7.2
Diastolic BP (mmHg) 67.9 ± 4.4 92.3 ± 4.7* 72.0 ± 5.0
Heart Rate (bpm) 70.0 ± 4.3 87.6 ± 6.1* 69.9 ± 4.5
Pulse Transit Time (ms) 312.2 ± 17.8 287.2 ± 17.4* 303.1 ± 17.5
Comparison   between   resting   and   peak   exercise   values:   *p<0.0001.     Statistical 
significance was assessed using a paired Student’s t-test after checking for normality 
using a Shapiro-Wilk test.  All values are mean ± standard error of the mean.
Table 4.4 The effects of post-exercise regional circulatory occlusion
Rest Peak exercise 3 min RCO
Systolic BP (mmHg) 126.0 ± 6.1 160.2 ± 6.3* 157.6 ± 8.3††
Diastolic BP (mmHg) 68.1 ± 4.2 94.7 ± 4.9* 89.0 ± 5.6†
Heart Rate (bpm) 68.9 ± 3.6 90.1 ± 5.0* 74.6 ± 4.8
Pulse Transit Time (ms) 314.8 ± 16.1 285.6 ± 16.9* 289.9 ± 17.9†
Values for RCO are taken as the “area under the curve” for the three minutes of post-
exercise RCO.  Comparison of rest and peak exercise *p<0.0001.  Comparison of RCO 
and equivalent period of control recovery (from table 4.3) †p<0.005, ††p<0.001. 
Statistical significance was assessed using a paired Student’s t-test after checking for 
normality using a Shapiro-Wilk test.Figure 4.1 The effects of post-exercise RCO on systolic blood pressure
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Figure 4.2 The effects of post-exercise RCO on diastolic blood pressure
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.  The diamonds signify the 
non-exercise run with control cuff inflation.
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** **Figure 4.3 The effects of post-exercise RCO on heart rate
80
90
100
110
120
130
140
Rest Peak
exercise
Cuff 1min Cuff 2min Cuff 3min Rest 1min Rest 2min
H
e
a
r
t
 
R
a
t
e
 
(
%
 
r
e
s
t
i
n
g
)
Control
RCO
No RCO
Figure 4.4 The effects of post-exercise RCO on pulse transit time
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.  The diamonds signify the 
non-exercise run with control cuff inflation.
**
** ** **4.5  The relationship between blood pressure and pulse transit time
The relationships between pulse transit time and systolic, diastolic and mean arterial 
blood pressure are shown in table 4.5 and figures 4.5- 4.8.  In all subjects, there was a 
significant correlation between pulse transit time and blood pressure.  Individual “r” 
values for each subject are shown in table 4.5, and figures 4.5- 4.8 illustrate the 
relationship graphically in two typical subjects (numbers 1 and 7).
Table 4.5 The relationship between pulse transit time and blood pressure
Subject no. No. of measurements Systolic BP Diastolic BP Mean arterial BP
1 99 -0.66 -0.76 -0.79
2 126 -0.77 -0.74 -0.78
3 63 -0.86 -0.82 -0.84
4 64 -0.74 -0.73 -0.74
5 74 -0.77 -0.73 -0.75
6 132 -0.68 -0.63 -0.66
7 109 -0.69 -0.68 -0.69
This table looks at the relationship between pulse transit time and blood pressure for 
each individual subject.   Pearson’s regression analysis was used to calculate the 
correlation coefficient for each subject.Figure 4.5 The relationship between PTT and systolic blood pressure (subject 1)
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Figure 4.6 The relationship between PTT and diastolic blood pressure (subject 1)
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These graphs show the relationship between pulse transit time and systolic (top) and 
diastolic blood pressure for subject 1 during testing for the muscle metaboreflex.
r = -0.66
r = -0.76Figure 4.7 The relationship between PTT and systolic blood pressure (subject 7)
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Figure 4.8 The relationship between PTT and diastolic blood pressure (subject 7)
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These graphs show the relationship between pulse transit time and systolic (top) and 
diastolic blood pressure for subject 7 during testing for the muscle metaboreflex.
r = -0.69
r = -0.684.6 Chapter discussion
This study set out to investigate the use of pulse transit time in the measurement of the 
muscle metaboreflex in a group of normal subjects.
Our finding that post-exercise muscle ischaemia led to a sustained increase in systolic 
and diastolic blood pressure compared with control recovery is in keeping with 
previous studies (see chapter 1 for a detailed discussion).  We also found that post-
exercise muscle ischaemia did not significantly affect heart rate recovery.  This is again 
in keeping with previous findings, with the sympathetic activation mediated by muscle 
metaboreflex activation being offset by the negatively chronotropic effects of the 
baroreceptor-mediated increase in vagal tone (see chapter 1).
The main findings of our study are the effects that handgrip exercise and post-exercise 
RCO have on pulse transit time.  There was a clear fall in rPTT with rhythmic handgrip 
exercise.  This could be explained by the rise in blood pressure leading to an increase in 
vascular tone.  It should, however, be remembered that rPTT also depends on the pre-
ejection period, which will also fall with exercise due to the increase in heart rate. 
Pulse transit time also appears to behave in much the same way as blood pressure 
during post-exercise RCO (figures 4.1, 4.2, 4.4), with a sustained fall in PTT for the 
duration of circulatory occlusion.  It could be argued that the pre-ejection period during 
post-exercise RCO should be similar to the pre-ejection period during control recovery, 
as heart rate recovers in much the same way.  This would suggest that the effects of post-exercise RCO on PTT are mediated through changes in vascular tone rather than 
pre-ejection period. 
There has been interest in muscle sympathetic nerve activity (MSNA) in the evaluation 
of the metaboreflex.  MSNA can be measured by inserting a tungsten microelectrode 
into the peroneal nerve in the popliteal fossa .  It has consistently been shown to remain 
elevated   in   the   non-exercising   limb   during   post-exercise   RCO   .     This   causes 
vasoconstriction of blood vessels to non-essential organs, diverting blood flow to the 
exercising muscle, where vasoconstriction is probably offset by local mediators .  It is 
also interesting to note that during fatiguing inspiratory muscle work, resting limb 
MSNA increases .  Increased neural activity is seen in group IV afferents from the 
fatiguing diaphragm of the anaesthetised rat , so it is hypothesised that metaboreceptor 
stimulation in the diaphragm mediates this rise in MSNA.  The measurement of MSNA, 
however, is a technique requiring specialist training and equipment, so PTT is perhaps 
another method of assessing trends in sympathetic activity.  Further work is needed in 
this field, and it would be interesting to compare trends in MSNA with trends in PTT 
during exercise followed by post-exercise RCO.  Studies looking at pPTT (which is 
rPTT  following   correction   for   pre-ejection   period)   in   addition   to  rPTT  during 
metaboreflex activation would also be useful.
A detailed study looking at the effects of various vasoactive drugs on both rPTT and 
pPTT was carried out by Payne et al .  It was found that there was a good correlation 
between rPTT and systolic blood pressure, but not diastolic blood pressure.  Diastolic 
and mean arterial blood pressure correlated well with pPTT, and this was thought to be 
consistent with the fact that arterial stiffness, and therefore vascular PTT (i.e. pPTT), is dependent on mean arterial pressure rather than systolic blood pressure.  It was also 
noted that PEP contributed significantly to rPTT (12% to 35%), which would make 
rPTT inappropriate for use purely for the measurement of arterial tone.  Perhaps future 
studies comparing MSNA with PTT in assessment of the muscle metaboreflex should 
either correct rPTT for PEP to obtain the pPTT, or directly measure PTT using two 
arterial sites.  It is also possible to use the phonocardiogram to time cardiac ejection for 
analysis along with a peripheral pulse, which would avoid the need for correction for 
PEP.
Our findings that there was a reasonable correlation between rPTT and systolic blood 
pressure during exercise are therefore not surprising, although we demonstrated a closer 
correlation between rPTT and diastolic blood pressure than Payne et al.  It should be 
emphasised that our correlation between blood pressure and PTT is by no means 
perfect, and highlights the fact that factors other than blood pressure have an effect on 
PTT.4.7 Chapter conclusions
In conclusion, muscle metaboreflex activation using the method of rhythmic forearm 
exercise followed by post-exercise muscle ischaemia has a clear effect on pulse transit 
time, likely to be due to a combination of effects on cardiac output, pre-ejection period 
and vascular tone.  Pulse transit time shows some promise in the assessment of muscle 
metaboreflex activity as it is easy to measure, non-invasive and provides a continuous 
reading.  Further work needs to be done looking at whether PTT shows any meaningful 
correlation with MSNA in this setting, and it is possible that  pPTT is a more 
appropriate parameter to measure.Chapter 5
The Muscle Metaboreflex in Patients with
Diabetic Autonomic Neuropathy5.1 Chapter introduction
Muscle metaboreflex control of ventilation and blood pressure during exercise is 
complex, and depends on intact sensory and autonomic nervous systems.  As discussed 
in chapter 1, the sensory arm of the reflex loop is mediated by group III and group IV 
afferent nerves, and the efferent arm predominantly relies on the sympathetic nervous 
system.  Sympathetic nervous system activation leads to an increase in cardiac output 
(through an increase in heart rate and stroke volume) and vasoconstriction of vessels 
supplying non-exercising muscle and non-essential organs, leading to an increase in 
blood pressure.
This leads to the interesting question of what happens to the muscle metaboreflex when 
either the sensory or autonomic nervous systems are damaged through injury or disease. 
This was touched on in chapter 1, where it was noted that severing of the dorsal spinal 
roots in anaesthetised animals abolishes the metaboreflex .  It has also been shown that 
a Brown-Séquard spinal lesion leads to attenuation of the metaboreflex on the side 
affected by sensory loss .   To our knowledge, there have been no studies to date 
assessing   the   muscle   metaboreflex   in   patients   with   autonomic   nervous   system 
dysfunction.
Autonomic neuropathy is an important complication of diabetes mellitus, and can often 
be detected prior to the development of symptoms .   It is also of prognostic 
significance:  impaired   heart  rate  recovery  following  exercise  is   an   independent 
predictor of mortality , and autonomic neuropathy is associated with an increased risk 
of sudden cardiac death .Subjects with diabetic autonomic neuropathy are recognised to demonstrate impaired 
cardiovascular responses to exercise.  Reduced VO2 max  and attenuated heart rate and 
blood pressure responses to exercise   have both been documented, even after the 
exclusion of subjects with occult ischaemic heart disease .  A reduction in myocardial 
contractility and failure of peripheral vasoconstriction during exercise are probably both 
important.   It has been noted that hepato-splanchnic vascular resistance does not 
increase on exercise to the same degree in patients with diabetic autonomic neuropathy 
as in control subjects, presumably a manifestation of impaired sympathetic nervous 
system function .   The possibility that an abnormal metaboreflex contributes to 
abnormal cardiovascular exercise responses in diabetic autonomic neuropathy has not 
been studied.   This chapter therefore set out to investigate whether patients with 
diabetic autonomic nervous system dysfunction had altered muscle metaboreflex 
function in comparison to a group of diabetic subjects without autonomic dysfunction.5.2 Research questions
The aims of this study were to answer the following research questions;
i) Is it possible to detect muscle metaboreflex activity in patients with 
impairment of the autonomic nervous system secondary to type I diabetes 
mellitus?
ii) Is there a difference in muscle metaboreflex activity between patients with 
diabetic autonomic neuropathy and patients with type I diabetes mellitus 
who do not have diabetic autonomic neuropathy?
5.3 Patient characteristics
Fifteen patients with a history of type I diabetes mellitus were entered into the study. 
They were stratified into 2 groups: those with autonomic dysfunction and those without 
autonomic dysfunction (see chapter 2 for criteria).  All subjects completed all parts of 
the protocol.  Equipment failure during an important part of the protocol meant that we 
were unable to include any meaningful results for one of the patients with autonomic 
dysfunction.  This patient was unwilling to repeat the protocol and is therefore excluded 
from further analysis.  Subject characteristics are described in table 5.1.
It can be seen from table 5.1 that there were no significant differences in age, weight or 
body mass index between the patient groups.  There was a trend towards a greater 
duration of diabetes and a higher serum creatinine in the group with autonomic neuropathy, although this was not statistically significant.  Mean HbA1C was 8.6 in both 
groups, suggesting sub-optimal diabetic control.
5.4 Characteristics of autonomic dysfunction
Autonomic dysfunction in patients with diabetes mellitus is a heterogeneous mix of 
abnormalities of sympathetic and parasympathetic nervous system dysfunction.  It is, 
however, necessary to define a “cut-off” to allow stratification into 2 groups.   As 
discussed in chapter 2, we used the criteria of Ewing and Clarke  to define autonomic 
dysfunction, namely an abnormality of 2 or more of the five tests carried out.  We have 
reported in detail the results of the autonomic tests for each patient in table 5.2.
It can be seen from table 5.2 that seven of the subjects had clear abnormalities in two or 
more of the autonomic tests carried out.  As mentioned earlier, subject 3 was excluded 
from further analysis due to equipment failure during testing.  It is noteworthy that only 
one subject (subject 2) had a completely normal set of tests.  Eleven out of the fourteen 
subjects had some evidence of parasympathetic nervous system dysfunction.Table 5.1 Subject characteristics
Control DAN p value
n 8 6
Age 46.3 ± 4.5 53 ± 2.7 NS
Sex (M/F) 4 / 4 3 / 3
Weight (kg) 70.8 ± 4.8 67.8 ± 2.1 NS
Body mass index (kg/m
2) 25.1 ± 1.4 26 ± 1 NS
Diabetes duration (years) 23.5 ± 2 27 ± 2.7 NS
Ischaemic heart disease (n) 1 1
Peripheral vascular disease (n) 1 2
Sensory Neuropathy (n) 3 5
Retinopathy (n) 5 4
Serum creatinine (µmol/l) 94 ± 4 101 ± 6 NS
HbA1C (%) 8.6 ± 0.5 8.6 ± 0.3 NS
Comparison of age, height, weight and characteristics of diabetes between the groups 
with and without diabetic autonomic neuropathy (DAN).  Data are presented as mean ± 
standard error of the mean.  Statistical significance was assessed using an unpaired 
Student’s  t-test after checking for normality using a Shapiro-Wilk test.   NS = not 
statistically significant.Table 5.2.  Autonomic function testing.
Patient Test 1 Test 2 Test 3 Test 4 Test 5 Classification
1 A B N N N Normal
2 N N N N N Normal
3 A A B B A DAN
4 N N N N B Normal
5 A B A B N DAN
6 A N N N N Normal
7 A A A B B DAN
8 A A A A A DAN
9 A B A A A DAN
10 A B N B A DAN
11 A N N B N Normal
12 N N N B N Normal
13 A N N B N Normal
14 N N N N N Normal
15 A A A N N DAN
Detailed results of autonomic function testing for each individual subject.  Tests 1-5 are 
as follows: 1. Heart rate response to deep breathing, 2. Heart rate response to the 
Valsalva manoeuvre, 3. Heart rate response to standing, 4. Diastolic blood pressure 
response to standing, 5. Diastolic blood pressure response to sustained handgrip.  N = 
normal, A = Abnormal, B = borderline.5.5 Resting and exercise measurements
Subjects with DAN had a lower resting systolic and diastolic blood pressure and a 
higher resting heart rate than patients without DAN at rest, although this did not reach 
statistical significance (see table 5.3).  This was also true of the peak exercise values, 
with only diastolic blood pressure reaching statistical significance (p<0.05).  Rhythmic 
handgrip exercise led to a significant rise in blood pressure, heart rate, minute 
ventilation and VO2 in both groups.  There was no difference in the magnitude of the 
blood pressure response to exercise between the groups, but the DAN group did have a 
significantly smaller heart rate response to exercise when expressed in absolute values 
(9.7±1.3 beats per minute (bpm) vs. 15.7±2bpm, p<0.05).
5.6 The effects of regional circulatory occlusion at rest
Regional circulatory occlusion following 20 minutes of rest did not have any effect on 
any of the variables measured (see figures 5.1-5.12, raw data not reported).5.7 The effects of post-exercise regional circulatory occlusion
Post-exercise regional circulatory occlusion led to a sustained increase in systolic and 
diastolic blood pressure until the sphygmomanometer cuff was deflated (see table 5.4 
and figures 5.1-5.12).  This achieved statistical significance in both groups of patients. 
There was no difference in the magnitude of the response between the patient groups 
(see table 5.5).  Post-exercise RCO did not affect heart rate recovery in either group.  
It was found that measurement of ventilation was susceptible to the effects of 
hyperventilation after exercise whether or not the sphygmomanometer cuff was 
inflated.  During post-exercise RCO, there was a trend towards a higher VO2 compared 
with control recovery in the DAN group, but not in the control group (table 5.4 and 5.5, 
figures 5.9 and 5.10).
5.8 Pulse transit time
Due to the nature of the recording equipment, it was not possible to tell if there were 
problems with the pulse transit time tracing obtained until it had been downloaded to 
computer at the end of the session.  Vascular insufficiency may make it difficult to 
obtain a good pulse oximetry signal at the toe.  Despite this, we managed to obtain very 
good tracings from all patients with the exception of subject 3 (already excluded) and 
subject 6.  Figures 5.13 and 5.14 show two sample tracings, with the control exercise 
run superimposed upon the exercise run with post-exercise RCO.  There is a clear 
muscle metaboreflex effect on pulse transit time in subject 10 (figure 5.14), and this is 
less obvious, though still present, in subject 1 (figure 5.13).  Signal averaging of the 9 seconds around each point has been performed to allow clearer graphical illustration 
(figures 5.13 and 5.14): each point on the graph represents the mean of that point and 
the 4 points either side of it.  All tracings used for analysis were of similar quality to 
these graphs.  It is reassuring that pulse transit time tracings are almost identical for the 
two exercise runs in each patient with identical peak exercise values, suggesting 
reproducibility of the method of exercise and the method of PTT measurement.
Pulse transit time fell during rhythmic handgrip exercise in both groups (p<0.05).  Pulse 
transit time was lower during post-exercise RCO than during the equivalent recovery 
period following control exercise in both groups, although this was only significant 
during the last 2 minutes of post-exercise RCO (table 5.4, figures 5.11 and 5.12).
5.9 Comparison with normal subjects
The results of muscle metaboreflex testing of the normal control group used in chapter 
4 are given in table 5.6.  There was no difference in the muscle metaboreflex effect on 
blood pressure, heart rate or pulse transit time between any of the three groups.Table 5.3 Comparison of the effects of rhythmic handgrip exercise
Control Autonomic dysfunction
Rest Peak 
exercise Rest Peak 
exercise
Systolic BP (mmHg) 138.9±7.5 178.8±7.8** 123.8±6.5 156.9±5.8**
Diastolic BP (mmHg) 71.8±3.5 98.5±5.1** 63.1±3.3 84.9±2.3**†
Heart Rate (bpm) 80.1±1.4 96.0±1.6* 88.1±5.4 97.8±4.7**
Ventilation (l/min) 8.4±0.7 13.6±0.9** 8.3±1.1 12.1±1*
VO2 (ml/min) 143.7±15.7 219.5±23.5** 117±14.7 193.8±16.3**
PTT (ms) 278.2±12.7 240.1±12.8** 292.5±8.3 264.0±7.3**
All data are presented as mean ± standard error of the mean.  To compare resting and 
peak exercise values, a paired Student’s t-test was used after checking for normality 
using a Shapiro-Wilk test.  To compare values between groups, an unpaired Student’s t-
test was used after checking for normality.  *p<0.05, **p<0.005, rest vs peak exercise; 
†p<0.05, values between groups.Table 5.4 The effects of post-exercise regional circulatory occlusion: absolute 
values
Control Autonomic dysfunction
Control RCO Control RCO
Systolic BP (mmHg) 142.8±9 166.9±5.9** 129.8±6.7 153.6±6.8*
Diastolic BP (mmHg) 73.3±4.9 87.3±4.0** 65.8±3.4 80.3±2.9*
Heart Rate (bpm) 77.4±3.0 79.5±3.2 88.0±6.1 89.7±4.8
Ventilation (l/min) 10.7±0.7 11.3±1.0 10.8±1.2 13.4±1.7
VO2 (ml/min) 172.9±13.7 165.8±17.8 140.7±14.4 147.7±16.5
PTT (ms) 261.8±12.3 255.2±12.3 281.7±8.0 269.3±6.5*
Values given represent the “area under the curve” of the 3 minutes following peak 
exercise, either during control recovery or during post-exercise regional circulatory 
occlusion (RCO).  Statistical significance was assessed using a paired Student’s t-test 
after checking for normality using a Shapiro-Wilk test.  Comparison between control 
recovery and RCO: *p<0.05, **p<0.005.Table 5.5 The effects of post-exercise regional circulatory occlusion: percentage 
values
Control Autonomic dysfunction
Control RCO Control RCO
Systolic BP 12.8±8.7 71.1±6.4** 14.7±7.7 77.5±10.0**
Diastolic BP 3.5±7.0 59.7±5.0** 14.0±8.1 74.1±11.4*
Heart Rate 3.7±5.8 18.3±14.2 4.3±12.1 11.0±13.6
Ventilation  47.0±10.5 50.7±9.5 70.9±42.0 287.1±118.0
VO2 42.3±8.0 26.2±10.4 31.8±4.6 40.3±9.2
PTT  43.8±7.2 59.9±12.6 33.2±4.8 78.0±12.9*
This time, values following either three minutes of post-exercise RCO or the equivalent 
period of control recovery are expressed as a percentage of the effects of exercise (see 
text in chapter 2 for further information).  All data are presented as mean ± standard 
error of the mean.  To compare control and RCO values, a paired Student’s t-test was 
used after checking for normality using a Shapiro-Wilk test.   To compare values 
between groups, an unpaired Student’s t-test was used after checking for normality. 
*p<0.05, **p<0.005, rest vs peak exercise.Table 5.6 The effects of post-exercise regional circulatory occlusion on the normal 
control group used in chapter 4 (percentage values)
Normal control subjects
Control RCO
Systolic BP 11.7±6.3 95.2±11.0**
Diastolic BP 16.0±6.2 82.2±9.0**
Heart Rate 1.1±5.8 20.3±12.8
PTT  38.7±4.7 92.5±14.1*
Values following either three minutes of post-exercise regional circulatory occlusion 
(RCO) or the equivalent period of control recovery are expressed as a percentage of the 
effects of exercise (see text in chapter 2 for further information).  All data are presented 
as mean ± standard error of the mean.  To compare control and RCO values, a paired 
Student’s t-test was used after checking for normality using a Shapiro-Wilk test.  To 
compare values between groups, an unpaired Student’s t-test was used after checking 
for normality.  *p<0.05, **p<0.005, rest vs peak exercise.Figure 5.1 The effects of exercise followed by RCO on systolic blood pressure: 
control group
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Figure 5.2 The effects of exercise followed by RCO on systolic blood pressure: 
diabetic autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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*Figure 5.3 The effects of exercise followed by RCO on diastolic blood pressure: 
control group
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Figure 5.4 The effects of exercise followed by RCO on diastolic blood pressure: 
diabetic autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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** **Figure 5.5 The effects of exercise followed by RCO on heart rate: control group
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Figure 5.6 The effects of exercise followed by RCO on heart rate: diabetic 
autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
*
*Figure 5.7 The effects of exercise followed by RCO on ventilation: control group
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Figure 5.8 The effects of exercise followed by RCO on ventilation: diabetic 
autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**Figure 5.9 The effects of exercise followed by RCO on oxygen consumption (VO2): 
control group
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Figure 5.10 The effects of exercise followed by RCO on oxygen consumption 
(VO2): diabetic autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.Figure 5.11 The effects of exercise followed by RCO on pulse transit time: control 
group
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 Figure 5.12 The effects of exercise followed by RCO on pulse transit time: diabetic 
autonomic neuropathy group
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**Figure 5.13 Pulse transit time tracing for subject 1
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Figure 5.14.  Pulse transit time tracing for subject 10 
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Graphs looking at changes in pulse transit time during rhythmic handgrip exercise 
followed by regional circulatory occlusion (pink lines) and control recovery (blue lines) 
for subjects 1 and 10.  To allow greater clarity, each point on the graph represents the 
mean of that point plus the 4 points to either side to give a moving average.5.10Chapter discussion
To our knowledge, this is the first attempt to assess muscle metaboreflex function in a 
group of patients with diabetic autonomic neuropathy.  Previous studies looking at the 
muscle metaboreflex in patients with neurological dysfunction have always centred on 
the sensory nervous system, as documented earlier in the chapter.
The principal finding of this study is that there appears to be no difference in 
metaboreflex function between patients with diabetic autonomic neuropathy (DAN) and 
a group of control subjects with diabetes who do not have DAN as per the criteria of 
Ewing and Clarke .
Diabetic neuropathy would be expected to cause damage to both the afferent and 
efferent limbs of this reflex.  It is therefore surprising that we were so convincingly able 
to demonstrate normal metaboreflex function in our patient groups.  Our patients with 
DAN had a normal blood pressure response to rhythmic handgrip exercise, and post-
exercise regional circulatory occlusion led to a similar sustained increase in blood 
pressure as in the control diabetic group and the group of non-diabetic subjects used in 
chapter 4.  This raises the possibility that patients with diabetic neuropathy suffer from 
selective damage to some sensory and autonomic pathways but not others.  It is also 
possible that the diagnosis of autonomic neuropathy by the criteria of Ewing and Clarke 
has selected a group of patients with predominantly parasympathetic dysfunction, so it 
is therefore perhaps not a surprise that the metaboreflex, which is sympathetically 
mediated, is intact in our group.  Our finding of intact metaboreflex function is in 
keeping with the observation that phase I oxygen kinetics are similar in patients with autonomic neuropathy to those with normal autonomic function and control subjects , 
suggesting adequate delivery of oxygen to skeletal muscle and adequate regulation of 
oxygen supply.
It is noteworthy that post-exercise circulatory occlusion, which caused a sustained 
increase in blood pressure, did not affect heart rate recovery in either group, with heart 
rate falling rapidly to resting levels.  Resting heart rate was slightly higher in the DAN 
group, presumably due to the loss of normal resting parasympathetic tone.  This would 
explain the smaller heart rate response to exercise, with both groups achieving the same 
peak heart rate.   These findings are in keeping with previous work looking at 
metaboreflex control of heart rate.  As discussed in chapter 1, the initial heart rate 
response to exercise is mediated through central command and a withdrawal of 
parasympathetic tone.   During post-exercise muscle ischaemia, the withdrawal of 
central command, along with the effects of relative hypertension on the baroreflex, lead 
to a rapid fall in heart rate to resting levels .   We had hypothesised that the 
parasympathetic   dysfunction   in   our   DAN   group   would   lead   to   an   unopposed 
metaboreflex-mediated increase in heart rate during post-exercise RCO.   This was 
clearly not the case, with heart rate rapidly falling to resting levels.  The implication is 
that baroreflex control of heart rate in this group of subjects was intact, and raises the 
possibility that the baroreflex is “reset” to a higher resting heart rate.
There are many potential confounding factors when performing a study on subjects 
with diabetic autonomic neuropathy.  Patients with neuropathy due to diabetes mellitus 
are a heterogeneous group who appear to suffer from varying degrees of both sensory neuropathy   and   parasympathetic   and   sympathetic   dysfunction.     All   of   these 
abnormalities could potentially affect metaboreflex function.  As 5 of the 6 patients 
with autonomic neuropathy also had sensory neuropathy, we could conclude that the 
presence of a sensory neuropathy does not affect the afferent (sensory) limb of the 
metaboreflex.  It is also clear that many patients with long-standing diabetes mellitus 
suffer from subclinical autonomic dysfunction that is only evident on detailed testing . 
It is therefore very difficult to recruit a group of subjects matched for age and duration 
of diabetes that have got no evidence of autonomic dysfunction.  It is also true that 
peripheral neuropathy tends to affect the longer nerves in the legs before the shorter 
nerves in the arms are involved.  Any abnormalities in metaboreflex function would 
therefore presumably affect the leg muscles before affecting the forearm muscles that 
we tested.
5.11Chapter conclusions
In conclusion, subjects with diabetic autonomic neuropathy appear to have normal 
metaboreflex function in the forearm, with a normal heart rate recovery during post-
exercise RCO suggesting normal baroreflex buffering of the metaboreflex.Chapter 6
The Effects of Creatine Supplementation on Patients with 
Stable Chronic Obstructive Pulmonary Disease6.1 Chapter introduction
Creatine is a naturally occurring compound found in abundance in skeletal muscle, 
mainly in the form of phosphocreatine.  As discussed in chapter 1, it plays an integral 
role in skeletal muscle energy metabolism, with phosphocreatine acting as a crucial 
energy buffer to maintain supplies of adenosine tri-phosphate (ATP) .  It is of particular 
importance during high intensity, short-term exercise.   Creatine supplementation in 
healthy subjects is known to improve athletic performance in sprint events  and increase 
fat free mass , and it is therefore legally used as an ergogenic aid in “power” events in 
athletics.   It has also been demonstrated that creatine supplementation may benefit 
patients with neuromuscular diseases  and congestive cardiac failure .  Other studies 
have failed to demonstrate benefit in patients with neuromuscular diseases .
The multiple causes of exercise limitation in chronic obstructive pulmonary disease 
(COPD) were dealt with in chapter 1, and it is clear that abnormalities in skeletal 
muscle play an important role.  With the additional importance attached to nutrition and 
the development of cachexia in COPD, one can see why there has been some interest in 
creatine supplementation.  It was shown by Fuld et al  that creatine supplementation in 
patients   with   stable   COPD   during   an   exercise-based   pulmonary   rehabilitation 
programme led to an improvement in skeletal muscle strength and endurance, health-
related quality of life and fat free mass.  In this study, there was also an increase in fat 
free mass and peripheral muscle strength following creatine loading without exercise 
training.It has been shown in the past that it is possible to alter muscle metaboreflex activity in 
patients with chronic heart failure.  Piepoli et al  studied the effects of physical training 
and found that a 6 week programme of handgrip endurance training significantly 
reduced muscle metaboreflex activity.  The same group showed that it is possible to 
attenuate the muscle metaboreflex acutely through infusion of sodium bicarbonate, 
lending weight to the argument that intramuscular acidosis leads to metaboreceptor 
activation .  It is reasonable to hypothesise that creatine supplementation may also lead 
to attenuation of the metaboreflex.   An increase in the intramuscular stores of 
phosphocreatine during exercise should improve the rate of ATP regeneration and 
availability of energy during intensive exercise .
It has been suggested that creatine may have some beneficial effects on inflammatory 
pathways.  In vitro studies looking at the effects of creatine on endothelial cells suggest 
that creatine supplementation inhibits endothelial permeability, neutrophil adhesion and 
adhesion molecule expression on cultured endothelial cells .  Creatine may also have 
direct antioxidant effects, with a study by Lawler et al  suggesting that creatine displays 
a significant ability to act as an antioxidant scavenger against radical ions.  Santos et al 
studied the effects of creatine supplementation in vivo in a group of amateur athletes 
participating in a 30 kilometre race.  It was found that creatine supplementation led to 
significant attenuation of the post-race increase in markers of muscle damage and 
inflammation such as creatine kinase, prostaglandin E2  and TNF-α.   All of these 
findings are of potential relevance in patients with COPD and skeletal muscle 
dysfunction.   Couillard  et al    found that local quadriceps exercise performed to 
exhaustion led to evidence of markers of oxidative stress in the plasma of a group of 
patients with COPD, but not in healthy control subjects.  The same group followed this research up by demonstrating that exercise caused oxidative stress in the quadriceps 
muscle of patients with COPD, and this was associated with reduced quadriceps 
endurance .  If creatine does have anti-inflammatory and anti-oxidant properties, this 
may partially explain the benefits seen in patients with chronic disease.
Creatine supplementation may also affect the metabolism of homocysteine.  Creatine is 
synthesised in the human body by two metabolic steps.  Guanidinoacetate is synthesised 
from glycine and arginine in the kidney, and this reaction is catalysed by the enzyme 
arginine: glycine amidinotransferase.  Guanidinoacetate is then transported to the liver 
where it is methylated to creatine by guanidinoacetate-methyltransferase .  There is a 
daily loss of 2% of total body creatine in the urine, which is compensated for by dietary 
supplementation and endogenous creatine synthesis.  Methylation of guanidinoacetate 
to form creatine has been estimated to account for up to 70% of the transmethylation 
reactions in the body, and homocysteine is a byproduct of this process (see figure 6.1) . 
It   is   known   that   creatine   supplementation   suppresses   arginine:   glycine 
amidinotransferase biosynthesis and endogenous production of creatine, so it could be 
hypothesised   that   creatine   supplementation   should   reduce   the   production   of 
homocysteine.  Studies looking at haemodialysis patients  and normal young females 
have failed to prove this hypothesis, and it is clear that further larger studies are 
required.   It is known that elevated plasma homocysteine concentrations are a risk 
factor for the development of atherosclerotic disease .  Patients with COPD are known 
to suffer an excess of deaths from vascular disease (even after correction for other 
factors such as cigarette smoking) , so it is possible that this is a group of patients that 
would benefit from a reduction in plasma homocysteine levels.Figure 6.1 The interaction between homocysteine and creatine metabolism.
SAM = S-adenosylmethionine
SAH = S-adenosylhomocysteine
THF = Tetrahydrofolate
Guanidinoacetate is synthesised from glycine and arginine using the enzyme arginine: 
glycine amidinotransferase (1).  This is methylated in the liver to form creatine (2). 
Homocysteine is also formed from methionine as a byproduct of the methylation 
process.  Exogenous creatine supplementation suppresses synthesis of arginine: glycine 
amidinotransferase and the endogenous production of creatine.  (Diagram taken from 
Steenge et al ).6.2 Research questions
The aims of this study were to answer the following primary research questions:
i) Does loading  with  creatine  attenuate  muscle  metaboreflex  activity in 
patients with stable COPD?
ii) Does loading with creatine lead to any improvements in forearm muscle 
strength, endurance or recovery in patients with COPD?
iii) Does   loading   with   creatine   improve   inspiratory   or   expiratory   mouth 
pressures in patients with stable COPD?
iv) Does  loading  with   creatine  lead  to  a  reduction   in   levels  of  plasma 
homocysteine?
v) Does loading with creatine lead to a reduction in markers of systemic 
inflammation (C-reactive protein or interleukin 6)?
We also had the secondary research question:
i)   Can we apply our findings relating to the use of pulse transit time to a study 
looking at the effects of an intervention on the muscle metaboreflex?6.3 Patient characteristics
Patient characteristics are given in table 6.1.  It can be seen that this is a group of 
patients with moderate to severe airflow obstruction, impaired diffusion capacity and 
significant air trapping at rest.  This is an overweight group of patients, as can be seen 
by the mean body mass index of 28.4±1.8kg/m
2.  Five of the patients in the creatine 
study had previously participated in the study looking at the muscle metaboreflex in 
COPD (chapter 3).
Four subjects out of 15 withdrew from the study prior to completion.   Subject 7 
suffered from an exacerbation of COPD following visit 3.  She therefore completed the 
creatine arm but not the placebo arm.  We were unable to bring her back for the rest of 
the study due to expiry of the supplements.  Subject 8 withdrew half way through the 
first arm due to vomiting (this turned out to be the “creatine” arm).  He blamed the 
sweet taste of the supplements and did not wish to take part any further.  Subject 11 
developed mild diarrhoea during the first part of the study, but completed the course of 
supplements.  This turned out to be the placebo arm, but she withdrew consent as she 
did not wish to go through further exercise testing.   Subject 15 developed a mild 
exacerbation shortly after visit 2 and did not take any supplements.  He was therefore 
withdrawn from the study.
Eleven subjects therefore completed all parts of the study.  In addition, one subject 
completed the placebo arm only and one subject completed the creatine arm only. 
Compliance was excellent, and the correct number of empty bottles was returned on 
every occasion.  There were no side effects reported other than those described above.Table 6.1 Patient characteristics.
Total Subjects who 
completed study
Male/ Female (n) 7/ 8 5/6
Age (years) 64.9±2.2 65.2±2.7
Height (cm) 161.7±2.6 163.0±3.4
Weight (kg) 73.9±4.6 74.3±6.0
Smoking history (pack years) 53.7±6.3 50.9±7.7
Body mass index (kg/m
2) 28.4±1.8 28.2±2.4
FEV1 (litres) 1.26±0.16 1.35±0.21
FEV1 (% predicted) 53.3±5.2 56.7±6.9
FEV1/ FVC 42.3±2.7 43.4±3.5
Corrected TLCO (% predicted) 52.4±6.5 54.1±8.0
Residual volume (% predicted) 165.8±11.9 165.9±15.2
Total lung capacity (% predicted) 122.3±6.2 124.7±7.8
Maximum handgrip right hand (kg) 27.9±2.8 28.3±3.7
Maximum handgrip (% predicted) 89.2±4.4 91.3±4.9
Peak inspiratory pressure (cmH2O) 67.8±8.0 65.1±9.5
Peak inspiratory pressure (% predicted) 98.4±11.1 95.1±14.2
Peak expiratory pressure (cmH2O) 60.8±4.2 60.8±5.3
Peak expiratory pressure (% predicted) 61.3±3.6 60.8±4.3
Baseline characteristics of this patient group.  Data are presented as mean ± standard 
error of the mean.  The right hand column excludes patients who did not complete the 
study.  Predicted values for handgrip strength and peak mouth pressures were obtained 
from standard formulae and tables .6.4 Weight
Weight increased by 0.6±0.3kg in the creatine group (p<0.05), and by 0.3±0.2kg in the 
placebo group (p=ns).  These data are given in table 6.2.
6.5 Handgrip strength, endurance and recovery
Creatine supplementation did not affect handgrip strength or endurance in this group of 
patients (see table 6.2).  There was also no improvement in muscle recovery following 
endurance exercise (see tables 6.3 and 6.4, figures 6.2 and 6.3).  Placebo did not have 
any effects on these measurements.
6.6 Respiratory muscle strength
Creatine supplementation led to a statistically significant increase in peak inspiratory 
pressure (from 68.0±8.8cmH2O to 73.8±8.9cmH2O, p<0.05) and peak expiratory 
pressure (from 62.0±3.6cmH2O to 70.3±4.0cmH2O, p<0.01).   Supplementation with 
placebo did not affect respiratory muscle strength (see table 6.2, figures 6.4-6.7).Table 6.2 The effects of creatine loading and placebo.
Placebo arm Creatine arm
Pre-loading Post-loading Pre-loading Post-loading
Weight (kg) 74.4±6.0 74.7±6.1 74.1±5.9 74.7±6.0 *
Handgrip strength 
Right (kg) 27.9±3.9 28.1±3.8 29.2±4.5 29.0±4.2
Handgrip strength 
Left (kg) 26.2±3.9 26.3±3.9 27.1±4.2 27.4±4.3
Handgrip endurance 
Right (repetitions) 30.5±3.4 34.5±3.8 29.4±4.9 32.6±5.4
Handgrip endurance 
Left (repetitions) 27.1±1.7 30.5±3.1 33.5±5.3 35.0±4.7
Peak inspiratory 
pressure (cmH2O) 68.8±8.9 67.8±7.7 68.0±8.8 73.8±8.9 *
Peak expiratory 
pressure (cmH2O) 61.4±4.4 60.6±3.7 62.0±3.6 70.3±4.0 **
This table shows the effects of creatine loading and placebo on weight, mouth pressures 
and forearm muscle strength and endurance.  Data are presented as mean ± standard 
error of the mean.  Statistical significance was tested using a paired Student’s t-test after 
checking for normality using a Shapiro-Wilk test.  For comparison of pre-loading with 
post-loading: *p<0.05 **p<0.01.Table 6.3 The effects of creatine and placebo on right forearm muscle recovery
Placebo arm Creatine arm
Pre-loading Post-loading Pre-loading Post-loading
10s recovery 22.7±3.2 22.4±2.6 23.6±3.3 23.7±3.0
20s recovery 23.6±3.0 23.1±2.6 24.1±3.4 23.9±3.0
40s recovery 24.9±3.1 24.2±3.1 24.8±3.6 24.6±3.1
80s recovery 26.2±3.0 25.6±3.1 26.0±3.9 26.2±2.9
160s recovery 26.9±3.4 25.6±3.3 28.0±4.0 27.3±3.2
300s recovery 27.4±3.7 27.0±3.3 28.6±4.5 27.3±3.5
Table 6.4 The effects of creatine and placebo on left forearm muscle recovery
Placebo arm Creatine arm
Pre-loading Post-loading Pre-loading Post-loading
10s recovery 20.7±3.1 21.5±2.8 22.1±3.7 21.0±3.0
20s recovery 21.1±3.0 21.9±2.8 22.5±3.4 21.3±3.2
40s recovery 21.5±3.1 22.4±2.8 23.1±3.5 22.1±2.9
80s recovery 22.5±3.2 23.4±2.9 24.1±3.6 23.8±3.3
160s recovery 22.3±3.4 24.8±3.1 25.3±3.8 25.1±3.2
300s recovery 24.0±3.4 25.6±3.4 26.5±3.9 25.5±3.5
These tables show the effects of creatine and placebo on forearm muscle recovery 
following endurance testing for the right (top) and left (bottom) arms.   Data are 
presented as mean ± standard error of the mean.Figure 6.2 The effects of placebo on forearm muscle recovery
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Figure 6.3 The effects of creatine on forearm muscle recovery
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These graphs show the effects of supplementation with placebo (top) and creatine 
(bottom) on right arm forearm muscle recovery after endurance testing.  Error bars 
represent the standard error of the mean.Figure 6.4 The effects of placebo on peak inspiratory mouth pressure
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Figure 6.5 The effects of creatine on peak inspiratory mouth pressure
0
20
40
60
80
100
120
140
Pre Post
P
e
a
k
 
I
n
s
p
i
r
a
t
o
r
y
 
P
r
e
s
s
u
r
e
 
(
c
m
 
w
a
t
e
r
)
These graphs illustrate the effects of supplementation with placebo (top) and creatine 
(bottom) on peak inspiratory mouth pressure.Figure 6.6 The effects of placebo on peak expiratory mouth pressure
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Figure 6.7 The effects of creatine on peak expiratory mouth pressure
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These graphs illustrate the effects of supplementation with placebo (top) and creatine 
(bottom) on peak expiratory mouth pressure.6.7 The muscle metaboreflex
Rhythmic handgrip exercise led to significant increases in heart rate, ventilation, blood 
pressure and oxygen consumption (data not presented).  These changes were of similar 
magnitude to those seen in chapter 3.  There was also a significant reduction in pulse 
transit time, as seen with control subjects in chapter 4.  There was no difference in 
resting or peak exercise measurements between any of the four exercise runs in each 
patient (data not shown).  Control regional circulatory occlusion (RCO) following a 
period of rest did not affect any of the variables measured, as demonstrated previously 
in chapters 3-5.
Post-exercise RCO led to a sustained increase in systolic blood pressure (p<0.0005) and 
diastolic blood pressure (p<0.0001) compared with control recovery without RCO. 
These differences were of a similar magnitude to those seen in the patients in chapter 3 
(table 6.5, figures 6.8 and 6.9).  Post-exercise RCO did not affect heart rate recovery, 
ventilation or oxygen consumption (table 6.5, figures 6.10 and 6.12).  This is at odds 
with the data in chapter 3, where a significant effect on ventilation was seen.  The fall in 
pulse transit time seen with exercise was sustained during post-exercise RCO compared 
with control recovery (p<0.0001, see table 6.5 and figure 6.11).  It is of note that good 
pulse transit time tracings (suitable for analysis) were obtained in all subjects except 
subject 3.  All of the PTT tracings from subject 3 were of poor quality: possible reasons 
include tremor obscuring the “R” wave of the ECG, poor peripheral circulation and low 
oxygen saturations.Table 6.5 Baseline measurement of the muscle metaboreflex in all patients.
Rest Peak exercise 3min recovery 3min RCO
Heart rate 77.2±1.7 87.4±2.0* 78.3±2.1 78.0±2.1
Systolic BP (mmHg) 127.4±3.3 164.1±5.4* 135.3±4.3 161.2±5.7†
Diastolic BP (mmHg) 64.1±1.7 86.8±3.2* 67.5±2.4 82.4±3.0††
Ventilation (l/min) 9.9±0.7 13.2±0.9* 12.8±1.1 12.4±0.8
VO2 (ml/min) 143.8±9.8 204.0±15.8* 180.5±12.8 169.6±11.8
Pulse transit time (ms) 271.9±6.0 242.2±6.5* 260.0±5.9 247.7±6.1††
All data are presented as mean ± standard error of the mean.  To compare resting and 
peak exercise values, statistical significance was tested using a paired Student’s t-test or 
after checking for normality using a Shapiro-Wilk test.   *p<0.0005 compared with 
resting values.   Values given for post-exercise recovery and regional circulatory 
occlusion (RCO) represent the “area under the curve” for the 3 minute time period.  To 
compare these values, statistical significance was assessed using a paired Student’s t-
test after checking for normality: †p<0.0005 ††p<0.0001.Figure 6.8 The effects of exercise followed by RCO on Systolic blood pressure
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Figure 6.9 The effects of exercise followed by RCO on diastolic blood pressure
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These are the results of baseline testing.  Error bars represent standard error of the 
mean.  Comparison between “control” exercise run and “RCO” exercise run: *p<0.05, 
**p<0.01.  Statistical significance was assessed using analysis of variance for repeated 
measures.
**
**
**
**
** **Figure 6.10 The effects of exercise followed by RCO on heart rate
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 Figure 6.11 The effects of exercise followed by RCO on pulse transit time
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These are the results of baseline testing.  Error bars represent standard error of the 
mean.  Comparison between “control” exercise run and “RCO” exercise run: *p<0.05, 
**p<0.01.  Statistical significance was assessed using analysis of variance for repeated 
measures.
**
** **Figure 6.12 The effects of exercise followed by RCO on ventilation
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These are the results of baseline testing.  Error bars represent standard error of the 
mean.  Comparison between “control” exercise run and “RCO” exercise run: *p<0.05, 
**p<0.01.  Statistical significance was assessed using analysis of variance for repeated 
measures.6.8 The effects of creatine supplementation on the muscle metaboreflex
Resting and peak exercise blood pressure, heart rate, ventilation, pulse transit time and 
oxygen consumption were not affected by either creatine supplementation or placebo 
(data not shown).  Duration and intensity of exercise was deliberately kept the same for 
all exercise runs to allow comparison of the muscle metaboreflex at a similar level of 
work.
Tables 6.6-6.9 show the effects of creatine and placebo supplementation on muscle 
metaboreflex activity.   Figures 6.13-6.18 graph exercise responses and the muscle 
metaboreflex pre- and post-creatine loading.  Post-exercise RCO had significant effects 
on systolic and diastolic blood pressure compared with control recovery during all 
exercise runs.  Post-exercise RCO had a significant effect on PTT during all except the 
post-placebo exercise runs (this did not quite achieve statistical significance).  Again, 
ventilation and oxygen consumption were not significantly affected by post-exercise 
RCO in this group.  Creatine supplementation had no effect on the muscle metaboreflex 
contribution to any of the measured variables.  This also applied to supplementation 
with placebo.6.9 Pulse transit time measurement
It should be noted that there were some difficulties with a few of the pulse transit time 
tracings.  Thirty nine of the 49 tracings taken were of sufficiently good quality to 
analyse.  There were two problems in particular:
1. Loss of the oximetry signal due to poor circulation or cold feet occasionally led 
to a gap in the tracing.  It was not possible to view the data online, so problems 
could not be rectified as they arose.  One significant gap in the tracing would 
prevent analysis of any of the data from that visit.  This problem has been 
resolved by obtaining the software for the RM60 and using a laptop to view the 
data during testing.
2. Variable PTT tracing.  Patients with COPD often have tremor secondary to 
inhaled β-agonist or theophylline use.   The hyperinflated chest can also 
contribute to a poor ECG signal.  As PTT depends on identification of the “R” 
wave of the ECG, this can lead to analysis problems and a variable PTT tracing.
Complete data were available for ten of the patients before and after the creatine arm of 
the study.  There was data missing from five of the patients for the placebo arm, and 
these subjects are therefore excluded from analysis.  This explains why the decrease in 
PTT with post-exercise RCO did not achieve statistical significance following placebo 
supplementation.Table 6.6 The effects of placebo on the muscle metaboreflex: pre-loading
3min recovery 3min RCO Absolute difference
Heart rate (beats/min) 78.0±2.8 76.4±4.4 -1.6±0.9
Systolic BP (mmHg) 137.8±6.0 161.6±5.2** 23.8±5.8**
Diastolic BP (mmHg) 68.7±3.8 82.4±3.2** 13.7±3.8**
Ventilation (l/min) 12.3±1.2 12.3±1.2 0.0±0.7
VO2 (ml/min) 180.5±15.1 169.6±13.9 -10.9±7.3
Pulse transit time (ms) 272.6±12.8 260.0±13.1** -12.6±2.6**
Table 6.7 The effects of placebo on the muscle metaboreflex: post-loading
3min recovery 3min RCO Absolute difference
Heart rate (beats/min) 76.6±1.5 76.5±1.7 -0.1±1.9
Systolic BP (mmHg) 130.2±5.2 154.8±6.5** 24.6±4.1**
Diastolic BP (mmHg) 65.1±3.1 79.5±4.0** 14.4±2.7**
Ventilation (l/min) 10.9±0.7 11.8±1.1 1.0±5.5
VO2 (ml/min) 163.2±12.3 174.3±14.5* 11.1±5.5*
Pulse transit time (ms) 273.5±10.7 265.1±13.7 -8.4±4.9
These tables look at the muscle metaboreflex before (top) and after (bottom) placebo. 
The figures given represent the “area under the curve” for the three minutes of post-
exercise regional circulatory occlusion (RCO) and the equivalent period of control 
recovery.  Statistical analysis was carried out using a paired Student’s t-test to compare 
RCO with control recovery and to compare pre- and post- loading values.  Normality 
was tested using a Shapiro-Wilk test.  *p<0.05, **p<0.005.Table 6.8 The effects of creatine on the muscle metaboreflex: pre-loading
3min recovery 3min RCO Absolute difference
Heart rate (beats/min) 80.5±2.5 79.6±2.4 -0.9±1.2
Systolic BP (mmHg) 133.6±3.5 163.9±7.3** 30.3±5.4
Diastolic BP (mmHg) 64.2±1.4 82.5±3.4** 18.2±3.0
Ventilation (l/min) 11.5±1.1 11.8±1.0 0.3±0.9
VO2 (ml/min) 189.5±12.9 188.4±14.8 -1.2±5.5
Pulse transit time (ms) 262.7±6.9 252.4±7.5* -10.3±3.8
Table 6.9 The effects of creatine on the muscle metaboreflex: post-loading
3min recovery 3min RCO Absolute difference
Heart rate (beats/min) 74.1±1.4 74.5±1.9 0.4±1.1
Systolic BP (mmHg) 131.0±3.6 151.6±3.3** 20.6±3.3
Diastolic BP (mmHg) 62.3±1.4 74.4±2.2** 12.0±2.3
Ventilation (l/min) 11.1±0.8 11.7±1.2 0.6±0.8
VO2 (ml/min) 177.0±17.1 176.5±14.9 0.5±4.0
Pulse transit time (ms) 271.3±8.6 258.2±9.1** -13.1±1.9
These tables look at the muscle metaboreflex before (top) and after (bottom) creatine. 
The figures given represent the “area under the curve” for the three minutes of post-
exercise regional circulatory occlusion (RCO) and the equivalent period of control 
recovery.  Statistical analysis was carried out using a paired Student’s t-test to compare 
RCO with control recovery and to compare pre- and post- loading values.  Normality 
was tested using a Shapiro-Wilk test.  *p<0.05, **p<0.005.Figure 6.13a The effects of exercise followed by RCO on systolic blood pressure: 
before creatine loading
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Figure 6.13b The effects of exercise followed by RCO on systolic blood pressure: 
after creatine loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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** **
*
** **
**Figure 6.14a The effects of exercise followed by RCO on diastolic blood pressure: 
before creatine loading
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Figure 6.14b The effects of exercise followed by RCO on diastolic blood pressure: 
after creatine loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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** **
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**
**Figure 6.15a The effects of exercise followed by RCO on heart rate: before 
creatine loading
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Figure 6.15b The effects of exercise followed by RCO on heart rate: after creatine 
loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.Figure 6.16a The effects of exercise followed by RCO on pulse transit time: before 
creatine loading
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Figure 6.16b The effects of exercise followed by RCO on pulse transit time: after 
creatine loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
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**
*
**
** ** **Figure 6.17a The effects of exercise followed by RCO on ventilation: before 
creatine loading
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Figure 6.17b The effects of exercise followed by RCO on ventilation: after creatine 
loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
**Figure 6.18a The effects of exercise followed by RCO on oxygen consumption: 
before creatine loading
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Figure 6.18b The effects of exercise followed by RCO on oxygen consumption: 
after creatine loading
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Error bars represent standard error of the mean.   Comparison between “control” 
exercise run and “RCO” exercise run: *p<0.05, **p<0.01.  Statistical significance was 
assessed using analysis of variance for repeated measures.
**
**6.10Analysis of serum
Baseline measurements of interleukin 6, C-reactive protein and homocysteine are given 
in table 6.10 for all patients except patient 12 (see below).
It was clear looking at the raw data that patient 12 had very abnormal results during 
visit 2.  C-reactive protein was 112.31mg/l at visit 2 and less than 10mg/l at subsequent 
visits.  Interleukin 6 was also much higher than expected.  It was not clear whether this 
was due to an error of analysis or a recent infective or inflammatory episode.  We 
therefore withdrew this patient’s results from analysis and the graphic representation.
Creatine loading did not have any significant effects on C-reactive protein, interleukin 6 
or homocysteine.  These results are given in table 6.11 and figures 6.19-6.21.  As 
expected, placebo supplementation did not affect any of these variables.Table 6.10 Baseline CRP, IL-6 and homocysteine
Baseline
C-reactive protein (mg/l) 5.9±1.1
Interleukin 6 (pg/ml) 4.5±0.30
Homocysteine (μmol/l) 19.5±3.0
Baseline measurements of C-reactive protein, interleukin 6 and homocysteine.  All data 
are given as mean ± standard error of the mean.  Patient 12 was excluded from the 
analysis for reasons that have been explained in the text.
Table 6.11 The effects of creatine loading on CRP, IL-6 and homocysteine
Placebo arm Creatine arm
Pre-loading Post-loading Pre-loading Post-loading
C-reactive protein 
(mg/l) 5.7±1.5 6.4±1.7 4.6±1.0 4.1±1.0
Interleukin 6 (pg/ml) 4.24±0.43 4.92±0.81 4.48±0.53 4.70±0.49
Homocysteine (μmol/
l) 18.0±1.5 19.1±4.1 21.8±5.1 19.9±7.2
Data are given as mean ± standard error of the mean.  Comparison of pre- and post-
loading values was carried out using a paired Student’s  t-test after checking for 
normality using a Shapiro-Wilk test.Figure 6.19a The effects of placebo on C-reactive protein
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Figure 6.19b The effects of creatine on C-reactive protein
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These graphs illustrate the effects of supplementation with placebo (top) and creatine 
(bottom) on C-reactive protein.Figure 6.20a The effects of placebo on interleukin 6
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Figure 6.20b The effects of creatine on interleukin 6
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These graphs illustrate the effects of supplementation with placebo (top) and creatine 
(bottom) on interleukin 6 (IL-6).Figure 6.21a The effects of placebo on homocysteine
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Figure 6.21b The effects of creatine on homocysteine
0
5
10
15
20
25
30
35
pre post
H
o
m
o
c
y
s
t
e
i
n
e
 
(
m
i
c
r
o
m
o
l
e
s
/
l
)
These graphs illustrate the effects of supplementation with placebo (top) and creatine 
(bottom) on homocysteine.6.11 Chapter Discussion
6.11.1 The muscle metaboreflex
The primary research question of this study was whether creatine supplementation had 
any effect on muscle metaboreflex activity in a group of patients with COPD.  As 
previously discussed, COPD is a disease characterised by histological, metabolic and 
functional abnormalities of skeletal muscle function very similar to those in patients 
with chronic heart failure.  We wished to test the hypothesis that creatine loading, 
which has already been shown to improve skeletal muscle function in patients with 
stable COPD, attenuates muscle metaboreflex activity.
It can be seen from the data presented that our exercise protocol was able to detect 
muscle   metaboreflex   activity   in   this   patient   group,   with   post-exercise   regional 
circulatory occlusion leading to a sustained increase in systolic and diastolic blood 
pressure, but not heart rate.  The results obtained for these variables are very similar to 
those presented in chapter 3 using a different group of patients with COPD.  Our data 
on the use of pulse transit time are also encouraging, with very good tracings obtained 
in most subjects.  Once we figured out how to view the pulse transit time data during 
exercise testing, it was possible to see when there was a problem with the tracing which 
could then be rectified.  As a result, pulse transit time recording was much more reliable 
in the later stages of the study.
It is worth noting that we did not see a sustained increase in ventilation during post-
exercise RCO in this study.  This is at odds with the data in chapter 3 of this thesis, and the previously published data in chronic heart failure.  As discussed in chapter 1, the 
contribution of the muscle metaboreflex towards ventilatory control is still somewhat 
controversial.  We found that measuring minute ventilation “online” with a metabolic 
cart led to variability in results which made them hard to interpret.  Breathing pattern 
often   changes   when   breathing   through   a   mouthpiece,   even   when   allowing 
familiarisation time with the equipment.   When exercise commenced, it was often 
found that minute ventilation fell as the subject started to concentrate on the handgrip 
display.   As handgrip exercise did not have a great effect on minute ventilation 
(compare the effects of total body exercise, where minute ventilation may increase 
30-40 fold), the effects of such voluntary control of ventilation are magnified.  This 
makes it difficult to pick out the effects of handgrip exercise and post-exercise RCO 
over the “noise” of other factors which affect ventilation.  Blood pressure and pulse 
transit time therefore appear to be more robust variables by which to measure muscle 
metaboreflex activity.
6.11.2 The effects of creatine supplementation on peripheral skeletal muscle
It is clear from our data that creatine supplementation did not have an effect on forearm 
skeletal muscle function or muscle metaboreflex activity in this group of patients. 
There   were   no   improvements   in   maximum   handgrip   strength,   forearm   muscle 
endurance or forearm muscle recovery following 10 days of creatine supplementation. 
These results are disappointing, given the previously documented improvements in 
skeletal muscle strength seen in patients with chronic heart failure and COPD following 
supplementation with creatine.  Gordon et al  demonstrated that 10 days of creatine loading in a group of patients with chronic heart failure led to an improvement in lower 
limb skeletal muscle performance . A study looking at 5 days of creatine loading in a 
similar group of patients by Andrews et al demonstrated improvements in ability to 
perform   repetitive   forearm  muscle   contractions   at   75%   of   maximum  voluntary 
contraction .  A reduction in ammonia and lactate production per muscle contraction 
was also seen.  This finding is potentially relevant to our study given that lactate has 
been implicated as an activator of the metaboreflex.  The effects of creatine loading in 
patients with COPD in the study by Fuld et al  were described in the introduction .  In 
contrast to this, Gosselink et al  found that creatine loading followed by maintenance 
dosing in patients with COPD did not improve the training effect seen with an exercise-
based pulmonary rehabilitation programme.   It should be noted that creatine was 
administered without carbohydrate in this study: carbohydrate administration has been 
shown to augment the uptake of creatine by skeletal muscle .
The quantity of creatine used in our study would appear adequate, as ingestion of 20g 
of creatine daily for 5 days by healthy volunteers has been shown to lead to an increase 
in muscle creatine concentration of 20%, the majority of tissue creatine uptake 
occurring during the initial few days of supplementation .  Compliance appeared to be 
excellent, though it is possible that not all supplements were taken.   Creatine 
supplementation did lead to a significant increase in body weight not seen in the 
placebo arm, in keeping with previous studies.
It is possible that our study was looking at the wrong muscle group.  The forearm 
muscles of patients with COPD have been shown to be relatively well preserved in 
comparison with the lower limb muscle groups .  This is thought to relate to greater 
disuse of the lower limb muscles.  It is feasible that creatine supplementation has a greater effect on the larger muscles of the legs, and we should perhaps have looked at 
muscle metaboreflex activity in the legs.
It is well documented that there is significant inter-subject variability in response to 
creatine supplementation.  Possible factors include nutritional status, creatine uptake by 
skeletal muscle and creatine excretion.  It has been reported that 20-30% of healthy 
subjects do not respond to creatine supplementation, in that no increase in muscle total 
creatine is seen .  In the study looking at creatine supplementation in chronic heart 
failure by Gordon et al, only the subjects with a low muscle total creatine demonstrated 
a significant response to supplementation .  Improvement in muscle function appeared 
to occur primarily in this group of patients.  The multi-system disease that is COPD 
encompasses a heterogeneous group of patients with varying degrees of airflow 
limitation, gas exchange abnormalities, skeletal muscle dysfunction and systemic 
inflammation.  It is therefore possible that creatine supplementation benefits a “sub-
group” of patients with COPD that a small study such as this will not identify.  It should 
also be noted that our study looked at a group of patients who were overweight (mean 
body mass index of 28.4±1.8), perhaps the group least likely to benefit from creatine 
supplementation.  Further studies should perhaps look at muscle biopsies and analysis 
of urinary excretion of creatine, and select a group of undernourished patients with 
COPD limited by “peripheral” rather than “ventilatory” factors.
The failure of creatine supplementation to attenuate muscle metaboreflex activity in this 
group of patients is therefore not surprising.  Creatine supplementation did not appear 
to alter any objective measurement of peripheral skeletal muscle function.  Attenuation 
in muscle metaboreflex activity would imply a change in muscle bioenergetics, which 
should also manifest as an improvement in muscle function.  It is possible that the reason that creatine supplementation does not have an effect on 
the  muscle  metaboreflex   is   that  it   targets   the  wrong  metabolic   process.    The 
measurement of the muscle metaboreflex uses post-exercise regional circulatory 
occlusion to “fix” the metabolic state of skeletal muscle at the point of fatigue 
following endurance exercise.  Creatine supplementation is known to improve muscle 
performance in “strength” and “sprint” events rather than “endurance” events.  It is 
inevitable that metabolic products of anaerobic metabolism will have accumulated at 
the point of fatigue, and it is difficult to see what impact creatine supplementation 
would have on the “metabolic environment” surrounding the metaboreceptors at this 
point.  In the context of a study looking at creatine supplementation, it would perhaps 
be more appropriate to measure the muscle metaboreflex following a very short period 
of intense exercise in a large muscle group rather than a longer period of forearm 
endurance exercise.  The importance of this concept is highlighted by looking at the 
only two studies demonstrating that an intervention can have an effect on the muscle 
metaboreflex.  Bicarbonate infusion, as studied by Scott et al, has an immediate effect 
on intramuscular acidosis, one of the main drivers of the muscle metaboreflex . 
Forearm muscle training, as studied by Piepoli  et al, has an effect on endurance 
exercise and the ability of skeletal muscle to avoid anaerobic metabolism .  The main 
effects of creatine supplementation, however, are on the performance of skeletal muscle 
during “short burst” exercise: cardiorespiratory control and regulation of muscle blood 
flow are not mediated by the muscle metaboreflex in such circumstances.
6.11.3 The effects of creatine supplementation on respiratory muscle functionThe   novel   finding   of   this   study   was   that   there   was   a   statistically   significant 
improvement in peak inspiratory and peak expiratory mouth pressures following 
creatine supplementation.  This improvement was not seen in the placebo arm.  This is 
an interesting and potentially important finding.   Respiratory failure is a serious 
consequence of an acute exacerbation of COPD, and ventilatory support in the form of 
invasive ventilation is often deemed inappropriate.  It can also be difficult to wean 
patients from a ventilator following a pronged period of invasive ventilation.  Such 
patients often have a negative protein balance, with loss of muscle mass due to disuse, 
muscle paralysis, poor nutrition and the acute inflammatory response.  It would be 
interesting to study creatine supplementation in this setting to see if it has any effect on 
muscle recovery.  It must be remembered, however, that the documented effects of 
creatine supplementation relate to “short burst” exercise rather than endurance: the 
muscles of respiration could be considered to be the ultimate muscles of endurance.6.11.4 The effects of creatine supplementation on markers of systemic inflammation
Creatine supplementation did not affect C-reactive protein or interleukin 6 levels in this 
patient group.  This presumably reflects the small numbers studied, and a larger study is 
needed to look at the effects of creatine supplementation on the systemic inflammatory 
response.  The baseline variability of such markers makes a longitudinal study difficult 
in such a small group.  A longer period of supplementation is perhaps also needed.
The potential effects of creatine supplementation on plasma homocysteine levels were 
discussed in the chapter introduction.  It is difficult to say what should be regarded as a 
“normal” homocysteine level, but it has been suggested that the normal range is 
between 5 and 16μmol/l .   The same paper suggested that 10μmol/l should be 
considered an achievable target, given the risk of atherosclerotic disease in patients with 
hyperhomocysteinaemia .  Only 2 of our 15 subjects had a plasma homocysteine level 
<10μmol/l.   Four subjects could be considered to have “moderate” (16-30μmol/l) 
elevations in plasma homocysteine, and a further 2 subjects had “medium” elevations 
(30-100μmol/l) .   It is possible that dietary factors are important given that intake of 
folate and vitamins B6 and B12 appear to affect levels of homocysteine: the West of 
Scotland has a poor dietary record with very low consumption of fresh fruit and 
vegetables.  It was disappointing that creatine supplementation in this study did not 
have an effect on the elevated plasma homocysteine seen in our patient group.  It is 
possible that studies looking at longer term supplementation in a larger group of 
patients are needed.6.12 Chapter conclusions
In conclusion, the effects of creatine supplementation in this group of patients were 
disappointing, particularly in light of the encouraging results of the study by Fuld et al 
in COPD  and the studies looking at creatine supplementation in chronic heart failure . 
It is possible that creatine affects skeletal muscle in a way that will not be picked up by 
measurement of the muscle metaboreflex using this protocol.  The effects of creatine on 
respiratory muscle dysfunction are of particular interest, and perhaps merit further 
detailed study. Chapter 7
Methodological issuesThe research undertaken for this thesis has raised a number of important issues 
regarding the methodology of these, and any future studies.   This chapter aims to 
address some of these issues.
7.1 Control subjects
When undertaking physiological research into a group of patients with a certain medical 
condition, it is important to know how a population of normal healthy subjects behaves: 
a control group.  Our failure to include a group of control subjects in chapter 3 of this 
thesis could be criticised, although we had significant difficulties in obtaining a group 
of age-matched control subjects locally.  This explains our decision to split the COPD 
patients into moderate and severe groups to see if there were any differences, although 
this was done post-hoc.  A substantial body of literature does, however, exist studying 
the muscle metaboreflex in a normal population.
One of the difficulties with selecting a group of normal control subjects to compare 
with a diseased population is that there are often many differences between the groups 
that may or may not be related to disease.  It is well known that patients with COPD 
perform less physical activity than an age-matched healthy population, and other 
confounding factors may include cigarette smoking, the effects of certain medications 
and genetic susceptibility.  There is often fierce debate as to whether the changes that 
are seen in skeletal muscle in patients with COPD are part of the disease process or are 
simply down to disuse and deconditioning.  Skeletal muscle abnormalities in COPD 
resemble those seen in an unfit population , albeit the changes are more pronounced.We did study a group of normal healthy subjects in our study looking at pulse transit 
time (chapter 4), and it is therefore possible to undertake a limited comparison between 
this group and our patients with COPD.
Table 7.1 Subject characteristics
Control group COPD group
Male/ Female (n) 7/0 8/6
Age (years) 32.3±2.2 63.7±3.1**
Height (cm) 179.6±2.7 164±2.6
Weight (kg) 82.6±2.8 73.3±4.8
Body mass index (kg/m
2) 25.6±1.2 27.4±1.7
FEV1 (litres) - 1.18±0.12
FEV1 (% predicted) - 46.4±3.7
FEV1/ FVC - 37.9±3
Values given are mean ± standard error of the mean.  Comparison was made between 
groups using unpaired Student’s t-test after checking for normality using a Shapiro-
Wilk test.  We did not have pulmonary function data on the control group.  *p<0.001.Table 7.2 Resting and peak exercise measurements
Control group COPD group
Rest Peak exercise Rest Peak exercise
Systolic BP (mmHg) 127.1 ± 6.1 158.9 ± 5.5* 128.0±5.0 156.1±5.5*
Diastolic BP (mmHg) 67.9 ± 4.4 92.3 ± 4.7* 77.5±3.7 102.1±5.3*
Heart rate (bpm) 70.0 ± 4.3 87.6 ± 6.1* 80.6±3.5 91.2±3.5*
All values are mean ± standard error of the mean.  Statistical significance within each 
group was assessed using a paired Student’s t-test after checking for normality using a 
Shapiro-Wilk test.  *p<0.0001 compared with resting values.Table 7.3 The effects of post-exercise regional circulatory occlusion
Control group COPD group
3 min 
recovery
Post-exercise 
RCO
3 min 
recovery
Post-exercise 
RCO
Systolic BP (mmHg) 130.2 ± 7.2 157.6 ± 8.3** 132.5±4.0 153.5±5.7*
Diastolic BP (mmHg) 72.0 ± 5.0 89.0 ± 5.6* 79.1±3.3 94.6±3.6**
Heart rate (bpm) 69.9 ± 4.5 74.6 ± 4.8 80.9±3.6 81.5±3.5
Values given represent the “area under the curve” of the 3 minutes following peak 
exercise, either during recovery from exercise without regional circulatory occlusion 
(RCO) or during post-exercise RCO.   Statistical significance was assessed using a 
paired (within groups) or unpaired (group comparison) Student’s t-test after checking 
for normality using a Shapiro-Wilk test.  *p<0.005, **p<0.001 (control recovery versus 
RCO).  No statistically significant difference between groups.It can be seen from table 7.1 that there was a significant difference in age between the 
control group and the group of patients with COPD.   Table 7.2 details the blood 
pressure and heart rate responses to rhythmic handgrip exercise to fatigue.  We were not 
able to obtain data on ventilation or gas exchange on the control group.  It can be seen 
that absolute blood pressure responses to exercise were almost identical between the 
groups.  There was a trend towards a higher resting heart rate in the COPD group 
(p=0.08).  This could reflect the age of the two groups, the younger control group 
having a higher resting parasympathetic tone.  It is also recognized that patients with 
COPD have an elevated resting heart rate, with possible explanations including 
hypoxaemic stimulation of peripheral chemoreceptors, activation of the respiratory 
metaboreflex or beta adrenergic medications .
The effects of muscle metaboreflex activation on blood pressure and heart rate are 
documented in table 7.3.   Rhythmic handgrip exercise followed by post-exercise 
regional circulatory occlusion led to a sustained elevation in systolic and diastolic blood 
pressure in both groups, suggesting muscle metaboreflex activation.  There was no 
effect on heart rate, reflecting a normal baroreflex-mediated return of parasympathetic 
tone and withdrawal of central command (discussed in chapters 1 and 3).  Comparison 
of the muscle metaboreflex effect on blood pressure and heart rate between controls and 
subjects with COPD did not reveal any significant differences.7.2 Historical control data
There are some limitations to the above comparisons between our healthy control group 
and our group of patients with COPD.  We did not obtain data on ventilation and gas 
exchange on our control group, as they had been selected to participate in a different 
study, during which we did not have access to a metabolic cart.  The control group was 
also significantly younger, although there has been one study suggesting that there is no 
difference in muscle metaboreflex activity between young subjects and a healthy older 
group .   Studies looking at the muscle metaboreflex in patients with chronic heart 
failure have, however, used age-matched control groups, and this allows some further 
comparisons to be made.
When selecting a study with which to compare our data, it is important to choose a 
study using a similar exercise protocol.  On review of the literature studying the muscle 
metaboreflex in patients with chronic heart failure, there are important differences in 
how the muscle metaboreflex is measured.  Some studies use static rather than dynamic 
handgrip exercise , some look at lower rather than upper limb , and some use handgrip 
exercise to a pre-determined point in time rather than exercise to fatigue .  The potential 
importance of these issues is discussed later in this chapter.
Piepoli et al studied the effects of a forearm exercise training programme on muscle 
metaboreflex activity in healthy control subjects and in patients with chronic heart 
failure .  The protocol used for metaboreflex assessment in this study was similar to our 
protocol: rhythmic handgrip exercise to fatigue using a handgrip dymamometer, with 
40   contractions   per   minute   at   50%   of   the   pre-determined   maximal   voluntary contraction.   Sphygmomanometer cuff inflation took place just before the end of 
exercise at 30mmHg above systolic blood pressure for 3 minutes.  Tables 7.4 and 7.5 
therefore compare our COPD population with the control and chronic heart failure 
subjects in this study.
It is obviously impossible to perform any statistical analysis on these groups due to the 
lack of access to the raw data from the study by Piepoli et al.  Resting parameters are 
similar between the chronic heart failure and COPD groups, with the exception of 
minute ventilation, which could be explained by increased dead space ventilation and 
V/Q mismatch in the COPD group.  Our group of patients with COPD appeared to have 
a reduced heart rate and systolic blood pressure response to exercise, which may reflect 
slight variation in the exercise protocol and work undertaken rather than any true 
difference between groups.Table 7.4 Comparison of the characteristics of control and chronic heart failure groups 
with our COPD group
Control group CHF group COPD group
Number 10 12 14
Age (years) 59.2±3.5 59.6±1.7 63.7±3.1
Weight (kg) 75.9±3.3 78.3±3.6 73.3±4.8
Body mass index (kg/m
2) Unclear Unclear 27.4±1.7
Resting VE (l/min) 7.6±0.1 7.5±0.1 10.7±0.4
Peak exercise VE (l/min) 14.3±1.0 20.2±1.9 18.1±0.7
Resting SBP (mmHg) 132.3±1.6 128.1±1.4 128.0±5.0
Peak exercise SBP (l/min) 189.6±6.6 176.0±7.3 156.1±5.5
Resting DBP (l/min) 73.8±0.6 77.4±0.7 77.5±3.7
Peak exercise DBP (l/min) 99.4±4.1 101.8±2.7 102.1±5.3
Resting HR (bpm) 67.1±0.7 77.9±0.5 80.6±3.5
Peak exercise HR (bpm) 92.2±3.7 96.2±2.7 91.2±3.5
Resting VO2 (ml/min) 235.5±5.0 215.0±4.1 187.0±10.0
Peak exercise VO2 (ml/min) 446.6±20.0 375.5±13.7 301.0±18.0
CHF = chronic heart failure, COPD = chronic obstructive pulmonary disease.  All data 
are given as mean ± standard error of the mean.  CHF data and control data are taken 
from Piepoli et al .  Further statistical analysis was not performed due to lack of access 
to the raw data.Table 7.5 Comparison of the effects of post-exercise regional circulatory occlusion 
(RCO) on control, CHF and COPD subjects
Control group CHF group COPD group
Systolic BP (mmHg)
· Control recovery
· RCO
· Percentage
135.4±9.2 129.0±6.2 132.5±4.0
166.2±8.1* 171.5±5.5* 153.5±5.7*
59.2 90.6 90.7
Diastolic BP (mmHg)
· Control recovery
· RCO
· Percentage
75.1±2.7 77.7±2.7 79.1±3.3
91.0±4.1* 101.5±2.4* 94.6±3.6*
67.2 98.8 69.5
Heart rate (bpm)
· Control recovery
· RCO
· Percentage
70.6±3.1 80.3±2.6 80.9±3.6
70.8±5.4 82.0±3.1 81.5±3.5
14.7 22.4 8.5
Ventilation (l/min)
· Control recovery
· RCO
· Percentage
8.3±0.5 8.6±0.8 12.4±0.5
11.6±0.9* 20.2±2.3* 14.7±0.8*
59.7 100 54.1
VO2 (ml/min)
· Control recovery
· RCO
· Percentage
251.2±10.4 219.4±11.6 205.0±13.0
240.0±16.0 219.7±16.1 231.0±15.0*
2.1 2.9 38.6
CHF = chronic heart failure, COPD = chronic obstructive pulmonary disease.  All data 
are given as mean ± standard error of the mean.  Control and CHF data are taken from 
Piepoli et al .  Statistical analysis between groups was performed using paired Student’s 
t-test after checking for normality using a Shapiro-Wilk test.  *p<0.005.Table 7.5 looks at muscle metaboreflex activity in a healthy control group, a group of 
patients with stable chronic heart failure and our group of patients with COPD.  It is 
difficult to compare the effects of post-exercise regional circulatory occlusion (RCO) 
on absolute values due to the differences in baseline and peak exercise variables 
between the groups.  That explains why percentage values are reported in table 7.5, 
which reflect the effect of post-exercise RCO on the change in a variable from rest to 
peak exercise, and these values can be directly compared across different groups.
It can be seen that there does not appear to be a difference in metaboreflex effect on 
ventilation between the healthy control group and our COPD group.  This is in keeping 
with our finding in chapter 3 of no differences between the group of patients with 
moderate COPD and the group with more severe airflow obstruction.  The data on 
blood pressure do, however, raise the possibility that there is a heightened muscle 
metaboreflex contribution to exercise blood pressure responses in patients with COPD. 
Further statistical analysis is not possible, so we cannot draw any further conclusions 
from this.
7.3. Method of exercise
It is difficult to compare studies on the muscle metaboreflex in humans due to the wide 
range of exercise protocols that can be employed.  There is considerable debate as to 
the contribution of the muscle metaboreflex to ventilation in humans, and different 
groups argue that the metaboreflex is more active or less active in patients with cardiac failure.  Some of this debate will no doubt reflect the variation in exercise protocols, as 
highlighted by the following discussion.
7.3.1 Static vs rhythmic forearm exercise
Many research groups appear to favour static rather than dynamic handgrip exercise 
when studying the muscle metaboreflex.   Sinoway’s group, who propose that the 
muscle metaboreflex is attenuated in heart failure, used static handgrip exercise at 30% 
of maximal voluntary contraction prior to cuff inflation .  Piepoli’s group, who propose 
that the muscle metaboreflex is upregulated in heart failure, use rhythmic handgrip 
exercise to fatigue .   There are important physiological differences between such 
exercise protocols that make comparison between such experiments very difficult.
During static exercise, an increase in intramuscular pressure will be transferred to 
intramuscular blood vessels, preventing blood flow into and within the muscle .  It can 
therefore be assumed that there is relatively little oxidative metabolism of muscle 
glycogen during such exercise.   During rhythmic handgrip exercise, blood flow is 
possible during the relaxation phase, thus allowing oxygen delivery to exercising 
skeletal muscle.  Total work performed will be greater with dynamic exercise, leading 
to some aerobic and anaerobic metabolism of muscle glycogen.  It could be argued that 
rhythmic exercise allows more meaningful study of the oxidative capabilities of skeletal 
muscle.  Our hypothesis does, after all, relate to impaired oxidative metabolism during 
exercise leading to metaboreflex upregulation.  There is surprisingly little literature studying the effects of static and dynamic exercise on measurement of the muscle 
metaboreflex, and this certainly merits further research.
7.3.2 Timing of cuff inflation
Many of the studies on the muscle metaboreflex use forearm exercise to fatigue 
followed by cuff inflation.  Some studies appear to use an arbitrary cut-off point such as 
“5 minutes after commencement of exercise” .  There are clear difficulties with both 
approaches.  The use of an arbitrary point in time risks some subjects not managing to 
reach this point.  On the other hand, skeletal muscle is bound to demonstrate an acidosis 
at the point of fatigue, and this will clearly lead to muscle metaboreflex activation.  It 
could therefore be argued that fatigue is not the correct point at which to measure 
metaboreflex activity if we are to demonstrate differences between subject groups.  In 
the creatine study (chapter 6), we were careful to ensure that subjects exercised at the 
same work rate for the same time during each leg of the study to avoid this confounding 
problem.
It is clear that the method of exercise to fatigue followed by cuff inflation will lead to 
supra-maximal stimulation of the muscle metaboreflex.  This may not be representative 
of the way in which the reflex behaves during normal day to day activity, and it is 
therefore possible that lower intensity exercise should be employed when studying the 
metaboreflex.Skeletal muscle fatigue may also explain why we could not detect differences in 
metaboreflex activity between our diabetic autonomic neuropathy group and diabetic 
control group (chapter 5): perhaps muscle fatigue generates a supra-physiological signal 
which overcomes any subtle abnormalities of the sensory or autonomic nervous 
systems.
7.3.3 Exercise intensity
Choice of exercise intensity is also of importance.  A heavy exercise load will cause 
rapid muscle fatigue and development of an intramuscular acidosis.   A very light 
exercise load will cause recruitment of a different muscle fibre type , and this may lead 
to barely perceptible increases in measured variables, with the effects of exercise lost in 
“noise”.  It is also known that there are differences in reflex physiological responses to 
different degrees of forearm exercise intensity.  Batman et al  showed that a prolonged 
bout of low intensity rhythmic handgrip exercise led to a gradual increase in muscle 
sympathetic nerve activity in the absence of an intramuscular acidosis, suggesting that 
mechanoreceptor activation is of greater importance in this context.7.3.4   Arm exercise vs leg exercise
Most muscle metaboreflex research in humans has concentrated on forearm muscle 
exercise.  The main reason for this is that it is far easier to exercise an isolated group of 
arm muscles without using “accessory” muscles that will confound the results.  It is also 
much simpler to isolate exercised forearm muscle from the rest of the body with a 
sphygmomanometer cuff than it is to isolate leg muscle: the bulkier quadriceps muscles 
make it difficult to occlude the vasculature reliably.
The question of whether to study arm muscle or leg muscle is important when looking 
at the muscle metaboreflex in disease.  It is known that the arm muscles are relatively 
preserved in patients with COPD when compared with the leg muscles .   This 
presumably reflects greater disuse and deconditioning of the leg muscles.  It would 
therefore be of interest to study the muscle metaboreflex in the leg in patients with 
COPD.  Although it is more difficult to study the lower limb, it has been done in 
patients with heart failure , and Scott  et al   found a correlation between muscle 
metaboreflex activity in the upper and lower limbs of patients with heart failure.7.4. Other factors
There are some other potential confounding factors that may affect studies looking at 
the muscle metaboreflex in humans.
7.4.1 Ventilatory data
We found that there was a metaboreceptor contribution to ventilation in our first study 
looking at patients with COPD (chapter 3), but failed to find this in the group of 
subjects with COPD in chapter 6.  As already discussed, there is considerable debate as 
to whether the muscle metaboreflex is relevant to the control of ventilation during 
exercise .  It is also possible that the metaboreflex is one of a number of mechanisms 
which control ventilation, some of which are redundant in some subjects, and that this 
may explain inter-subject variability.
We had some difficulty in the measurement of ventilation, which may explain some of 
our results.  When a mouthpiece is inserted, breathing pattern often changes, although 
we did allow time for breathing pattern to normalise.  It is also true that the relatively 
small increase in ventilation that we were trying to detect may be lost in the “noise” of 
variations in breathing pattern.  The contribution of voluntary control to ventilation is 
significant when compared with other measured variables such as heart rate and blood 
pressure.7.4.2 Reproducibility of technique
The potential contribution of voluntary control to ventilation calls into question the 
reproducibility   of   the   technique   of   forearm   exercise   followed   by   post-exercise 
circulatory occlusion.  This has been studied by Scott et al in a group of subjects with 
chronic heart failure .  It was found that there was satisfactory reproducibility when the 
technique was performed 5 days apart.
7.4.3 Age
The effects of age on the muscle metaboreflex were studied by Roseguini et al in a 
group of healthy subjects .   Three minutes of static handgrip exercise at 30% of 
maximum voluntary contraction followed by cuff inflation was used to evaluate the 
metaboreflex in a group of young (mean age 23±3) and a group of older (mean age 
62±7 years) subjects.   It was found that there was no difference in metaboreflex 
activity, suggesting that age alone does not lead to attenuation of this reflex.
7.4.4 Weight
The effects of obesity on the muscle metaboreflex have been studied , with a suggestion 
that metaboreflex control of muscle sympathetic nerve activity is impaired in obese 
women.   The authors hypothesized that insulin resistance led to a reduction in 
glycolysis   in   skeletal   muscle,   thus   attenuating   exercise-induced   acidosis. Quantification of skeletal muscle acidosis was not undertaken, and it is equally possible 
that difficulty in adequately occluding blood flow to and from the obese arm led to 
escape of metabolites and attenuation of the reflex.
The effects of muscle bulk may also be important, although this has not been 
specifically studied.  One could speculate that an increase in muscle bulk would simply 
lead to an increase in ventilatory response to exercise, with no effect on the muscle 
metaboreflex.     Any  change   in   muscle   fibre  type  could   conceivably   affect   the 
metaboreflex, with a shift towards type 2 (glycolytic) fibres leading to increased 
production of lactate and increased metaboreflex activation.  This merits further study.
7.4.5 Prescribed medications
A final potential confounding factor is the use of prescribed medications.  Patients with 
chronic medical conditions are frequently prescribed a combination of tablets which 
affect electrolyte balance, the renin-angiotensin system, the glucocorticoid axis and 
adrenergic or muscarinic receptors.  In reality, it is difficult to exclude such subjects, 
and careful note should be taken of the medication list.  One study has suggested that 
beta blockade in patients with chronic heart failure reduces the ventilatory response to 
exercise, in keeping with the hypothesis that excessive exercise ventilation in heart 
failure is mediated through a metaboreflex driven increase in sympathetic nervous 
system activity .  The individual effects of different classes of drugs on the muscle 
metaboreflex merits further research.  We were careful to exclude patients on beta 
blockers or other rate-limiting cardiac medications from all of our studies.7.5. Statistical issues
The failure to include a control group in chapter 3 led to a decision to test the 
hypothesis that muscle metaboreflex activity would be affected by disease severity in a 
group of patients with COPD.  This decision was taken after completion of the study, 
and the data analysis was therefore performed post-hoc.  In future, it would be both 
desirable and more statistically valid to select patients according to disease severity at 
the point of recruitment.  How disease severity is determined should also be given 
consideration for future studies.  Although FEV1 is the traditional marker of disease 
severity, it is a relatively poor predictor of exercise performance.  Perhaps the BODE 
index , which also considers nutritional status, dyspnoea and exercise tolerance, would 
be a more valid parameter to use.  New York Heart Association symptom class has 
been shown to correlate with muscle metaboreflex activity in heart failure , so Medical 
Research Council dyspnoea score may be worth studying, although a much larger 
subject group would be needed.
Chapter 6 looked at the effects of creatine supplementation on a number of variables. 
The effects of creatine supplementation were disappointing, although there appeared to 
be statistically significant effects on inspiratory and expiratory mouth pressures.  In 
retrospect, we should have brought this group of patients back for one final “washout” 
visit to see if mouth pressures returned to baseline.  Time constraints prevented us from 
measuring lung volumes at each visit, which would have allowed us to determine 
whether the change in mouth pressures was due to a change in lung volumes rather than muscle strength.  It is also possible that the chance element of performing multiple 
Student’s t-tests could explain our results: use of analysis of covariance would be more 
statistically robust in this situation, removing the element of chance.
7.6. How big should future studies be?
Although our creatine study (chapter 6) was largely negative, our data does allow us to 
perform a more detailed power calculation to guide planning for future studies.  The 
numbers recruited for this study were based on previous studies looking at the effect of 
forearm muscle training on the muscle metaboreflex, and we had similarly hoped to 
detect a 25% change in muscle metaboreflex activity .  We did find that there was more 
variation in metaboreflex activity between subjects, which would have affected power 
calculations.  This probably reflects greater patient heterogeneity in our COPD group.
Using the data from the study by Piepoli et al along with the standard deviations from 
our COPD population, it can be estimated how many subjects would be needed to 
detect a similar difference between our COPD group and a control group.  To have a 
90% chance of detecting a similar difference at a 95% significance level, we would 
need between 18 and 27 subjects in each group, depending on the variable used.  This 
does suggest that our study was underpowered due to the greater variation in muscle 
metaboreflex activity seen in our COPD group.
It is difficult to predict what magnitude of a difference in muscle metaboreflex we 
should expect between two groups of diabetic patients (with and without autonomic neuropathy).  Looking at the standard deviations from our data, power calculations 
suggest that we would need 9 subjects in each group to have a 90% chance of detecting 
a 30% difference in muscle metaboreflex activity at a 95% significance level.
7.7 Chapter conclusion
In conclusion, our research has highlighted a number of methodological issues that 
should be considered before designing any further research projects looking at the 
muscle metaboreflex in patients with COPD.Chapter 8
General Discussion8.1  General points
The question of how the human body matches the varying demands of exercising 
skeletal   muscle   with   a   constant   supply   of   oxygen   has   long   been   debated   by 
physiologists.  Although central (voluntary) command  and mechanoreceptors sensitive 
to movement and stretch  are of clear importance, it is now established beyond doubt 
that the muscle metaboreflex plays a vital part in this feedback loop .  The individual 
contribution   of   central   command,   the   mechanoreflex   and   the   metaboreflex   to 
ventilation, blood pressure, sympathetic nervous system activity and heart rate would 
appear to differ, and this remains a source of some controversy.  As an example, it is 
well established that the immediate increase in heart rate at the start of exercise is due 
to a centrally mediated withdrawal of resting vagal tone , but it is less clear whether 
ventilation is controlled by the metaboreceptor  or mechanoreceptor activation, venous 
distension or higher cortical centres .
There is also debate surrounding the question of the importance of such reflexes in 
human disease.  This was highlighted in a recent Point: Counterpoint article in the 
Journal of Applied Physiology, with one group arguing that the exaggerated exercise 
pressor response in heart failure is due to an increase in mechanoreceptor activity, and 
the other group countering that it is due to an increase in metaboreflex activity .  Both 
groups were able to support a substantial body of evidence supporting their respective 
causes.   As highlighted in chapter 1, the question of whether the metaboreflex is 
attenuated in patients with McArdle’s disease is also controversial .8.2  The muscle metaboreflex in patients with stable COPD
The first study in this thesis looked at whether we could measure muscle metaboreflex 
activity in patients with chronic obstructive pulmonary disease (COPD).  As already 
discussed, there are many similarities between the syndromes of chronic heart failure 
and COPD including exercise intolerance, skeletal muscle dysfunction and cachexia . 
Our data would suggest that there is a metaboreflex contribution to the blood pressure 
response to exercise in patients with COPD.  We also found that muscle metaboreflex 
activation in this group led to a significant increase in ventilation, in keeping with the 
work of Piepoli et al in patients with heart failure and in normal healthy volunteers . 
Our lack of a healthy control group makes it difficult to tell whether muscle 
metaboreflex activity was increased in this population.
We then looked at whether there was any difference in muscle metaboreflex activity 
between patients with moderate and severe COPD as determined by FEV1, although this 
was a post-hoc analysis of data and results should therefore be interpreted with caution. 
We found no difference in metaboreflex contribution to blood pressure, heart rate or 
ventilation between the two groups.  There are several possible reasons for this.
Although FEV1  is used as an indicator of disease severity in COPD in most 
international guidelines, it is known to be poorly predictive of exercise tolerance in 
much the same way as ejection fraction in patients with chronic heart failure .  Both 
measurements only reflect the function of one organ and ignore the other variables that 
contribute to the body’s ability to exercise.   It is therefore possible that use of a 
measurement that reflects functional disability, such as Medical Research Council dyspnoea score, would be more appropriate.   Most of the evidence for increased 
metaboreflex activity in patients with chronic heart failure centres on NYHA class, 
which reflects functional status .  Our study was too small to stratify patients into four 
different groups, so perhaps a larger study should look in detail at whether the 
metaboreflex is more active in patients who are more breathless.  We did not find any 
correlation between muscle metaboreflex activity and any other variable, including 
body mass index, handgrip strength or transfer factor.
It is also possible that differences in the pathophysiology of exercise limitation between 
patients with CHF and COPD are important.  It has consistently been shown in patients 
with CHF that acute improvements in cardiac output do not lead to an improvement in 
exercise tolerance .  This was taken as evidence that peripheral factors such as the 
muscle metaboreflex were of vital importance in causing abnormal exercise responses . 
Patients with COPD, however, are often limited by ventilatory constraints: about two 
thirds of patients will reach their predicted maximum minute ventilation during an 
incremental exercise test.  It is therefore possible that the muscle metaboreflex is of 
secondary importance to ventilatory limitation.  It is noteworthy that offloading the 
respiratory muscles with non-invasive ventilation can lead to an improvement in 
exercise tolerance , suggesting that central factors are more important.   The good 
relationship   between   inspiratory   capacity,   which   in   turn   predicts   dynamic 
hyperinflation, and exercise capacity again supports the argument that central limitation 
is more important .
This argument does not take account of the significant number of patients with COPD 
who terminate an exercise test before reaching their predicted maximum ventilation.  A study by Troosters et al suggested that patients in this subset are more likely to benefit 
from an exercise-based pulmonary rehabilitation programme .  It is therefore possible 
that it is this group who are more likely to have abnormal skeletal muscle responses to 
exercise and an abnormal muscle metaboreflex: any further work should perhaps 
address this issue.
One more factor which makes study of this population of patients difficult is the 
heterogeneity of the study population.  Two patients with COPD may have similar 
disease severity when stratified according to FEV1, but vast differences in other aspects 
of their disease.   Body mass index, muscle dysfunction, systemic inflammatory 
response, concomitant disease, degree of gas exchange abnormality, smoking status and 
corticosteroid   use   could   all   conceivably   affect   measurement   of   the   muscle 
metaboreflex.   It is likely that study of a very large group of patients would be 
necessary to evaluate the metaboreflex properly in COPD.  Even selection of a control 
group   is   difficult   given   the   considerable   debate   over   whether   skeletal   muscle 
abnormalities are simply due to deconditioning- it would be impossible to find a truly 
activity-matched group of healthy control subjects.
The muscle metaboreflex relies on an intact sensory and autonomic nervous system to 
function effectively.   It is well recognised that patients with COPD develop subtle 
abnormalities of the autonomic nervous system , and it is therefore possible that this has 
an effect on the muscle metaboreflex.  It should be noted, however, that the similar 
abnormalities of the autonomic nervous system that exist in patients with cardiac failure 
do not seem to affect the metaboreflex.8.3  Creatine supplementation in COPD
Our study looking at the effects of short-term creatine supplementation in patients with 
COPD followed on from the work of Fuld et al , who found that both short term and 
long term creatine supplementation led to an increase in fat free mass and skeletal 
muscle strength and endurance.  We hypothesised that creatine supplementation would 
also lead to attenuation of the muscle metaboreflex through an improvement in muscle 
bioenergetics, and we hoped to find similar improvements in skeletal muscle strength 
and endurance.
Our main finding was that there was no change in upper limb muscle metaboreflex 
activity following 10-14 days of creatine supplementation in our patient group.  This is 
perhaps not a surprise, given that we did not see an improvement in forearm muscle 
strength or endurance with creatine loading.  This finding contrasts with the work of 
Fuld et al, who found that quadriceps strength and endurance improved significantly 
following creatine loading .  It is, however, recognised that upper limb skeletal muscle 
function in COPD is well preserved ; perhaps study of the muscle metaboreflex in the 
lower limbs would be more appropriate, although regional circulatory occlusion of the 
leg is technically difficult .  It is also possible that a subset of patients with COPD who 
are “peripherally limited”, as discussed above, merits further study.  The increase in 
weight that was seen in this study following creatine supplementation was also less than 
that seen in previous studies .Our other finding was of a significant increase in peak inspiratory and expiratory mouth 
pressures following creatine loading, although as we do not have full lung function data 
for each visit, we cannot exclude the possibility that this was due to changes in lung 
volumes.  The study by Fuld et al found a trend towards an improvement in mouth 
pressures following creatine loading , but this was not quite statistically significant. 
This finding is of potential importance, as respiratory failure is often a consequence of 
an exacerbation of COPD.   It would perhaps be interesting to look at creatine 
supplementation in patients recovering from an exacerbation of COPD or weaning from 
a ventilator in the intensive care unit, or whether creatine improves respiratory muscle 
endurance in patients with COPD.
Creatine supplementation did not seem to affect markers of systemic inflammation in 
this group, but the size of our study is too small to draw any conclusions.  The effects of 
creatine supplementation on homocysteine merit further attention in a larger study.
8.4 Pulse transit time
Pulse transit time would appear to show promise in the measurement of the muscle 
metaboreflex.  Our findings of a reasonable correlation with blood pressure are not new, 
although it is still a matter of debate as to what pulse transit time is actually measuring. 
It would be interesting to do more detailed studies comparing pulse transit time with 
more invasive measurements such as muscle sympathetic nerve activity during exercise. 
The fact that PTT is able to detect the muscle metaboreflex reliably means that it is 
potentially of use in other studies.  We found measuring blood pressure with arterial tonometry difficult, and it only gave us a reading every 10-15 seconds.  There were 
occasional difficulties with measurement of blood pressure during exercise, and the 
wrist probe sometimes slipped out of place necessitating a repeat of the exercise run. 
Invasive arterial blood pressure monitoring is clearly not appropriate in this setting, and 
alternatives such as the “Finapres” are very expensive.   Pulse transit time has the 
advantage of ease of use and continuous measurement.
8.5 The autonomic nervous system
The final study sought to investigate what happens to the muscle metaboreflex in a 
group of patients with autonomic nervous system dysfunction.  We studied a group of 
patients with type I diabetes mellitus, in whom autonomic neuropathy is relatively 
common.  Our finding that muscle metaboreflex activity is unaffected by autonomic 
neuropathy was a surprise, given the involvement of the sensory and autonomic nervous 
systems in the metaboreflex loop.  This either suggests that the pathways involved in 
the metaboreflex are not damaged in autonomic neuropathy, or that activation of the 
muscle metaboreflex in this manner leads to a supra-physiological response which 
overrides autonomic and sensory nervous system abnormalities.  
Although we made an effort to recruit two distinct groups of patients, it is possible that 
the control group had more subtle peripheral nervous system abnormalities.  It should 
be noted that detailed autonomic function testing revealed this group to have varying 
degrees of sympathetic and parasympathetic dysfunction, which may make detection of 
an abnormal muscle metaboreflex in one group difficult.  Our group was too small to 
allow sub-stratification into groups with specific problems such as an abnormal blood pressure response on standing.  It is worth pointing out that the results obtained from 
both of our patient groups are very similar to those seen using a similar exercise 
protocol in normal subjects.
One confounding factor is our use of the arm muscles to measure metaboreflex activity. 
It is recognised that the longer nerves supplying the lower limbs are affected earlier in 
autonomic neuropathy, so this perhaps needs further work.  It is also impossible to 
select a group of patients without concomitant disease.  Although we tried to select 
patients without overt cardiac disease, it is likely that some had silent cardiac or 
peripheral vascular disease.
8.6 Pathophysiological relevance of the muscle metaboreflex
The evidence in support of the existence of the muscle metaboreflex is overwhelming, 
and it is clear that it is one of a number of mechanisms by which the human body 
regulates blood flow to exercising skeletal muscle.  There is also increasing evidence 
that there are differences in circulatory and ventilatory responses to exercise between 
patients with chronic disease and healthy subjects.  Although the current weight of 
evidence appears to favour upregulation of the metaboreflex in patients with heart 
failure, this remains controversial.   As previously discussed, there have been few 
studies looking at the metaboreflex in other diseases.  One recent study suggested that 
calf vasoconstrictor responses to metaboreflex activation are actually blunted in patients 
with moderate to severe COPD , although the reasons for this are not clear and further work is needed including the measurement of muscle sympathetic nerve activity during 
such a protocol.  This study also used static rather than dynamic handgrip exercise.
It is important at this stage to consider why alterations in muscle metaboreflex activity 
may be of clinical or pathological relevance rather than a mere physiological curiosity. 
Like any other physiological system, the human body seems to support a number of 
mechanisms and reflexes by which oxygen supply to exercising skeletal muscle is 
matched with demand.  Perhaps the human body would be able to cope without such a 
reflex, and it is genetic diversity that governs whether the metaboreflex is active or 
redundant?
To   attempt   to   answer   the   question   of   the   potential   clinical   relevance   of   the 
metaboreflex, it is worth taking a closer look at the syndrome of chronic heart failure. 
By conventional wisdom, a failure to increase cardiac output with exercise leads to 
inadequate   oxygen   delivery   to   skeletal   muscle   .     This,   in   combination   with 
deconditioning,   will   lead   to   changes   in   skeletal   muscle   favouring   anaerobic 
metabolism, which can be detected as a reduced lactate threshold on exercise testing. 
The muscle metaboreflex, designed to divert blood flow to exercising muscle, will be 
active in all exercising muscle groups, leading to an increase in sympathetic nervous 
system activity, a rise in blood pressure and systemic vasoconstriction.   This may 
initially be a beneficial compensatory mechanism, assisting with the physiological 
response to exercise .  In a chronic disease state, such excessive stimulation of these 
reflexes may cause persistent sympathetic overactivity, with an increase in cardiac 
afterload putting extra stress on the failing heart and vasoconstriction leading to a 
reduction in peripheral blood flow: thus a protective mechanism aimed at preserving oxygen supply to muscle becomes a deleterious one.  This “muscle hypothesis” was 
illustrated by Piepoli  et al  (figure 1.2) .   Muscle training appears to attenuate the 
metaboreflex in heart failure, perhaps interrupting the cycle of decline: this possibly 
goes some way to explaining the benefits of exercise rehabilitation programmes.
It would be physiologically interesting to study the metaboreflex in other diseases 
characterised by skeletal muscle dysfunction, but is it of relevance?  One could argue 
that measured metaboreflex activity is simply a reflection of skeletal muscle fitness, and 
that it is bound to be altered in such conditions.   It is telling that the forearm 
metaboreflex is attenuated in the very well trained muscle of rock climbers .
It is worth mentioning the muscle metaboreflex in COPD in the context of some more 
recent research.  It is thought that metaboreceptors exist in diaphragmatic muscle, and 
that diaphragm fatigue causes muscle metaboreflex activation .  Reductions in calf 
blood flow can be seen with fatiguing inspiratory muscle work, reflecting metaboreflex 
mediated vasoconstriction to non-exercising muscle .  It has since been shown that 
expiratory muscle fatigue causes a reduction in leg exercise capacity, presumably 
through metaboreflex mediated vasoconstriction to exercising muscle , and that 
inspiratory muscle training attenuates the human respiratory metaboreflex .   When 
patients with COPD exercise, work of breathing is significantly increased for a number 
of reasons, and respiratory muscles account for an increased fraction of oxygen 
consumption.   It is possible that increased activation of the respiratory muscle 
metaboreflex causes a reduction in blood flow to exercising limbs, limiting oxygen 
delivery.  This may partially explain why a plateau in limb blood flow may be seen 
during incremental exercise , and the observation that unloading the respiratory muscles with Heliox  or non-invasive ventilation  improves exercise performance.  Here may lie 
the “missing link” between exercise dyspnoea and limb fatigue in patients with chronic 
disease.
8.7 Further work
Further work should be done on the muscle metaboreflex in patients with COPD, with 
attention to the methodological issues described in chapter 7.  A large scale study using 
a similar protocol to the one used here would help answer the question of whether the 
metaboreflex is of as much importance in COPD as it appears to be in chronic heart 
failure.  Stratification should be done according to MRC dyspnoea score rather than 
FEV1, and it would be possible to select out a subset of patients who are not 
“ventilatory limited” to study further.  It would also be interesting to see if an exercise-
based pulmonary rehabilitation programme has any effect on metaboreflex activity.
Study of the muscle metaboreflex could also be applied to other chronic diseases.  One 
would suspect that the main problem with studying the metaboreflex in patients with 
COPD is that most patients seem to be limited by pulmonary mechanics.  It would be of 
interest to study the muscle metaboreflex in patients with idiopathic pulmonary 
hypertension.   It is well recognised that minute ventilation is greater for a given 
workload in patients with idiopathic pulmonary hypertension than in healthy control 
subjects, and that there is also an increase in the VE/VCO2 ratio during exercise .  It is 
not possible to explain this through ventilation/ perfusion mismatch alone, so it is 
possible that a change in muscle fibre type, with a shift towards anaerobic metabolism 
and a consequent increase in muscle metaboreflex activity plays an important role. Patients with type II diabetes mellitus have also been shown to demonstrate a shift in 
muscle fibre type from type I (oxidative) to type II (glycolytic), favouring anaerobic 
metabolism .  Sympathetic overactivity in the metabolic syndrome and type II diabetes 
mellitus is well recognized  and the possibility that the muscle metaboreflex contributes 
to this phenomenon may also merit study.
Another group of patients that would be worth studying is those with chronic renal 
failure who are on haemodialysis.  Patients undergoing haemodialysis have rapid shifts 
in acid-base balance during dialysis.  Given that an intramuscular acidosis is thought to 
be important in activation of the metaboreflex , it would be interesting to measure 
muscle metaboreflex activity before and after haemodialysis.
Work   is   ongoing   in   our   department   looking   at   the   effects   of   acetazolamide 
supplementation on the metaboreflex.  Acetazolamide is known to stimulate breathing 
by creating a mild metabolic acidosis , and has been shown to improve resting paO2 and 
paCO2  in patients with COPD .   Acetazolamide also reduces the ability of skeletal 
muscle to exercise in a hypoxic environment , and this study is aimed at assessing 
whether this is due to an increase in metaboreflex activity.
The benefits of creatine supplementation in COPD are unclear.  The study of Fuld et al 
suggested that creatine loading and supplementation during a pulmonary rehabilitation 
are of benefit.  Work by Gosselink et al  contradicts these findings.  Perhaps further 
work   should   target   patients   who   demonstrate   impairment   of   peripheral   muscle 
dysfunction.  It would also be interesting to study whether creatine supplementation is of benefit following an exacerbation of COPD, during non-invasive ventilation or 
during weaning from invasive ventilation in an intensive care unit.
The potential of pulse transit time in assessment of the muscle metaboreflex also merits 
further study.  Although it is clear that metaboreflex activation has an effect on pulse 
transit time, it is less clear exactly what pulse transit time represents.  Work could 
perhaps be carried out looking at the relationship between pulse transit time and muscle 
sympathetic nerve activity.8.8 Concluding remarks
In conclusion, it is possible to measure muscle metaboreflex activity in patients with 
chronic obstructive pulmonary disease, but we could not find any difference in activity 
between patients with moderate and severe disease.   Creatine loading did not alter 
forearm muscle strength, endurance or muscle metaboreflex activity in this small group 
of patients, although there was a modest increase in peak inspiratory and expiratory 
mouth pressures.
Muscle metaboreflex activity appears to be normal in patients with diabetic autonomic 
neuropathy, suggesting preservation of the afferent and efferent pathways of this reflex 
in this patient group.  In addition, pulse transit time shows promise in the evaluation of 
the muscle metaboreflex, and this merits further study.Bibliography
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